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Abstract 
Kaposi's sarcoma-associated herpesvirus (KSHV) is an oncogenic γ-
herpesvirus that is the etiologic agent of Kaposi sarcoma (KS). KS is an 
angioproliferative neoplasm composed of cells of endothelial origin. For the 
work described in this thesis, KSHV infection of endothelial cells was used as a 
tractable model to study the role of microRNAs (miRNAs) in endothelial cell 
biology. Previous work in the laboratory had identified miRNAs which are either 
upregulated or downregulated upon KSHV infection of lymphatic endothelial 
cells (LEC). Target prediction analysis of these miRNAs and cross-comparison 
of predicted targets with expression levels of pro- and anti-angiogenic genes 
following KSHV infection, revealed the predicted targeting of  Delta-like 4 
(DLL4) by the miR-30 family. DLL4 is significantly upregulated in KSHV-infected 
lymphatic endothelial cells (KLEC) whereas the miR-30 family is significantly 
downregulated. 
 
DLL4 is a membrane-bound ligand belonging to the Notch signalling family that 
plays a fundamental role in vascular development and angiogenesis. Targeting 
of DLL4 by miR-30b and miR-30c was confirmed by examining mRNA and 
protein expression following transfection of endothelial cells with miR-30 mimics 
and inhibitors or infection with miR-30-expressing lentiviruses. The exact target 
site within the DLL4 3’UTR was identified using a luciferase reporter assay and 
site-directed mutagenesis.  
 
Overexpression of miR-30b in endothelial cells led to increased vessel number 
and length in an in vitro model of sprouting angiogenesis. Microinjection of miR-
30 into zebrafish embryos resulted in suppression of dll4 and subsequent 
excessive sprouting of intersegmental vessels and reduction in dorsal aorta 
diameter. Use of a target protector against the miR-30 site within the dll4 3’UTR 
upregulated dll4 and synergised with Vegfa signalling knockdown to inhibit 
angiogenesis. Furthermore, restoration of miR-30b or miR-30c expression 
during KSHV infection attenuated viral induction of DLL4. Overall, the work 
presented in this thesis demonstrates that the miR-30 family targets DLL4 to 
regulate angiogenesis. 
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VEGFR2  vascular endothelial growth factor receptor 2 
VEGFR3  vascular endothelial growth factor receptor 3 
vFLIP   viral FLICE-inhibitory protein 
vGPCR  viral G-protein coupled receptor 
VHL   von Hippel-Lindau tumor suppressor, E3 ubiquitin protein 
vIL-6   viral interleukin-6 
VSV-G  Vesicular stomatitis virus-G 
v/v   volume/volume 
wnt5b   wingless-type MMTV integration site family member 5b 
WT   wildtype 
w/v   weight/volume 
XPO5   exportin 5 
YSL   yolk syncytial layer 
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Chapter 1. Introduction 
1.1 Kaposi sarcoma-associated herpesvirus 
Kaposi sarcoma (KS) was first described by Moritz Kaposi in 1872, when he 
published the case histories of five elderly men suffering from “idiopathic 
multiple pigmented” sarcomas of the skin (Kaposi, 1972). The aetiological agent 
of KS was determined in 1994 using PCR-based Representational Difference 
Analysis, which identified two unique DNA sequences in Acquired 
Immunodeficiency Syndrome (AIDS)-associated KS (AIDS-KS) that were 
absent in adjacent skin (Chang et al., 1994). This novel herpesvirus was termed 
Kaposi sarcoma-associated herpesvirus (KSHV) and is also known as human 
herpesvirus 8 (HHV8). It is a γ-herpesvirus with a double-stranded DNA 
genome that encodes over 80 open reading frames (ORFs), flanked by multiple 
GC-rich terminal repeats, giving it a total size of approximately 170kb 
(Dourmishev et al., 2003). Sixty-seven of the ORFs have homologues in 
herpesvirus saimiri (HVS) and a number of KSHV genes are homologous to 
cellular host genes (Longnecker and Neipel, 2007). 
 
1.1.1 Kaposi sarcoma 
KS initially presents as multifocal skin lesions, which are red to the naked eye 
due to an extensive vascular component (Ganem, 2010). Aggressive forms of 
the disease also involve lesions in the oral cavity, lymph nodes and visceral 
organs (Mesri et al., 2010). These vascular tumours consist of abnormal, slit-
like blood vessels, an inflammatory infiltrate and sheets of proliferating spindle 
cells (the tumour cell) (Mesri et al., 2010).  
 
1.1.1.1 Stages of disease development 
Classically, KS has been considered to progress through three clinical stages: 
patch, plaque and nodular. Patch lesions are flat dermal lesions containing 
inflammatory cells, elongated, spindle-shaped cells and many new blood 
vessels (Ganem, 2010). Progression to the plaque stage is denoted by a harder 
lesion in which fluid has accumulated and erythrocyte extravasation has 
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occurred (Ganem, 2010). It is the extravasation of erythrocytes and their 
subsequent degeneration that gives the lesions their colouration. As the spindle 
cells continue to proliferate, a raised lesion develops in which the network of 
slit-like blood vessels has further extended (Ganem, 2010). This is the final 
nodular stage. The stages of KS described would suggest that this disease 
progresses in a clear linear fashion. However, not all the lesions within the 
same patient will develop at the same rate. Additionally, whilst patch and plaque 
lesions may be widely disseminated throughout the body, the patient may 
present with more localised nodular lesions. Therefore, the AIDS Clinical Trials 
Group (ACTG) tumour classification has now been adopted as a more accurate 
measure of disease progression (Krown et al., 1997; Mesri et al., 2010). 
 
1.1.1.2 Clinical manifestations 
There are four discrete forms of KS: classic, endemic, iatrogenic and AIDS-KS 
(Mesri et al., 2010). Classic KS occurs predominantly in elderly men of 
Southern European, Middle-Eastern or Jewish origin, and is a rare, indolent 
disease that often affects the skin of the lower extremities (Dourmishev et al., 
2003). The endemic form of KS is more aggressive than classic KS, involving 
the lymphatic and/or visceral organs of both children and adults; cases have 
been reported for many decades in some equatorial regions of Africa (Bhagwat, 
1980; Dourmishev et al., 2003; Oettle, 1962; Slavin, 1970). Iatrogenic (post-
transplant) KS develops in transplant patients who have received 
immunosuppressive therapy (Siegel et al., 1969). AIDS-KS is associated with 
human immunodeficiency virus (HIV)-infected individuals and is the most 
aggressive and prevalent form of the disease; it affects the oral cavity, 
gastrointestinal tract and visceral organs, as well as the skin. It was in fact an 
epidemic of KS in young, homosexual American men which was the first 
indicator of the AIDS pandemic (Centers for Disease Control, 1981; Gottlieb et 
al., 1981). HIV-1 infection exponentially increases the risk of developing KS, 
due to its associated immunosuppressive environment (Boshoff and Weiss, 
2002). The direct action of the HIV-1 trans-activator of transcription (Tat) protein 
has also been implicated in KS development (Vogel et al., 1988). 
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1.1.1.3 Cellular origin 
The exact cellular origin of KS has yet to be defined. The most common cell 
type in nodular lesions is the spindle cell, which expresses both endothelial 
(PECAM1, CD34, Factor VIII) and lymphatic (VEGFR3, LYVE1, PDPN) markers 
(Beckstead et al., 1985; Dupin et al., 1999; Jussila et al., 1998). However, some 
spindle cells also express markers of macrophages (CD68), dendritic cells 
(Factor XIII) and smooth muscle cells (ACTG2). Additionally, KSHV infection of 
lymphatic endothelial cells (LEC) promotes reprogramming towards a blood 
endothelial cell (BEC) expression profile and the opposite scenario has also 
been observed in BEC (Hong et al., 2004; Wang et al., 2004). Viral-induced 
reprogramming in LEC has been partially attributed to silencing of the 
transcription factor v-maf avian musculoaponeurotic fibrosarcoma oncogene 
homolog (MAF) by the KSHV-encoded miRNAs (Hansen et al., 2010). MAF is 
expressed in LEC but not BEC and maintains LEC identity by repressing the 
expression of BEC-specific genes (Hansen et al., 2010). One current 
hypothesis is that KSHV infects circulating endothelial precursor cells and 
drives them towards a lymphatic lineage (Mesri et al., 2010). This theory is 
supported by the fact that circulating vascular progenitors display KS spindle 
cell markers (Beckstead et al., 1985; Jussila et al., 1998). It would also help to 
explain the multifocal presentation of advanced KS.   
 
1.1.1.4 Tumour microenvironment 
Angiogenesis, proliferating spindle cells and a prominent immune infiltrate are 
the characteristic hallmarks of KS lesions. All three processes are continually 
active and necessary for KS progression. The inflammatory cell infiltrate 
appears before spindle cell formation, highlighting the importance of this 
component to KS pathogenesis (Ensoli and Stürzl, 1998). The immune infiltrate 
is largely comprised of CD8+ T cells and monocyte-macrophages. Dendritic 
cells, CD4+ T cells and B cells are also present, although not in such 
abundance (Ensoli and Stürzl, 1998). Consequently, KS lesions are typified by 
high levels of inflammatory cytokines secreted by immune cells, including 
interferon gamma (IFNG), tumour necrosis factor (TNF), interleukin-1 (IL-1), 
interleukin-6 (IL-6) and colony stimulating factor 2 (CSF2). This cytokine profile 
influences endothelial cell activation and induces the production of angiogenic 
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factors, leading to blood vessel formation and further recruitment of T cells and 
monocytes. KSHV-infected spindle cells also secrete pro-angiogenic (ANG2, 
VEGFA, TGF-β) and pro-inflammatory factors (IL-1, IL-6, CSF2). This augments 
the cytokine profile and has a direct mitogenic effect on infected endothelial 
cells (Ensoli et al., 1989). The virus also contributes to the pro-inflammatory and 
pro-angiogenic environment by encoding its own array of cytokines such as viral 
interleukin 6 (vIL-6) and viral chemokines (vCCL1-3) (Boshoff et al., 1997). KS 
tumourigenesis is driven by this combination of inflammatory cells, angiogenic 
factors and cytokines, hence it can be defined as a paracrine neoplasia (Mesri 
et al., 2010).   
 
1.1.2 Lymphoproliferative disorders 
KSHV is also the aetiological agent of two lymphoproliferative disorders, 
multicentric Castleman’s disease (MCD) and primary effusion lymphoma (PEL) 
(Cesarman et al., 1995).  
 
PEL is an aggressive non-Hodgkin’s B cell clonal lymphoma that lacks a distinct 
tumour mass and presents as malignant effusions in the pericardial, pleural or 
peritoneal cavities (Jenner and Boshoff, 2002). PEL is characterised as a post-
germinal centre B cell lymphoma, however PEL cells often lack B cell specific 
markers (Boshoff et al., 1998; Cesarman et al., 1995; Jenner et al., 2003). The 
majority of patients with PEL are co-infected with HIV and/or Epstein-Barr Virus 
(EBV) (Cesarman et al., 1995; Jenner et al., 2003). Cell lines established from 
PEL samples are commonly used for experimental investigation because they 
maintain the KSHV genome at high copy numbers.  
 
MCD is a polyclonal tumour that arises from naïve B cells. Only a small 
population of the tumour cells are KSHV-positive in KSHV-linked MCD. These 
attract uninfected B cells to the tumour site, possibly through the action of both 
viral and human IL6 and other cytokines (Dupin et al., 2000). Only 50% of MCD 
cases in HIV-negative patients are KSHV-positive; however, nearly all cases of 
MCD in HIV-positive patients are KSHV-positive (Moore and Chang, 2003; 
Soulier et al., 1995). EBV co-infection does not occur in MCD tumours (Du et 
al., 2001).   
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1.1.3 Viral life cycle 
1.1.3.1 Virus entry 
KSHV has been shown to have a broad tropism, both in vivo and in vitro. KSHV 
is able to bind to cells via the glycoproteins that coat the virion: K8.1, gB, gH 
and gL. K8.1 and gB connect with heparan sulphate, which is ubiquitously 
displayed on the membrane of many human cells (Boshoff, 2012). gB may also 
directly interact with integrins to induce intracellular signalling (Boshoff, 2012). It 
has recently been shown that a heterodimer of gH and gL binds to EPH 
receptor A2 (EPHA2) on epithelial and endothelial cells, which triggers 
intracellular signal transduction pathways including focal adhesion kinase (FAK) 
activation (Hahn et al., 2012). This creates a permissive environment for KSHV 
entry into the cell, thereby triggering endocytosis of the viral particle (Boshoff, 
2012). Once inside the cell, viral capsids are released by fusion of the viral 
envelope with the endosomal membrane. The capsids then move to the 
perinuclear region and the viral genome enters the nucleus via nuclear pores 
(Boshoff, 2012). Once in the nucleus, KSHV can undergo two modes of 
infection: lytic replication, culminating in the production of new virions, or latent 
infection resulting in persistent host cell infection. 
 
1.1.3.2 Latent infection 
The establishment of latency enables KSHV to maintain long term infection in 
quiescent or proliferating cells by ensuring viral genome replication and 
avoiding initiation of the anti-viral response. Most new KSHV infections result in 
the latent programme and both KS and PEL tumour cells are latently infected 
(Bechtel et al., 2003; Cesarman et al., 1995; Zhong et al., 1996). During latency 
the viral genome is maintained as a circularised extrachromosomal episome 
(Renne et al., 1996). To ensure that KSHV infection persists, the episome is 
copied by the cellular machinery during DNA replication and is attached to host 
chromatin during mitosis. There is a restrictive pattern of gene expression 
during latent infection which minimises the number of antigens available for 
presentation and recognition by the host immune response. The KSHV latent 
genes are latent nuclear antigen 1 (LANA; ORF73), viral cyclin (vCyclin; 
ORF72), viral FLICE-inhibitory protein (vFLIP; ORF 71), Kaposin (K12) and 
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several viral miRNAs (Dittmer et al., 1998; Dittmer, 2003; Zhong et al., 1996). 
The persistent expression of these latent genes is concomitant with progression 
to malignant KS.  
 
1.1.3.3 Lytic infection 
Reactivation of latent KSHV can occur sporadically, leading to lytic replication. 
Within KS lesions the vast majority of cells are latently infected including the 
spindle cells, which arise from latently infected endothelial cells after the 
establishment of the initial inflammatory lesion. However, there is a small lytic 
population of cells producing new virions, which enables propagation of the 
virus and recruitment of new cells to the lesion (Jenner and Boshoff, 2002). 
Lytic infection is induced by expression of replication and transcription activator 
(RTA). Subsequently, lytic immediate-early, delayed-early and late genes are 
expressed sequentially, viral DNA is amplified, and the infected cell is lysed, 
allowing the release of virions (Longnecker and Neipel, 2007). A number of 
factors have been shown to trigger the switch from latent to lytic infection, but 
the most potent and widely used chemical inducer is 12-O-tetradecanoyl 
phorbol-13-acetate (TPA) (Renne et al., 1996). 
 
1.1.4 Angiogenic gene expression in KLEC 
The transcriptional signature of KSHV-infected LEC (KLEC) has previously 
been described by obtaining gene expression microarray (GEM) profiles from 
six pairs of LEC and KLEC using an Affymetrix hg-u133+2 GeneChip (Lagos et 
al., 2007). When these data was compared to a list of 239 genes that are 
associated with angiogenesis it was found that 33% are significantly altered 
upon KSHV infection of LEC (Figure 1.1.) (Vart et al., 2007). Among the 
upregulated genes are many known pro-angiogenic factors. These include the 
transcription factor hypoxia inducible factor 1 alpha subunit (HIF1A), which 
activates the transcipriton of other pro-angiogenic genes in response to 
hypoxia, and matrix metallopeptidase 1 (MMP1), which enables endothelial cell 
migration by degrading the extracellular matrix (Figure 1.1).  
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Figure 1.1. KSHV infection regulates an array of angiogenic factors. Heat map of 79 
angiogenesis genes which are significantly changed between LEC and KLEC samples (q <  
0.001).  Each gene is represented by a single probe.  Genes were ordered by amount of fold 
change between conditions with the uppermost gene displaying the highest positive differential 
expression and the lowermost gene displaying the highest negative differential expression.  
(Figure adapted from Supplementary Figure 3 of Vart et al., 2007.) 
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1.2 Angiogenesis 
Angiogenesis is strictly defined as the growth of new blood vessels from pre-
established ones and occurs in response to pro-angiogenic stimuli (Risau et al., 
1988). These stimuli occur during development and in response to hypoxia 
during growth, wound healing and pathological conditions. For sprouting 
angiogenesis to occur, endothelial cells must undergo several stages of 
morphological change. These transformations are summarised below, however 
for further detail regarding the role of Notch signalling in this process, see 
Section 1.4.5. 
 
1.2.1 Initiation of sprouting 
Upon stimulation by pro-angiogenic factors, predominantly by vascular 
endothelial growth factor A (VEGFA), endothelial cells must emerge from a pre-
existing vessel. During quiescence this is prevented by the existence of a 
basement membrane, shared by both mural and endothelial cells, which forms 
a covering around the vessel (Eble and Niland, 2009). Therefore, at the onset of 
sprouting, matrix metalloproteases (MMPs) are released to degrade the 
basement membrane. This also serves to release pro-angiogenic growth factors 
that are contained within the extracellular matrix (Potente et al., 2011). In 
parallel, release of angiopoietin 2 (ANGPT2) by endothelial cells stimulates the 
detachment of mural cells (Augustin et al., 2009).  
 
Nascent sprouts are led by endothelial tip cells (see Section 1.3.5.2) that 
generate long, dynamic filopodia upon VEGFA stimulation (Gerhardt et al., 
2003; Ruhrberg et al., 2002), most probably as a result of cell division cycle 42 
(CDC42) activation (De Smet et al., 2009). These filopodia are coated in 
receptors that enable the tip cells to respond to directional cues, thereby leading 
the sprout to the required location (Potente et al., 2011). One such receptor is 
vascular endothelial growth factor receptor 2 (VEGFR2), which binds VEGFA, 
enabling the tip cell to follow the pro-angiogenic signal. Other guidance 
receptors which are known to be expressed on endothelial cells are unc-5 
homolog B (UNC5B), roundabout axon guidance receptor homolog 4 (ROBO4), 
plexin D1 (PLXND1), various neuropilins (NRPs) and several ephrin (EPH) 
family members (Potente et al., 2011).  
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1.2.2 Sprout elongation and lumen formation 
The endothelial cells which make up the body of the growing sprout are known 
as stalk cells (see Section 1.4.5.2). These cells proliferate in response to 
VEGFA and display fewer filopodia than the leading tip cells (Gerhardt et al., 
2003). As the sprout extends, adherens junctions containing VE-cadherin form 
between neighbouring stalk cells to ensure the integrity of the sprout (Potente et 
al., 2011). It is the stalk cells that form the lumen of the new vessel; however, 
the mechanism of lumen formation varies depending on the situation in which 
angiogenesis is occurring (Iruela-Arispe and Davis, 2009; Zeeb et al., 2010). 
Cell hollowing has been observed extensively in vitro and during the formation 
of the zebrafish intersomitic vessels, although this is now contested (See 
Section 1.3.2.3) (Blum et al., 2008; Kamei et al., 2006). Intracellular vacuoles 
form in the stalk cells and then coalesce with vacuoles in the neighbouring cells 
to create a continuous lumenal space. A second mechanism, cord hollowing, 
has been reported in axial vessels (Iruela-Arispe and Davis, 2009). For cord 
hollowing to occur, apical-basal polarity must first be established in the stalk 
cells. Subsequently, the apical (lumenal) membrane delivers a repulsive signal 
by displaying charged glycoproteins and hence begins to open the lumen. 
Expansion of the lumen requires morphological changes in the stalk cells and 
the rearrangement of cell-cell junctions. VEGFA drives the necessary 
endothelial cell changes by increasing Rho-associated protein kinase (ROCK) 
activity (Strilić et al., 2009).  
 
1.2.3 Vessel stabilisation and maturation 
When the tip cell from one sprout comes into contact with a tip cell from another 
sprout, vessel fusion can occur, known as anastomosis (Blum et al., 2008). This 
can be facilitated by macrophages, possibly through cell-to-cell communication 
(Fantin et al., 2010). Adherens junctions then form between the tip cells to 
stabilise the initial connection and allow blood to flow through the now 
continuous lumen. Aided by the action of tissue inhibitors of metalloproteinases 
(TIMPs), extracellular matrix proteins are laid down by the endothelial cells in 
order to establish a basement membrane which will stabilise the new vessel 
(Potente et al., 2011). However, the vessel is not fully mature until mural cell 
interactions have been established. Once blood flow has commenced through 
33 
 
the nascent vessel, tissue oxygenation is achieved and consequently pro-
angiogenic signals are turned off, namely by a reduction in VEGFA production.  
 
The mural cells of immature vessels and capillaries are pericytes, whereas 
larger arteries and veins are covered by a layer of vascular smooth muscle cells 
(Gaengel et al., 2009). Transforming growth factor β (TGF-β) signalling is 
required to stimulate mural cell induction, differentiation, proliferation and 
migration. Accordingly, loss of function of TGF-β receptor 2 (Tgfbr2), activated 
receptor-like kinase 1 (Alk1) or endoglin (Eng) in mice causes impaired mural 
cell development and hence vessel instability (Pardali et al., 2010). However, it 
is the platelet-derived growth factor (PDGF) signalling pathway that controls 
mural cell recruitment to blood vessels (Gaengel et al., 2009). Platelet-derived 
growth factor B (PDGFB) is released by endothelial cells and binds to PDGF 
receptor-β (PDGFRB) on mural cells which stimulates their migration and 
proliferation. Consequently, inactivation of Pdgfb or Pdgfrb in mice leads to 
vascular dysfunction due to pericyte deficiency (Gaengel et al., 2009). 
Sphingosine-1-phosphate receptor (S1PR) signalling is also required for mural 
cell recruitment and to strengthen the endothelial cell-pericyte connections by 
inducing N-cadherin trafficking (Gaengel et al., 2009). The mural cells 
themselves release angiopoietin 1 (ANGPT1) which binds to TEK tyrosine 
kinase, endothelial (TEK) on endothelial cells to tighten endothelial cell 
junctions and promote pericyte adhesion (Augustin et al., 2009). 
 
1.2.4 Vascular remodelling 
Once blood flow has been initiated, the resulting haemodynamic forces cause 
remodelling of the newly established vascular network (Lucitti et al., 2007). 
When shear forces are exerted on the endothelium, Kruppel-like factor 2 (KLF2) 
is upregulated in endothelial cells. KLF2 is a mechano-sensitive transcription 
factor which promotes endothelial cell quiescence, by downregulating VEGFR2, 
and ensures that the newly formed vessel remains open (Potente et al., 2011). 
If the vessel is poorly perfused, KLF2 expression is not stimulated and the 
endothelial cells undergo apoptosis leading to vessel regression (Potente et al., 
2011). In zebrafish aortic endothelial cells, the miRNA miR-126 has been shown 
to act downstream of Klf2a to regulate vascular remodelling (Nicoli et al., 2010). 
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Other vascular alterations which can occur include intussusceptive growth, to 
split new vessels, and an element of additional sprouting (Phng and Gerhardt, 
2009).      
 
1.3 Zebrafish development 
The zebrafish, Danio rerio, is a small tropical freshwater fish that is commonly 
used to investigate factors regulating angiogenesis and tumour development, in 
addition to its established role in genetics, developmental biology and 
neuroscience. Working with zebrafish embryos does not have the time 
constraints of some other models as zebrafish breed easily, produce many 
offspring per laying and have a very short generation time. The embryos have 
generally hatched by 72 hours post-fertilisation (hpf) and embryonic 
development is considered complete by the fifth day. 
 
The zebrafish is an attractive in vivo model because fertilisation of their eggs 
occurs externally, therefore live embryos can be easily accessed for 
manipulations, such as the injection of mRNA or morpholinos (MOs). Small 
molecules can also be added directly to the water that holds the fish as they will 
diffuse into the embryo. Once the embryos have been treated, they can be 
monitored through all developmental stages under a microscope and individual 
embryos can be harvested and used for further study, such as in situ 
hybridisations. The availability of transgenic zebrafish embryos with fluorescent 
blood vessels has greatly aided the study of angiogenesis throughout 
development (Lawson and Weinstein, 2002). Vascular morphogenesis within 
zebrafish embryos can be easily visualised due to their optical transparency. 
Pigmentation of the embryos, which begins at 25 hpf, can be inhibited so that 
microscopic examination of the vasculature can be continued throughout 
development.  
 
1.3.1 General embryonic development 
Embryonic development in the zebrafish is a rapid process, especially when 
compared to other vertebrates. Embryogenesis takes approximately 2-3 days, 
the larvae hatch around the third day of development and by day 5 the vast 
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majority of cell types have differentiated and the organs have all begun 
functioning. Embryogenesis can be divided into seven periods: the zygote, 
cleavage, blastula, gastrula, segmentation, pharyngula and hatching (Kimmel et 
al., 1995). Within each period are defined developmental stages which are 
detailed in Table 2.7.  
 
Between 0 and 0.75 hpf the newly fertilised egg completes the first zygotic cell 
division and then enters the cleavage period where cell divisions 2 to 7 occur 
synchronously at approximately 15 minute intervals (Kimmel et al., 1995). At 
~2.25 hpf the embryo enters the blastula period, during which midblastula 
transition (MBT) occurs, the yolk syncytial layer (YSL) is formed and epiboly 
begins (Kimmel et al., 1995). During the MBT cell cycles are lengthened and 
start to occur asynchronously (Kane and Kimmel, 1993). The MBT also denotes 
the start of zygotic gene transcription (Kane and Kimmel, 1993). Prior to this 
point, the zygotic chromatin is condensed, hypoacetylated and hypermethylated 
whilst the embryo relies upon maternal mRNA for translation (Kimmel et al., 
1995; Meehan et al., 2005). Epiboly is the process by which the YSL and the 
blastoderm thin out and spread across the yolk cell until it is completely 
encompassed.  
 
The gastrula period, which occurs between 5.25 and 10 hpf, is marked by the 
morphogenetic movements of involution, convergence and extension that 
generate the epiblast, hypoblast and the embryonic axis. The epiblast evolves 
into the ectoderm but also contains cells capable of generating the mesoderm 
and endoderm. The cells of the hypoblast contribute to the formation of the 
embryonic endoderm, from which derive the respiratory and digestive tracts. It 
is also during the gastrula period that epiboly is completed (Kimmel et al., 
1995). During segmentation the somites, pharyngeal arch primordia and the 
neuromeres develop. It is also during this period that organogenesis begins and 
involuntary tail movements are first observed (Kimmel et al., 1995).  
 
The pharyngula period (24-48 hpf) is the point when the final morphology of the 
zebrafish really becomes apparent as the body axis of the embryo, which was 
curved around the yolk sac, straightens. Blood circulation commences during 
the segmentation period, pigmentation is observed and the fins begin to 
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develop (Kimmel et al., 1995). Hatching occurs from 48 hpf onwards, although 
not all embryos of the same clutch will hatch together. The larvae that emerge 
then inflate their swim bladders and by 72 hpf they actively respond to external 
stimuli and display food-seeking behaviour (Kimmel et al., 1995). 
 
1.3.2 Development of the vasculature 
During the developmental programme of vertebrates, the cardiovascular system 
is one of the first organs to evolve. This is because the development and growth 
of all other organs depends upon a functioning circulatory network. The 
establishment of this network occurs through two distinct morphogenetic 
processes: vasculogenesis and angiogenesis (Poole and Coffin, 1989; Risau et 
al., 1988). Vasculogenesis occurs when angioblasts aggregate to form a 
vascular cord which is then lumenised. Angiogenesis is the sprouting of new 
capillaries from pre-existing blood vessels (Poole and Coffin, 1989; Risau et al., 
1988). These processes are clearly demonstrated in the vascular 
morphogenesis of zebrafish embryos.    
 
1.3.2.1 Origin of endothelial cells  
The ventrolateral mesoderm is the source of angioblasts, precursors of the 
endothelial cell lineage (Kimmel et al., 1995; Stainier et al., 1995). 
Haematopoeitic cells also arise from the ventrolateral mesoderm and 
specification of these two major cell types is highly conserved across a range of 
vertebrate species, including zebrafish. It is controlled by transcription factors 
belonging to the E-twenty six (ETS), GATA and (LIM-only) LMO families (De Val 
et al., 2008; Detrich et al., 1995; Liu and Patient, 2008; Thompson et al., 1998). 
These transcription factors are initially expressed in the anterior and posterior 
lateral mesoderm at the beginning of somitogenesis. They denote the 
haemangioblasts, the multipotent precursor cells that can differentiate into both 
haematopoietic and endothelial cells. During somitogenesis the two cell 
populations are differentiated by changes in gene expression. For example, 
those that will become haematopoietic cells express T-cell acute lymphocytic 
leukemia 1 (tal1) but not kinase insert domain receptor like (kdrl) and vice versa 
for the angioblast progenitors (Gering et al., 1998). By 12-14 hpf, genetic 
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markers of angioblasts, such as friend leukemia integration 1a (fli1a), can be 
visualised in two lateral stripes along the body of the embryo (Roman et al., 
2002). 
 
1.3.2.2 Vasculogenesis: dorsal aorta and cardinal vein formation 
From 14 hpf onwards, angioblasts migrate in two waves towards the midline of 
the embryo, following guidance cues generated by the endoderm (Fig. 1.2A, i) 
(Jin et al., 2005; Lawson and Weinstein, 2002). Once at the midline the 
angioblasts aggregate to form a vascular cord between the mesoderm and the 
hypochord (Fig. 1.2A, i) (Eriksson and Löfberg, 2000). There are two theories 
regarding the subsequent formation of the dorsal aorta (DA) and posterior 
cardinal vein (PCV). It has been proposed that the first wave of angioblasts form 
the DA and the second wave of angioblasts form the PCV (Jin et al., 2005). 
However, following expression of arterial and venous markers, ventral sprouting 
of angioblasts from the vascular cord has been observed to generate the PCV 
(Herbert et al., 2009). Therefore, it is now generally thought that the angioblasts 
from both migratory waves coalesce to form a single vascular primordium, from 
which both the DA and the PCV originate (Fig. 1.2A, ii) (Herbert et al., 2009). 
 
At ~17 hpf the angioblasts of the vascular primordium begin to express either 
arterial or venous markers (Fig. 1.2A, ii). Vegfa signalling through Kdrl and 
subsequent Notch pathway activation induces arterial differentiation in a subset 
of angioblasts (also discussed in Section 1.4.5.1) (Lawson et al., 2001; Lawson 
et al., 2002; Lawson et al., 2003; Zhong et al., 2001). Vegfa signalling is 
stimulated in the ventral somites due to Sonic hedgehog signals from the 
notochord (Lawson et al., 2002). Venous differentiation however, does not 
require Vegfa signalling (Covassin et al., 2006; Lawson et al., 2003). 
 
The arterially-defined angioblasts express ephrin B2 (efnb2) whilst the venous 
precursors express eph receptor B4a (ephb4) (Herbert et al., 2009; Jin et al., 
2005). The differential expression of these markers in arteries and veins is well 
established and it now appears that repulsive Ephb4-Efnb2 signalling results in 
ventral migration of the ephb4-expressing angioblasts (Fig. 1.2A, ii) (Herbert et 
al., 2009; Lawson et al., 2001). 
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Figure 1.2. Development of the 
zebrafish vasculature. (A) 
Schematic cross sections of the 
zebrafish trunk during dorsal aorta 
(DA) and posterior cardinal vein 
(PCV) formation. (i) Migration of 
angioblasts (purple) to the 
midline. en: endoderm; h: 
hypochord; s: somites; nc: 
notochord; nt: neural tube. (ii) 
Arterio-venous differentiation to 
generate venous (blue) and 
arterial (red) angioblasts followed 
by ventral sprouting of venous 
angioblasts. (iii) Lumen formation 
of the DA occurs by cord 
hollowing whereas venous 
angioblasts aggregate around red 
blood cells (brown) to form a tube. 
(iv) By 30 hpf both the DA and the 
PCV are fully formed and can 
carry blood flow. Endothelial cell 
junctions are indicated in green. 
(B) Diagrammatic representation 
of intersegmental vessel (ISV) 
formation. Two neighbouring 
sprouts are depicted as 
representative examples. The 
leading tip cells are indicated in 
green and purple. Lumenal 
spaces are shown in yellow. SA: 
segmental artery; SV: segmental 
vein; DLAV: dorsal longitudinal 
anastomotic vessel. Diagrams 
adapted from (Ellertsdóttir et al.,   
2010). 
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These coalesce around blood cells (Fig. 1.2A, iii) and by 30 hpf blood flow is 
established in the PCV (Fig. 1.2, iv) (Herbert et al., 2009). Lumen formation in 
the DA begins prior to lumenisation of the PCV at ~21 hpf and occurs through 
the process of cord hollowing (Herbert et al., 2009; Jin et al., 2005), as 
described in Section 1.2.2. Endothelial cell junctions form between the cells of 
the DA and apical-basal polarisation occurs (Fig. 1.2A, iii) (Jin et al., 2005). By 
24 hpf the DA is fully lumenised (Fig. 1.2A, iii) and blood flow commences 
between 28 and 30 hpf (Fig. 1.2A, iv).  
 
1.3.2.3 Angiogenesis: intersegmental vessel formation 
The intersegmental vessels (ISVs) of the zebrafish embryo link the DA and the 
PCV with the dorsal longitudinal anastomotic vessel (DLAV) and are formed by 
two waves of angiogenic sprouting, from the DA and PCV respectively (Isogai et 
al., 2003; Yaniv et al., 2006). At ~22 hpf the primary wave of sprouting begins 
from the DA when one or two endothelial cells move out of the DA (Fig. 1.2B, i) 
(Blum et al., 2008; Isogai et al., 2003). This requires functional Vegfa signalling 
through Kdrl and kinase insert domain receptor (Kdr) and downstream 
phospholipase c gamma 1 (Plcg1) activity (Bahary et al., 2007; Covassin et al., 
2009; Habeck et al., 2002). The growing sprout consists of 3-4 endothelial cells, 
one tip cell and two or three stalk cells which migrate dorsally until they reach 
the level of the dorsal neural tube (Fig. 1.2B, ii) (Blum et al., 2008; Isogai et al., 
2003). Having reached this point, the tip cells of the nascent sprouts connect 
with their anterior and posterior neighbours to form the basic scaffold of the ISV 
and DLAV (Fig. 1.2B, iii). Due to endothelial cell proliferation and further cell 
rearrangements, each ISV and connecting T-junction is finally composed of 4-6 
endothelial cells which overlap in a staggered fashion to form a multicellular 
tube with an extracellular lumen (Fig. 1.2B, iv and Fig. 1.3) (Blum et al., 2008). 
This mode of lumenisation has only been recently accepted, as it was 
previously thought that ISV lumens were formed by cell hollowing (see Section 
1.2.2) (Kamei et al., 2006). 
 
The second wave of sprouting starts at 32 hpf when endothelial cells of the PCV 
begin migrating dorsally (Fig 1.2B, iii) (Isogai et al., 2003; Yaniv et al., 2006). 
Some of these sprouts connect to a pre-existing ISV (Fig. 1.2B, iv) whilst the 
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remainder proceed up to the level of the horizontal myoseptum where they form 
the parachordal lymphangioblasts that later give rise to the lymphatic network 
(Hogan et al., 2009a; Isogai et al., 2003). Blood flow commences at ~48 hpf and 
at this point two types of ISVs are clearly visible: segmental arteries (SAs), 
which connect the DA to the DLAV, and segmental veins (SVs), formed by the 
merging of the secondary sprouts with the primary vessels to connect the PCV 
to the DLAV (Fig. 1.2B, v; Fig. 1.3). 
 
1.3.2.4 VEGFR signalling 
In humans and other placental mammals there are three paralogous genes 
which make up the VEGF receptor family: fms-related tyrosine kinase 1 
(FLT1;VEGFR1), KDR (VEGFR2) and fms-related tyrosine kinase 4 
(FLT4:VEGFR3). Zebrafish possess orthologues of all three receptors: flt1, kdr 
and flt4. However, along with other teleosts and some higher vertebrates such 
as chickens, they also encode a fourth VEGF receptor gene: kdrl (Bussmann et 
al., 2008). Both kdr and kdrl are functional orthologues of KDR and the Kdrl 
protein acts synergistically with Kdr to mediate Vegfa signalling (Bahary et al., 
2007). 
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Figure 1.3. The arrangement of endothelial cells comprising the zebrafish intersegmental 
vessels. The intersegmental vessels (ISVs) are multicellular tubes consisting of 4-5 cells per 
vessel (each shown in a different colour). These cells are arranged so that they overlap in a 
staggered fashion in both the ISV and the dorsal longitudinal anastomotic vessel (DLAV). 
Extensive intercellular junctions maintain the integrity of the vessel. Diagram from (Blum et al., 
2008).  
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1.4 Notch signalling 
The Notch pathway is an intercellular signalling pathway that transduces signals 
between adjacent cells through the interaction of ligands on the surface of the 
“signal generating” cell and membrane-associated receptors on the “signal 
receiving” cell (Fig 1.4). The concept of the Notch gene was first identified in 
Drosophila almost 100 years ago due to the existence of a mutant strain which 
displayed wing “notches” (Morgan, 1917). Notch was originally classified as a 
neurogenic gene because Notch mutants were shown to develop an excessive 
number of neurons (Lehmann et al., 1983; Poulson, 1945). It was not until 
Notch homologues in C. elegans were discovered and characterised (lin-12 and 
glp-1), that the role of Notch in the control of cell fate was revealed (Roehl et al., 
1996; Yochem et al., 1988). It is this key function that regulates pattern 
formation during embryonic development and is why the Notch pathway is 
conserved throughout the animal kingdom (Lai, 2004).  
 
1.4.1 Notch receptors and ligands 
In mammals there are five canonical Notch ligands: delta-like 1 (DLL1), delta-
like 3 (DLL3), delta-like 4 (DLL4), jagged 1 (JAG1) and jagged 2 (JAG2). These 
can bind to one of four Notch receptors: NOTCH1, NOTCH2, NOTCH3 and 
NOTCH4. Both ligands and receptors are single-pass transmembrane proteins. 
The extracellular domains of these proteins contain arrays of epidermal growth 
factor (EGF) repeats through which ligand-receptor contact occurs (Rebay et 
al., 1991).  
  
1.4.2 Notch signal transduction 
Ligand-receptor binding triggers proteolytic cleavage of the Notch receptor to 
release the Notch intracellular domain (NICD) (Fig. 1.4). Cleavage occurs do to 
the action of two proteases. The metalloproteinase tumour necrosis 
factor(TNF)-α-converting enzyme (TACE) cleaves the Notch receptor within the 
juxtamembrane region (Fig 1.4). This occurs because ligand binding induces 
conformational changes that allow access to the cleavage site (Brou et al., 
2000). Subsequently, the receptor is cleaved within the transmembrane domain 
by γ-secretase (Fig 1.4) (De Strooper et al., 1999). The NICD then translocates 
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to the nucleus where it directly interacts with the transcription factor CSL, also 
known in mammals as recombination signal binding protein for Ig kappa J 
region (RBPJ) (Fig 1.4) (Jarriault et al., 1995). When not bound to NCID, CSL 
acts as a transcriptional repressor by interacting with a corepressor complex 
containing a histone deacetylase (Kao et al., 1998). The corepressor complex is 
displaced by NCID which instead recruits mastermind-like 1 (MAML1), and a 
histone acetyltransferase such as p300 (Fig 1.4). This converts CSL into a 
transcriptional activator and leads to the transcription of Notch target genes 
belonging to the Hairy/Enhancer of Split (HES) and HES-related (HEY) families 
(Fig 1.4) (Davis and Turner, 2001; Nakagawa et al., 2000). HES and HEY 
proteins are basic-helix-loop-helix (bHLH) proteins that act as transcriptional 
repressors to regulate a diverse range of developmental processes (Fischer 
and Gessler, 2007). Notch target gene specificity is determined by CSL binding 
to a cis-element with the consensus GTGGGAA, although variants of this 
consensus, including CTGAGAA, also bind CSL with high affinity (Lam and 
Bresnick, 1998). 
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Figure 1.4. The Notch Signalling 
Pathway.  Diagrammatic 
representation of Notch signal 
transduction between a signal 
generating cell and a signal 
receiving cell. Ligands of the 
Serrate (JAG1 and JAG2) or Delta 
(DLL1, DLL3 and DLL4) families 
on the signal generating cell bind 
to Notch receptors (NOTCH1-4) 
on the signal receiving cell. This 
triggers proteolytic cleavage of the 
Notch receptor by tumour necrosis 
factor (TNF)-α-converting enzyme 
(TACE) and γ-secretase to 
release the Notch intracellular 
domain (NICD). The NICD 
translocates to the nucleus where 
it binds to the transcription factor 
CSL and recruits coactivators 
such as mastermind-like (MAML1) 
and the histone acetyltransferase 
p300. This causes the 
transcription of Notch target genes 
such as those of the 
Hairy/Enhancer of Split (HES) and 
HES-related (HEY) families. 
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1.4.3 Regulation of the Notch pathway 
1.4.3.1 Expression patterns 
Notch receptor expression is spatially and temporally restricted in order to 
ensure that Notch signalling occurs at the proper time and in the correct cell 
type during development and in the adult organism. The expression patterns of 
NOTCH1 and NOTCH2 are the broadest and display some overlap. NOTCH1 is 
found in the majority of tissues, including brain, liver, heart, lung, kidney, 
intestine, bone marrow, skeletal muscle, spinal cord, eye and thymus (Swiatek 
et al., 1994). NOTCH2 expression is more restricted, being found in the brain, 
liver, kidney and stomach (McCright et al., 2001). NOTCH3 and NOTCH4 are 
the most cell-type specific Notch receptors. NOTCH3 has been detected in 
vascular smooth muscle, the central nervous system and in certain 
haematopoietic cells whilst NOTCH4 is endothelial cell specific (Joutel et al., 
2000; Lardelli et al., 1994; Uyttendaele et al., 1996). These diverse expression 
patterns are reflected in the wide range of biological functions that have been 
assigned to the various Notch receptors (Wu and Bresnick, 2007). Tight 
transcriptional control of Notch receptor expression is required to maintain these 
expression patterns. The transcription factors SRY-box 2 (SOX2), FBJ murine 
osteosarcoma viral oncogene homolog (FOS) and jun proto-oncogene (JUN) 
have all been identified as downstream effectors of Notch regulation (Wu and 
Bresnick, 2007).  
 
1.4.3.2 Post-transcriptional regulation 
Although the differential expression patterns of Notch receptors and ligands are 
a key element of Notch pathway regulation, they are not sufficient to explain the 
differences in signalling activity which have been observed (Kopan and Ilagan, 
2009). For instance, two cells that express the same panel of receptors and 
ligands may have varying levels of Notch signalling in response to the same 
stimuli. An additional level of regulation is provided in the form of post-
transcriptional modifications.  
 
The EGF repeats of Notch receptors are subject to two forms of O-
glycosylation, addition of O-glucose and O-fructose (Kopan and Ilagan, 2009). 
46 
 
Once a Notch receptor has been translated in the endoplastic reticulum (ER), 
protein O-fucosyltransferase 1 (POFUT1) is able to add fructose to the EGF 
repeats. POFUT1 function is essential for Notch signalling in mammals; 
however, it is actually the ER chaperone function of POFUT1 that is required for 
optimal protein folding (Kopan and Ilagan, 2009). O-fructose additions can be 
extended further by Fringe glycosyltransferases. It is these modifications which 
affect ligand-receptor binding; Serrate ligands (JAG1 and JAG2) have a higher 
affinity for fucosylated Notch whereas Delta ligands (DLL1-4) preferentially bind 
to Fringe-modified receptors (Xu et al., 2007). It is also possible that O-
glycosylation by protein O-glucosyltransferase 1 (POGLUT1) may contribute to 
receptor activation (Kopan and Ilagan, 2009). Although the exact contributions 
of fucosylation, glycosylation and Fringe modifications have yet to be 
determined and appear to differ greatly between species, these adjustments are 
undoubtedly involved in modifying the strength of receptor-ligand binding and 
hence act to modulate overall signal strength (Kopan and Ilagan, 2009). 
 
Mono-ubiquitination of the NICD by a variety of E3 ubiquitin ligases induces 
endocytosis and subsequent degradation of the Notch receptors (Kandachar 
and Roegiers, 2012). This controls the level of Notch receptor presentation at 
the cell surface and hence limits receptor-ligand binding. Notch ligands are also 
subject to ubiquitin-induced endocytosis; however, this process appears to 
generate a more effective ligand and it is required for Notch activation. The 
mechanism behind this occurrence is not yet fully defined but two models have 
been proposed. The Notch ligand may be modified upon internalisation in such 
a way that it then becomes capable of inducing functional Notch signals 
(Kandachar and Roegiers, 2012). Alternatively, when ligand that is bound to a 
Notch receptor is endocytosed, the TACE cleavage site on the Notch receptor 
may be revealed due to transendocytosis of the Notch receptor extracellular 
domain (Itoh et al., 2003).  
 
1.4.4 Role in development 
Notch signalling has been shown to function during the development of a wide 
range of tissues and organs. These include the circulatory and nervous 
systems, muscles, the kidney, the pancreas and in keratinocytes (Wu and 
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Bresnick, 2007). The importance of Notch signalling during development has 
been demonstrated by the targeted deletion of individual Notch receptors. Loss 
of either Notch1 or Notch2 in mice is embryonically lethal. Notch1 is require for 
efficacious somitogenesis, angiogenesis and neurogenesis whereas Notch2 
deletion causes kidney, heart and neural defects (Conlon et al., 1995; Hamada 
et al., 1999; Krebs et al., 2000; McCright et al., 2001; Swiatek et al., 1994). 
Neither Notch3 nor Notch4 deletion is lethal to mouse embryos; however, 
Notch1/Notch4 double mutants die due to impaired vascular development 
(Domenga et al., 2004; Krebs et al., 2000). Interestingly, DLL4, which signals 
through both NOTCH1 and NOTCH4, displays haploinsufficient lethality due to 
the development of extensive arterial defects (Krebs et al., 2004).  
 
1.4.5 Role in angiogenesis 
Many members of the Notch pathway and related signalling components are 
expressed in endothelial cells: receptors NOTCH1 and NOTCH4 (Favre et al., 
2003; Villa et al., 2001); ligands DLL1, DLL4, JAG1 and JAG2 (Claxton and 
Fruttiger, 2004; Favre et al., 2003; Mailhos et al., 2001; Villa et al., 2001); target 
genes HEY1, HEY2 and NOTCH-regulated ankyrin repeat protein (NRARP) 
(Fischer and Gessler, 2007; Krebs et al., 2001); the transcriptional factors RBPJ 
and MAML1 (Dou et al., 2008; Liu et al., 2006); the negative regulator numb 
homolog (NUMB) (Favre et al., 2003). Extensive functional studies in both mice 
and zebrafish have revealed that Notch signalling is required at all stages of the 
vertebrate angiogenic programme.  
 
1.4.5.1 Arterio-venous differentiation 
During development of the cardiovascular system, angioblasts, the endothelial 
cell precursors, are directed towards either an arterial or venous fate by a tightly 
regulated cell specification pathway. VEGFA signalling is sensed by angioblasts 
through VEGFR2 and those cells that receive a sufficiently strong signal are 
driven towards an arterial fate by the combined action PLCG1, mitogen-
activated protein kinase (MAPK), Wnt and Notch signalling (Corada et al., 2010; 
Hong et al., 2006; Lawson et al., 2001; Lawson et al., 2002; Lawson et al., 
2003; Wythe et al., 2013; Zhong et al., 2001). EFNB2, both a marker and a 
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driver of arterial differentiation, is in fact a direct transcriptional target of the 
Notch pathway (Grego-Bessa et al., 2007; Herbert et al., 2009).  Targeted 
deletion or knockdown of various Notch signalling components results in the 
loss of correct arterial and venous specification and severe vascular 
abnormalities. When the expression of notch3, rbpja and hey2 were reduced in 
zebrafish embryos, artery formation was disturbed, efnb2 expression was 
impaired and there was an increase in expression of the venous marker ephb4 
(Lawson et al., 2001; Siekmann and Lawson, 2007; Zhong et al., 2001). 
Additionally, endothelial cell specification defects are observed in mindbomb 
mutants (Lawson et al., 2001). Mind bomb (Mib) is a RING ubiquitin ligase 
which is required for efficient Notch activation by Delta ligands (Itoh et al., 
2003).  
 
In the mouse, Dll1, Dll4, Notch1, Notch4, Rbpj, Hey1 and Hey2 are all required 
for successful arterio-venous differentiation (Carlson et al., 2005; Duarte et al., 
2004; Fischer et al., 2004; Gale et al., 2004; Kim et al., 2008; Krebs et al., 2004; 
Limbourg et al., 2007; Trindade et al., 2008). Venous differentiation does not 
require Vegfa signalling and venous identity has long been considered the 
default position in the absence of Notch signalling (Covassin et al., 2006; 
Lawson et al., 2001; Lawson et al., 2003). However, there does appear to be 
some element of active Notch inhibition in venous endothelial cells. It was found 
that the transcription factor nuclear receptor subfamily 2 group F member 2 
(Nr2f2) is only expressed in venous endothelial cells and that deletion of Nr2f2 
in endothelial cells allowed them to acquired arterial characteristics (You et al., 
2005). These characteristics included an upregulation of the Notch signalling 
components Notch1, Jag1 and Hey1. It appears that Nr2f2 acts to suppress 
Notch signalling by downregulating the VEGF receptor neuropilin 1 (Nrp1) (You 
et al., 2005). 
  
1.4.5.2 Tip cell specification 
DLL4/Notch signalling has been implicated in tip cell specification in 3D 
endothelial cell cultures, zebrafish ISV development, the mouse retina and in 
tumour angiogenesis (Hellström et al., 2007; Leslie et al., 2007; Lobov et al., 
2007; Noguera-Troise et al., 2006; Ridgway et al., 2006; Sainson et al., 2005; 
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Siekmann and Lawson, 2007; Suchting et al., 2007). DLL4 expression is 
highest in murine tip cells whereas the greatest Notch signalling activity has 
been observed in the stalk cells of nascent sprouts (Claxton and Fruttiger, 2004; 
Hellström et al., 2007). However, it should be noted that this does not directly 
translate to zebrafish as dll4 and the tip cell marker flt4 are expressed in both tip 
and stalk cells (Hogan et al., 2009b; Leslie et al., 2007; Siekmann and Lawson, 
2007).  
 
When Notch signalling was suppressed in mice by a γ-secretase inhibitor, 
genetic deletion of one Dll4 allele or endothelial-specific deletion of Notch1, 
increased angiogenic sprouting and branching was observed (Hellström et al., 
2007; Suchting et al., 2007; Tammela et al., 2008). This was attributed to an 
expansion in the number of tip cells. This conclusion was made because there 
was an increase in the expression of genes that are highly expressed in tip cells 
such as Kdr, Flt4, Unc5b and Pdgfb and also extensive filopodia formation 
(Hellstrom et al., 2007; Suchting et al., 2007; Tammela et al., 2008). 
Conversely, Notch signalling activation using exogenous Jag1 peptide reduced 
tip cell formation and filopodia extension in the mouse retina (Hellström et al., 
2007). Similar observations have been made in the zebrafish embryo. In this 
system γ-secretase inhibition, dll4 MO injections and genetic deletion of dll4 all 
caused excessive sprouting and branching of the ISVs (Leslie et al., 2007; 
Siekmann and Lawson, 2007). These phenotypes were shown to be due to a 
loss of notch1b signalling via rbpja, as when these two genes were knocked 
down, hyperbranching was also observed (Leslie et al., 2007; Siekmann and 
Lawson, 2007). In fact, rbpja-deficient Tg(fli1a:EGFP) cells that were 
transplanted into wildtype zebrafish embryos showed an increased propensity 
to occupy the tip cell position in the developing ISVs (Siekmann and Lawson, 
2007).  
 
Overall it appears that tip cell fate is the default programme in the absence of 
Notch signalling, whereas active Notch signalling is needed to promote stalk cell 
specification (Hellström et al., 2007).  When endothelial cells are activated by 
VEGFA they compete for tip cell position via DLL4/Notch signalling. This 
appears to be a dynamic process, where tip and stalk cell specification is not 
finalised (Jakobsson et al., 2010). It is likely that it is the cell that produces the 
50 
 
most DLL4 that remains a tip cell by suppressing tip cell specification in 
neighbouring cells. Exactly how this suppression occurs has yet to be 
completely defined but a general model has been proposed. VEGF is known to 
induce DLL4 expression through KDR (Liu et al., 2003; Lobov et al., 2007; 
Suchting et al., 2007). So if one endothelial cell receives greater VEGF 
stimulation, it will express more DLL4 and activate Notch signalling in 
neighbouring cells. Notch activation downregulates expression of KDR,  FLT4 
and the VEGF co-receptor NRP1 and upregulates expression of the VEGFA 
decoy receptor FLT1 (Harrington et al., 2008; Henderson et al., 2001; Hogan et 
al., 2009b; Li et al., 2006; Suchting et al., 2007; Trindade et al., 2008; Williams 
et al., 2006). This acts to reduce the responsiveness of the neighbouring cells to 
any further VEGFA or vascular endothelial growth factor C (VEGFC) 
stimulation, thereby reinforcing the direction of Notch signalling. Computational 
modelling of this scenario has suggested that it could result in alternating tip 
and stalk cells when applied to a row of endothelial cells in the presence of a 
VEGF gradient (Bentley et al., 2008). By preventing excessive tip-cell formation, 
DLL4 maintains the optimal ratio between tip and stalk cells required for the 
correct branching patterns in both the murine retina (Hellström et al., 2007; 
Lobov et al., 2007) and the intersegmental vessels of zebrafish embryos (Leslie 
et al., 2007; Siekmann and Lawson, 2007). 
 
1.4.5.3 Endothelial cell motility 
Several studies have demonstrated that Notch signalling via DLL4 acts to limit 
endothelial cell migration (Biyashev et al., 2011; Leslie et al., 2007; Siekmann 
and Lawson, 2007; Trindade et al., 2008). When Dll4/Notch signalling was 
inhibited by either dll4 knockdown or γ-secretase inhibition in zebrafish 
embryos, endothelial cells displayed increased filopodial activity and migrated 
into ectopic locations (Leslie et al., 2007). These phenotypes were observed at 
a time point (54 hpf) at which the endothelial cells of the DLAV and ISVs are 
normally quiescent (Leslie et al., 2007). Similarly, knockdown of rbpja increased 
the number of cells that migrated into both the ISVs and the DLAV, while 
transplanted Tg(fli1a:EGFP) cells expressing activated Notch were restricted to 
the DA and the base of the ISVs (Siekmann and Lawson, 2007). More recently, 
a hyper-migratory phenotype has been reported in dll4 morphants which leads 
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to individual endothelial cells breaking away from sprouting ISVs (Biyashev et 
al., 2011). The control of endothelial cell migration by DLL4 is not a function 
which is restricted to zebrafish. Overexpression of Dll4 in mouse embryos 
resulted in reduced migration of endothelial cells into the ISVs (Trindade et al., 
2008). Equally, overexpression of DLL4 in human umbilical vein endothelial 
cells (HUVEC) significantly reduced their migratory behaviour, even in response 
to exogenous VEGF (Trindade et al., 2008).  
 
Although DLL4-induced Notch signalling has been established as a molecular 
brake on inappropriate endothelial cell migration, the mechanism through which 
this occurs has not been elucidated. One possibility is that the Notch pathway 
acts via suppression of NRP1 expression. NRP1 is a semaphorin and VEGF co-
receptor which is significantly downregulated by Notch signalling in vitro 
(Harrington et al., 2008; Williams et al., 2006). Both the Semaphorin and VEGF 
binding activities of NRP1 have been blocked using monoclonal antibodies and 
in HUVEC this prevented cell migration in a transwell in vitro assay (Pan et al., 
2007). The pro-migratory activity of NRP1 was suggested to stem from the C-
terminal domain, which has been shown to promote HUVEC migration via 
phosphatidylinositol 3-kinase (PI3K), v-akt murine thymoma viral oncogene 
homolog (AKT) and ras homolog family member A (RHOA) (Wang et al., 2003). 
However, the cytoplasmic domain of NRP1 is not required for murine 
angiogenesis but is necessary for normal arterio-venous patterning in the retina 
and for both developmental and adult arteriogenesis (Fantin et al., 2011; 
Lanahan et al., 2013). Nrp1 knockout has been shown to inhibit endothelial cell 
migration and is required for normal angiogenesis in the central nervous system 
(CNS) (Gerhardt et al., 2004; Jones et al., 2008). Recent work by Fantin and 
colleagues has demonstrated that NRP1 promotes tip cell function, as Nrp1-
positive endothelial cells preferentially adopted the tip cell position over Nrp1-
negative endothelial cells in chimeric vessel sprouts (Fantin et al., 2013). NRP1 
may also be required for successful substrate switching by tip cell filopodia, as 
in the absence of NRP1, sprouts failed to change direction at key points in the 
developing hindbrain (Gerhardt et al., 2004).   
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1.4.5.4 Endothelial cell proliferation 
During sprouting angiogenesis, endothelial cell proliferation is required in order 
for the new vessel to growth in length, and if necessary, in diameter. This is 
another element of endothelial angiogenic behaviour which Notch signalling 
controls in order to prevent excessive or inappropriate sprouting. Inhibition of 
Notch signalling in various in vivo models causes increased endothelial cell 
proliferation (Dou et al., 2008; Hellström et al., 2007; Leslie et al., 2007; Lobov 
et al., 2007; Noguera-Troise et al., 2006; Ridgway et al., 2006; Siekmann and 
Lawson, 2007; Suchting et al., 2007). Conversely, Notch pathway activation, 
both in vitro and in mice, reduced the rate of endothelial cell propagation 
(Harrington et al., 2008; Liu et al., 2006; Noseda et al., 2004; Trindade et al., 
2008). 
 
In zebrafish, Dll4 signalling via Notch1b is required to prevent endothelial cell 
proliferation once ISV sprouting is complete (Leslie et al., 2007). At an earlier 
point in development, rbpja or dll4 knockdown caused an increase in the 
number of ISV endothelial cells, due to a combination of increased proliferation 
and migration (Siekmann and Lawson, 2007). Enhanced endothelial cell 
proliferation has also been observed in both embryonic and adult mice upon 
Notch inhibition (Dou et al., 2008; Hellström et al., 2007; Lobov et al., 2007; 
Suchting et al., 2007).  For example, deletion of a single Dll4 allele or inhibition 
of Dll4/Notch signalling by intraocular injection of blocking antibodies promoted 
endothelial cell division in the developing mouse retina (Lobov et al., 2007). 
When DLL4 signalling is blocked in murine tumour models it causes an increase 
in tumour vascularity which can be partly attributed to an increase in endothelial 
cell proliferation (Noguera-Troise et al., 2006; Ridgway et al., 2006). 
 
Liu and colleagues identified the MAPK and PI3K pathways as the 
intermediaries that suppress endothelial cell proliferation in response to Notch 
stimulation (Liu et al., 2006). Both signalling pathways were repressed in 
endothelial cells following NOTCH1 activation; this required MAML1 expression 
and could be recapitulated by HES1 overexpression (Liu et al., 2006). 
Furthermore, the expression of cyclin-dependent kinase inhibitor 1A (CDKN1A) 
is increased by NOTCH1 and NOTCH4 but inhibited upon endothelial deletion 
of Rbpj (Dou et al., 2008; Noseda et al., 2004). When Notch signalling was 
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activated, upregulation of CDKN1A caused a reduction in the nuclear 
translocation of cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4). This 
resulted in cell cycle arrest due to a lack of CCND1/CDK4-mediated 
retinoblastoma 1 (RB1) phosphorylation (Dou et al., 2008; Noseda et al., 2004). 
 
1.4.5.5 Endothelial cell adhesion and vessel stability 
Maturation of nascent blood vessels requires the deposition of extracellular 
matrix proteins by endothelial cells in order to form a basement membrane. 
Endothelial cells overexpressing DLL4 display increased transcription of 
fibronectin (FN1) and various collagen and laminin genes (see Table 5.1) 
(Harrington et al., 2008; Trindade et al., 2008). These findings correlate with the 
observation that Dll4-/- embryos have an irregular basement membrane around 
the DA with which not all endothelial cells are in contact (Benedito et al., 2008).  
 
Integrins are transmembrane receptors that mediate adhesion by attaching cells 
to each other or the extracellular matrix. Microarray analysis of HUVECs 
transduced with empty vector and DLL4-encoding retroviruses has shown that 
integrin beta 3 (ITGB3) mRNA is down-regulated in DLL4-expressing HUVECs 
(Harrington et al., 2008). However, a CSL-independent pathway has been 
identified that positively regulates the activation of β1-integrins upon Notch 
signalling (Hodkinson et al., 2007). In this pathway the NICD does not 
translocate to the nucleus but instead activates the GTPase R-Ras to increase 
integrin binding affinity and hence integrin-mediated adhesion (Hodkinson et al., 
2007). Exogenous NICD was also able to reverse the suppressive effect of H-
Ras/Raf on integrin activity and NOTCH1/DLL4 signalling activated α5β1 
integrins in a R-Ras-dependent manner to increase FN1 binding in myeloid cells 
(Hodkinson et al., 2007). It is not yet known if this pathway is relevant in 
endothelial cells; however, expression of constitutively active NOTCH4 in 
human dermal microvascular endothelial cells (HMEC) increases β1-integrin-
mediated adhesion to collagen which could occur via the R-Ras mechanism 
(Leong et al., 2002).  
 
Another key molecule involved in the stabilisation of new blood vessels is the 
Notch target NRARP. This gene is upregulated upon Notch activation and acts 
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as a negative regulator of Notch signalling by promoting the degradation of 
NICD (Krebs et al., 2001; Lamar et al., 2001; Pirot et al., 2004). However, 
NRARP also stabilises the β-catenin cofactor, lymphoid enhancer-binding factor 
1 (LEF1), to promote Wnt signalling (Ishitani et al., 2005; Phng et al., 2009). It is 
the combined regulation of both Notch and Wnt signalling that enables NRARP 
to stabilise nascent blood vessels during ISV formation and retinal angiogenesis 
(Phng et al., 2009). Nrarp knockout mice and nrarp zebrafish morphants both 
displayed ectopic vessel regression due to a reduction in endothelial stalk cell 
proliferation, endothelial cell retraction and abnormal junctional rearrangements 
(Phng et al., 2009). A certain level of Notch signalling is clearly required to 
maintain quiescence in established blood vessels as loss of Rbpj in the 
endothelial cells of adult mice caused spontaneous angiogenesis in multiple 
tissues (Dou et al., 2008). However, during stabilisation of vessels endothelial 
proliferation is still required and NRARP appears to modulate both Notch and 
Wnt signalling to allow this to occur (Phng et al., 2009).   
 
1.4.5.6 Pathological angiogenesis 
DLL4 has been found to be upregulated in tumours of the colon, bladder and 
breast and in renal clear cell carcinoma (Jubb et al., 2009; Jubb et al., 2010; 
Patel et al., 2005; Patel et al., 2006), where is acts to prevent excessive 
angiogenesis and stabilise existing vessels (Patel et al., 2006). This has proven 
relevant to the development of new cancer therapeutics. Several studies have 
demonstrated that blocking DLL4 in murine tumour models, using neutralising 
antibodies, inhibits tumour growth by promoting non-productive, deregulated 
angiogenesis (Haller et al., 2010; Hoey et al., 2009; Li et al., 2007; Noguera-
Troise et al., 2006; Oishi et al., 2010; Ridgway et al., 2006). Although tumour 
vascularity was increased upon DLL4 blockade, the resulting vessels were 
poorly perfused and tumour growth was inhibited due to hypoxic conditions 
(Noguera-Troise et al., 2006).  
 
The increased vascularity observed in tumours following DLL4 signalling 
blockade is a result of the crucial role that DLL4 plays in regulating the ratio of 
tip cells to stalk cells. Expression of DLL4 by the tip cells of new sprouts 
stimulates Notch signalling in the adjacent cells, thereby maintaining stalk cell 
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identity and restricting tip cell specification (Hellström et al., 2007). When DLL4 
signalling or expression is inhibited, tip cell specification is not controlled, 
leading to excessive sprouting from existing vessels. Enhanced sprouting upon 
DLL4 inhibition in tumours also concurs with earlier work which demonstrated 
that DLL4 promotes the switch between the proliferative phase of angiogenesis 
to the maturation and stabilisation phase (Benedito et al., 2008; Harrington et 
al., 2008; Phng et al., 2009).  
 
DLL4 blockade can also inhibit tumour growth by causing a reduction in cancer 
stem cell frequency (Fischer et al., 2011; Hoey et al., 2009). These discoveries 
have subsequently led to a Phase I clinical trial of a DLL4 blocking antibody. 
However, chronic blockade of DLL4 using antibody therapy may not be a viable 
treatment option because this leads to the pathological activation of endothelial 
cells, disruption of normal organ homeostasis and induces vascular tumours in 
mice and rats (Yan et al., 2010). More recently it has been suggested that 
combined targeting of DLL4 and EPHB4 may overcome this safety issue as this 
treatment combination displayed cumulative efficacy and did not result in the 
liver vascular lesions reported by Yan and colleagues (Djokovic et al., 2010).  
 
Manipulation of DLL4/NOTCH signalling may also be a possible treatment 
option in other angiogenic pathologies. For example, Dll4 blockade in a model 
of ischaemic retinopathy enhanced the angiogenic sprouting required for the 
regrowth of retinal vessels but suppressed pathological neovascularisation 
(Lobov et al., 2007). 
 
1.5 microRNAs 
MicroRNAs (miRNAs) are a class of highly conserved, small, non-coding RNAs 
that negatively regulate gene expression by binding to cellular mRNA 
transcripts. The current release of the miRBase database (miRBase 19, August 
2012) contains over 20,000 miRNA gene loci across 193 species which 
amounts to 25,000 mature miRNA sequences (Kozomara and Griffiths-Jones, 
2011). To date over 2000 human miRNAs have been identified which are 
predicted to control the activity of at least 50% of all protein-coding genes (Krol 
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and Loedige, 2010). Thus miRNAs constitute one of the most abundant classes 
of gene-regulatory molecules in animals.  
 
1.5.1 Discovery and classification 
The first miRNA, lin-4, was described in C. elegans in 1993 by Lee and 
colleagues (Lee et al., 1993). Whilst characterising loss of function mutations 
that caused developmental timing defects, the authors showed that the lin-4 
gene gave rise to a 22 nucleotide (nt) RNA molecule, rather than encoding for a 
protein (Lee et al., 1993). The 3 prime untranslated region (3’UTR) of the 
protein coding gene lin-14 was found to contain antisense sites complimentary 
for lin-4 (Lee et al., 1993; Wightman et al., 1993). These sites enabled lin-4 to 
reduce lin-14 protein output without affecting mRNA levels (Wightman et al., 
1993). These findings provided the first model of post-transcriptional gene 
regulation by an endogenous small RNA and led to the creation of a new term 
for this class of small RNAs: miRNAs. A second temporally regulated small 
RNA, let-7, was also described in C. elegans and shown to target the 3’UTR of 
lin-41 (Reinhart et al., 2000; Slack et al., 2000). Detection of let-7 RNAs in a 
wide range of animal species, including Drosophila, revealed that miRNAs were 
not specific to C. elegans, but a widely distributed class of regulatory molecules 
(Pasquinelli et al., 2000). This was confirmed when an additional 60 C. elegans 
miRNAs and 20 Drosophila miRNAs were identified by small RNA cloning 
(Lagos-Quintana et al., 2001; Lau et al., 2001; Lee and Ambros, 2001). The first 
human miRNAs were also characterised in 2001 (Lagos-Quintana et al., 2001) 
and since then miRNAs have been found throughout the animal kingdom as 
well as in plants, algae, slime moulds and viruses (miRBase 19, August 2012).   
 
Since their first discovery as regulators of developmental timing, miRNAs have 
been implicated in a hugely diverse range of cellular processes, including 
angiogenesis, immunity and the stress response (Baltimore et al., 2008; Leung 
and Sharp, 2010; Wang and Olson, 2009). It is therefore not surprising that 
many miRNAs have been found to be dysregulated in various pathological 
conditions such as cancer and heart disease (Bauersachs and Thum, 2011; 
Croce, 2009). Several studies support the theory that miRNAs act as rheostats 
by fine-tuning protein expression (Baek et al., 2008; Selbach et al., 2008). 
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However, this belies the crucial role they fulfil in cellular function. This is evident 
during development, where loss of miRNA biogenesis is embryonically lethal 
(Bernstein et al., 2003). More recent work has suggested that miRNAs can 
behave as both fine-tuners and switches, depending on where target mRNA 
levels lie in relation to a pre-defined threshold (Mukherji et al., 2011). 
  
1.5.2 Biogenesis 
The majority of miRNA genes are located either in intergenic regions or in an 
anti-sense orientation to annotated genes (Lagos-Quintana et al., 2001; Lau et 
al., 2001; Lee and Ambros, 2001). Although some miRNAs are individually 
produced from separate transcription units, the majority of miRNA genes are 
arranged in clusters and transcribed polycistronically (Lee et al., 2002). RNA 
polymerase II is the predominant enzyme responsible for miRNA transcription in 
animals (Lee et al., 2004). The primary transcript, termed the primary miRNA 
(pri-miRNA), can range from hundreds to thousands of nucleotides in length 
and is capped and polyadenylated (Cai et al., 2004). Each pri-miRNA contains 
one or more hairpin structures that are composed of a stem and a terminal loop 
(Fig.1.5). These hairpins are recognised and cleaved by DROSHA, an RNase III 
enzyme, to form hairpin-shaped precursor miRNAs (pre-miRNAs) of ~60-70nt 
(Fig. 1.5) (Lee et al., 2003).  
 
DROSHA acts as part of a Microprocessor complex and the other core 
component is DiGeorge syndrome critical region gene 8 (DGCR8), a double-
stranded RNA binding protein (dsRBP) (Gregory et al., 2004). DGCR8 binds to 
the junction between the single-stranded and double-stranded region of the pri-
miRNA stem and directs DROSHA to cleave ~11bp away from this junction 
(Han et al., 2006). The Microprocessor complex also contains a variety of 
cofactors which may function to promote the fidelity, specificity and/or activity of 
DROSHA (Gregory et al., 2004). Whilst most pre-miRNAs are generated by this 
canonical pathway, some are produced by splicing and debranching of short 
hairpin introns, known as mirtrons (Fig.1.5) (Okamura et al., 2007; Ruby et al., 
2007). 
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Fig. 1.5. MicroRNA biogenesis in mammalian cells. MicroRNAs (miRNAs) are processed 
from RNA polymerase II (RNAPII)-specific transcripts of independent genes or from introns of 
protein-coding genes. In the canonical pathway, primary miRNAs (pri-miRNAs) are cleaved by 
Drosha, with the assistance of DGCR8, to generate the ~70nt precursor miRNA (pre-miRNA) 
hairpin. However, some pre-miRNAs bypass this step as they are produced from very short 
introns (mirtrons) by splicing and debranching of precursor mRNA transcripts. The pre-miRNA is 
exported from the nucleus by Exportin 5 and then processed further by Dicer, with the 
assistance of the dsRBP TRBP, to generate a ~20bp mature miRNA duplex (miRNA/miRNA*). 
In mammals argonaute 2 (AGO2) can cleave the 3’ arm of the pre-miRNA to form a processing 
intermediate called AGO2-cleaved pre-miRNA (ac-pre-miRNA). One strand of the mature 
miRNA duplex (the guide strand) is preferentially incorporated into the miRNA-induced silencing 
complex (miRISC). Diagram adapted from Krol and Loedige, 2010. 
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The pre-miRNA generated by DROSHA cleavage has a characteristic 2 nt 3’ 
overhang. Exportin-5 (XPO5) recognises this overhang and transports the pre-
miRNA into the cytoplasm via a Ran-GTP-dependent mechanism (Fig 1.5) (Yi 
et al., 2003). Upon entering the cytoplasm the pre-miRNA is cleaved by a 
second RNase III enzyme, DICER1 (Bernstein et al., 2001). This forms a 
miRNA duplex of approximately 22bp, known as the mature miRNA, which is 
loaded onto an Argonaute (AGO) protein, such as argonaute 2 (AGO2) (Fig. 
1.5) (Kim et al., 2009). DICER is assisted in this process by another dsRBP, 
TAR RNA binding protein 2 (TARBP2), also known as TRBP. This dsRBP is not 
required for pre-miRNA cleavage but recruits DICER to AGO2 and is required 
for the formation of the miRNA-induced silencing complex (miRISC) 
(Chendrimada et al., 2005; Haase et al., 2005; Lee et al., 2006). Some pre-
miRNAs are cleaved on the 3’ arm by AGO2, before being passed on for further 
DICER processing (Diederichs and Haber, 2007). This forms an additional 
processing intermediate called AGO2-cleaved precursor miRNA (ac-pre-
miRNA) (Fig 1.5).  
 
After AGO-loading, one strand of the mature miRNA duplex is degraded (the 
passenger strand or miRNA*), whilst the strand with the least stable 5’ end (the 
guide strand) is preferentially incorporated into miRISC (Khvorova et al., 2003). 
However, passenger strands can also be loaded into miRISC to function as 
miRNAs (Ghildiyal et al., 2010). The guide strand directs miRISC to the 3’UTRs 
of target mRNAs, leading to their subsequent silencing (Kim et al., 2009).  
 
1.5.3 Target recognition 
The majority of miRNA target sites are found within the 3’UTR of target mRNAs, 
which is explained by the inhibition of miRISC association by active translation 
(Gu et al., 2009). The main basis for miRNA target recognition is conserved 
Watson and Crick base pairing between the miRNA seed region (nucleotides 2-
7) and the target site (Brennecke et al., 2005; Krek, 2005; Lewis et al., 2003; 
Lewis et al., 2005). This explains why the 5’ portion of the miRNA is the most 
conserved region across metazoan miRNAs (Lewis et al., 2005; Lim et al., 
2005). Target recognition is impaired if there are any mismatches or G:U base 
pairings between the seed region and the target site, whilst an adenosine at 
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position 1 of the target site has been shown to increase efficacy, although it 
does not necessarily have to be paired with the miRNA (Lewis et al., 2005). An 
optimal target site contains the seed match, augmented by both the additional 
adenosine at position 1 and base pairing to nucleotide 8 of the miRNA 
(Brennecke et al., 2005; Krek, 2005; Lewis et al., 2003; Lewis et al., 2005). 
Although complementarity outside the seed region is not essential, base pairing 
at nucleotides 13-16 of the miRNA can improve target identification and 3’ 
complementarity has been shown to compensate for single-nucleotide bulges or 
mismatches within the seed (Brennecke et al., 2005; Friedman et al., 2009).  
 
Several additional factors besides complementarity have been shown to affect 
target recognition. Target sites located at either end of a 3’UTR are known to be 
more effective than those in the middle, although the first 15nt downstream of 
the stop codon is inhospitable for targeting (Grimson et al., 2007). The 
nucleotides surrounding functional sites have been found to be enriched in 
adenosine or uracil, when compared to non-functional sites (Grimson et al., 
2007). Finally, target sites which are surrounded by secondary RNA structures 
are less favourable because they cannot be easily accessed by miRISC 
(Kertesz et al., 2007). 
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Figure 1.6. Suggested mechanisms of miRNA-mediated silencing. (Top) mRNAs which are not subject to repression recruit initiation factors (eIF6, eIF4F and 
PABP1) and ribosomal subunits (60S and 40S) to form circularised structures that enhance translation. (Upper left) miRISC can inhibit translation initiation at the cap 
recognition stage by competing for cap binding. (Lower left) Translation initiation can also be prevented by miRISC at the 60S recruitment stage. (Bottom) miRISC 
binding can induced deadenylation of the mRNA by CCR4, CAF1 and NOT. This prevents circularisation of the mRNA. (Lower right) Inhibition of translation 
elongation can occur due to miRISC promoting the drop-off of ribosomes. (Upper right) Deadenylation of the mRNA and decapping by Dcp1 leads to mRNA 
degradation. eIF6: eukaryotic translation initiation factor 6; eIF4F: eukaryotic translation initiation factor 4F; PABP1: poly-A binding protein 1; CAF1: chromatin 
assembly factor 1; Dcp1: decapping enzyme 1. Diagram from Carthew and Sontheimer, 2009. 
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1.5.4 Mechanisms of silencing 
The mediator of miRNA-induced silencing, miRISC, is composed of the miRNA 
guide strand, an AGO protein, GW182 and various subsidiary proteins involved 
in regulation and assembly (Carthew and Sontheimer, 2009).  GW182 has been 
found to be both necessary and sufficient for AGO/miRNA directed silencing; 
therefore, miRNA-bound AGO in association with GW182 are considered the 
minimum requirements for a functioning miRISC (Ding and Groszhans, 2009; 
Eulalio et al., 2008; Jakymiw et al., 2005; Liu et al., 2005). Much debate still 
abounds in the literature regarding the predominant method of miRNA-mediated 
silencing and to what extent these methods may co-exist. If there is complete 
complementarity between the entire miRNA and the target, mRNA degradation 
has been observed and attributed to the RNase H activity of AGO (only AGO2 
in mammals) (Hutvágner and Zamore, 2002; Liu et al., 2004). This was 
considered the dominant mechanism in plants (Jones-Rhoades et al., 2006). 
Where complete complementarity is lacking, silencing was said to occur via 
inhibition of translation. It is now thought that the default mechanism in both 
plants and animals is translational repression, although exactly how this occurs 
and whether it involves mRNA destabilisation has not been defined (Carthew 
and Sontheimer, 2009).  
 
Inhibition of translation initiation is commonly given as the mechanism 
underlying translational repression. Three models for this have dominated until 
recently: competition between miRISC and eukaryotic translation initiation factor 
4E (eIF4E) for binding to the mRNA 5’ cap structure; deadenylation of the 
mRNA tail to prevent mRNA circularisation; recruitment of eukaryotic translation 
initiation factor 6 (eIF46) by miRISC to block the association between the 60S 
ribosomal subunit and the 40S pre-initiation complex (Fig. 1.6) (Carthew and 
Sontheimer, 2009). Now, eukaryotic translation initiation factor 4A2 (eIF4A2) 
has been highlighted as the key factor through which miRISC blocks translation 
(Meijer et al., 2013). Additionally, miRISC may also prevent translation 
elongation by promoting premature disassociation of ribosomes from the mRNA 
transcript (Fig. 1.6) (Carthew and Sontheimer, 2009).  
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Whilst some targets can be repressed without detectable changes in mRNA 
levels, those which are translationally repressed by more than a third also 
display clear mRNA destabilisation and it has been argued that this is the 
predominant cause of reduced protein output (Baek et al., 2008; Guo et al., 
2010). The increase in mRNA degradation caused by some miRNAs has been 
attributed to deadenylation, decapping and exonucleolytic digestion (Behm-
Ansmant et al., 2006; Giraldez et al., 2006; Wu et al., 2006). It has not yet been 
definitively determined whether increased mRNA degradation occurs 
independently of or as a consequence of translational inhibition; however recent 
findings point towards the latter scenario (Carthew and Sontheimer, 2009; 
Meijer et al., 2013).  
 
1.5.5 Role in angiogenesis 
Disruption of DICER and DROSHA has been shown to impair both embryonic 
and postnatal angiogenesis and reduce angiogenic behaviour in HUVEC in vitro 
(Kuehbacher et al., 2007; Suarez et al., 2007; Suarez et al., 2008; Yang et al., 
2005). These findings suggest that miRNAs play a key role in regulating 
endothelial cell behaviour and are crucial for successful angiogenesis. Defined 
as “angiomiRs”, many different miRNAs have now been identified as regulators 
of angiogenesis (Table 1.1) (Wang and Olson, 2009). These include both pro- 
and anti-angiogenic miRNAs. For example, miR-126 is required for vascular 
development in both zebrafish and mouse embryos (Fish et al., 2008; Wang et 
al., 2008).  Reduced or ablated miR-126 expression resulted in haemorrhaging 
and embryonic lethality due to a loss of vascular integrity, phenotypes which 
resemble the defects seen following VEGF signalling inhibition (Fish et al., 
2008; Wang et al., 2008). It was determined that the functional targets of miR-
126 in these systems are the negative regulators of VEGF, sprouty-related 
EVH1 domain containing 1 (SPRED1) and phosphoinositide-3-kinase regulatory 
subunit polypeptide 2 (PIK3R2) (Fish et al., 2008; Wang et al., 2008). 
Additionally, it has been shown that miR-126 is upregulated by the transcription 
factor Klf2 in response to shear stress (Nicoli et al., 2010). The subsequent 
downregulation of spred1 results in activation of Vegf signalling which is 
required for aortic arch remodelling during zebrafish development (Nicoli et al., 
2010).    
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miRNA Angiogenic function Relevant gene targets References 
let-7 
Promotes endothelial cell proliferation and motility. 
Hypoxia induced.  
TIMP1 and AGO1 (Chen et al., 2013; Otsuka et al., 2008) 
miR-1 and miR-206 
Negatively regulate angiogenesis during zebrafish 
development. 
vegfaa (Stahlhut et al., 2012) 
miR-10 
Promotes VEGFR2 signalling during zebrafish 
development. 
flt1 (Hassel et al., 2012) 
miR-106/107 
Promotes angiogenesis by releasing VEGF from AGO1-
mediate suppression. Hypoxia induced. 
AGO1 (Chen et al., 2013) 
miR-15a Overexpression in tumour cells inhibits angiogenesis. VEGFA (Sun et al., 2013) 
miR-15b Hypoxia regulated miRNA. VEGFA (Hua et al., 2006) 
miR-16 
Overexpression in tumour cells inhibits angiogenesis. 
Hypoxia regulated miRNA.  
VEGFA (Hua et al., 2006; Sun et al., 2013) 
miR-17~92 cluster 
Contradictory pro- and anti-angiogenic reports. miR-20a 
and miR-20b regulated by hypoxia.  
CTGF; THBS1; TIMP1; ITG5A; 
JAK1; MAP2K3; KDR 
(Bonauer et al., 2009; Dews et al., 2006; Doebele et al., 2010; Otsuka 
et al., 2008; Pin et al., 2012; Suarez et al., 2008; Yin et al., 2013) 
miR-125b & miR-
199a 
Overexpression inhits tumour-induced angiogenesis. HER2 and HER3 (He et al., 2013) 
miR-126 Required for vascular integrity and angiogenesis in vivo.  SPRED1 and PIK3R2  
(Fish et al., 2008; Kuhnert et al., 2008; Nicoli et al., 2010; Wang et al., 
2008) 
miR-130a 
Antagonises the anti-angiogenic activity of GAX and 
HOXA5. 
GAX and HOXA5 (Chen and Gorski, 2008) 
miR-132 Induces pathological neovascularisation . RASA1 (Anand et al., 2010) 
miR-145 Inhibits tumour angiogenesis. NRAS and VEGFA (Zou et al., 2012) 
miR-155 Promotes tumour angiogenesis VHL (Kong et al., 2013) 
miR-210 
Enhances angiogenesis and survival response to hypoxia 
in vitro.  
EFNA3 (Fasanaro et al., 2008; Pulkkinen et al., 2008) 
miR-218 Essential for normal vascularisation of the retina. ROBO1, ROBO2 and GLCE (Small et al., 2010) 
miR-2188 
Overexpression disrupts ISV development in zebrafish 
embryos. 
nrp2a (Soares et al., 2012) 
miR-221/222 
Impair SCF-induced angiogenesis in vitro but required for 
tip cell proliferation and migration in vivo.  
KIT (Nicoli et al., 2012; Poliseno et al., 2006) 
miR-27a/b 
Promotes angiogenesis during zebrafish development but 
inhibits tumour angiogenesis. 
sema5a, spry2, dll4 and VEGFC (Biyashev et al., 2011; Urbich et al., 2012; Ye et al., 2013) 
miR-29a Regulates the angiogenic properties of HUVEC HBP1 and PTEN (Wang et al., 2013a; Yang et al., 2013) 
miR-296 Required for tumour angiogenesis. HGS (Würdinger et al., 2008) 
miR-320 
Inhibition improves angiogenesis in diabetic endothelial 
cells. 
IGF1 (Wang et al., 2013b) 
miR-378 Promotes tumour angiogenesis. SUFU and FUS (Lee et al., 2007) 
miR-503 Inhibits tumour angiogenesis FGF2 and VEGFA (Zhou et al., 2013) 
miR-93 Promotes angiogenesis. ITGB8 (Fang et al., 2011) 
Table 1.1. miRNAs that have been shown to modulate the angiogenic response. Gene targets have been given using the nomenclature of the species in which 
they were identified.  
65 
 
Conversely, miR-1 and miR-206 have been identified as anti-angiogenic 
miRNAs as they inhibit vegfaa during zebrafish development to negatively 
regulate angiogenesis in muscle (Stahlhut et al., 2012). For some miRNAs the 
data is more confusing. The miRNA family members miR-221 and miR-222 
were originally identified as negative regulators of angiogenesis in vitro because 
they target KIT, thereby inhibiting the angiogenic activity of stem cell factor 
(SCF) and preventing HUVEC tube formation (Poliseno et al., 2006). However, 
it has recently been shown that knockdown of miR-221 but not miR-222 
reduces tip cell migration and proliferation during ISV development in zebrafish 
embryos, an exact phenocopy of flt4 knockdown (Nicoli et al., 2012). It was 
demonstrated that miR-221 promotes tip cell behaviour by targeting cyclin 
dependent kinase inhibitor 1b (cdkn1b), and phosphoinositide-3-kinase 
regulatory subunit 1 (pik3r1), which control endothelial proliferation and 
migration respectively. Alongside those miRNAs which have been shown to 
regulate physiological angiogenesis, many miRNAs have been identified as 
mediators of pathological angiogenesis (Anand et al., 2010; Fang et al., 2011; 
He et al., 2013; Lee et al., 2007; Sun et al., 2013; Ye et al., 2013; Zhou et al., 
2013; Zou et al., 2012). 
 
1.5.6 MicroRNA expression in KLEC 
Many studies have revealed important roles for miRNAs in regulating 
endothelial cell function, especially during angiogenesis (Anand et al., 2010; 
Biyashev et al., 2011; Bonauer et al., 2009; Chen and Gorski, 2008; Fang et al., 
2011; Fasanaro et al., 2008; Fish et al., 2008; Lee et al., 2007; Poliseno et al., 
2006; Suarez et al., 2008; Urbich et al., 2012; Wang et al., 2008), however the 
full extent of miRNA involvement in vascular biology has yet to be determined. 
KSHV infection of endothelial cells, including LEC, is a tractable model to study 
endothelial cell biology (Mesri et al., 2010; Wang et al., 2004).  
 
The miRNA signature of KLEC was previously described by this laboratory 
(Lagos et al., 2010) and the GEM data from this study has been used to 
establish lists of miRNAs which are upregulated or downregulated upon KSHV 
infection of LEC (Tables 1.2 and 1.3). This work has already revealed that 
several miRNAs which enhance KSHV gene expression are upregulated within 
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the first 6h post-infection (p.i.). These include miR-132, which is induced by 
cAMP response element-binding protein (CREB) and promotes KSHV 
replication by inhibiting the expression of interferon-stimulated genes (Lagos et 
al., 2010). It is known that KSHV infection of LEC alters the expression of many 
pro- and anti-angiogenic factors (Vart et al., 2007). The miRNA GEM data of 
KLEC provides a valuable resource which may allow miRNAs to be identified 
that directly regulate these angiogenic factors. 
 
1.5.7 Role in zebrafish development 
To date, 247 mature miRNAs have been identified in zebrafish (miRBase v19, 
Aug 2012). Expression of these miRNAs begins in the zebrafish embryo at 4 hpf 
and displays variable temporal and spatial patterns (Chen et al., 2005; 
Wienholds et al., 2005). Zebrafish defective in miRNA processing due to dicer1 
knockout arrest during the larval stage, indicating that correct miRNA 
expression is critical for the developmental programme (Wienholds et al., 2003). 
A certain level of miRNA processing is actually maintained in dicer1 knockout 
embryos due to residual Dicer from the maternal gamete (Wienholds et al., 
2003). When this pool of Dicer was eliminated, embryonic defects were evident 
at a much earlier stage of development (Giraldez et al., 2005). Zebrafish 
miRNAs are now known to be involved in a diverse range of developmental 
processes including clearance of maternal mRNAs, germ cell migration, cardiac 
patterning, erythropoiesis and angiogenesis (Dore et al., 2008; Giraldez et al., 
2006; Morton et al., 2008; Staton et al., 2011; Urbich et al., 2012). 
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MicroRNA LEC #1 LEC #2 LEC #3 LEC #4 KLEC #1 KLEC #2 KLEC #3 KLEC #4 Av LEC Av KLEC Fold ∆ 
 hsa-miR-193a 2.680585 1.348849 2.132635 1.219923 4.859499 4.645699 4.986489 4.307769 1.85 4.70 7.232 
hsa-miR-132 1.826182 1.722629 3.400029 2.246356 4.986564 5.145566 5.221302 4.696019 2.30 5.01 6.559 
hsa-miR-31 3.05232 2.425748 2.541032 3.051801 5.106421 4.744857 5.39024 5.181373 2.77 5.11 5.056 
hsa-miR-338 1.084668 1.028672 0.769259 1.691475 3.762336 2.467751 3.866759 2.619417 1.14 3.18 4.100 
hsa-miR-210 2.951988 2.294344 3.007216 2.361736 4.488102 4.257033 4.711666 4.087814 2.65 4.39 3.323 
hsa-miR-95 -0.47737 0.521868 0.634429 0.423345 2.148923 0.994032 2.826692 1.712227 0.28 1.92 3.127 
hsa-miR-7 1.064877 0.714747 2.659138 0.239624 2.783792 2.663663 3.45435 2.260789 1.17 2.79 3.076 
hsa-miR-503 0.843835 0.305265 1.301496 0.890123 2.913552 1.293139 3.28055 2.168257 0.84 2.41 2.987 
hsa-miR-487b 2.918355 1.536502 3.630647 1.877718 3.954395 3.398166 4.47727 3.853369 2.49 3.92 2.694 
hsa-miR-455 -0.15252 -0.76701 1.079673 0.092445 1.360908 0.241524 1.708958 1.740183 0.06 1.26 2.297 
hsa-miR-155 4.511507 4.246431 4.980054 4.2406 5.645527 5.615625 5.751856 5.64262 4.49 5.66 2.249 
hsa-miR-582 2.625819 2.51956 2.94155 2.922895 4.051159 3.120076 4.29004 4.003197 2.75 3.87 2.164 
hsa-miR-432 1.07585 0.887918 1.069105 1.247066 2.66177 1.762803 2.831428 1.334421 1.07 2.15 2.111 
hsa-miR-663 4.279541 3.716615 3.917612 4.328053 5.424328 4.86849 5.44294 4.804473 4.06 5.14 2.106 
hsa-miR-495 1.119139 0.598585 2.475687 1.377378 3.133842 1.909225 3.703947 0.786906 1.39 2.38 1.987 
hsa-miR-557 1.114524 -0.1702 1.55363 -0.83023 1.263937 1.458058 1.089999 1.507333 0.42 1.33 1.883 
hsa-miR-329 0.213809 0.209639 0.701756 0.70124 0.756478 0.63174 1.871883 2.055166 0.46 1.33 1.830 
hsa-miR-501 2.256172 1.45594 1.236825 1.490307 3.385179 2.413441 2.88236 1.009389 1.61 2.42 1.757 
hsa-miR-365 5.212407 5.252085 5.766608 5.452514 6.235574 6.267207 6.379127 6.043093 5.42 6.23 1.754 
hsa-miR-629 1.952087 0.760611 1.140278 1.398318 2.721102 1.756193 2.604975 1.316302 1.31 2.10 1.725 
hsa-miR-148a 0.981573 0.69433 1.731296 2.50495 2.107042 1.570001 3.108787 2.257229 1.48 2.26 1.720 
hsa-miR-136 0.549913 0.624604 0.951379 1.146028 2.181421 0.684636 2.130751 1.324116 0.82 1.58 1.696 
hsa-miR-140 3.705566 2.889446 3.405749 3.494798 4.416159 3.67074 4.531536 3.794439 3.37 4.10 1.658 
hsa-miR-212 -0.24741 -0.28662 0.565864 0.491734 0.552387 0.182662 1.53361 0.941824 0.13 0.80 1.593 
hsa-miR-126 11.79386 12.28393 12.62988 12.43303 12.97338 12.93326 13.10441 12.77123 12.29 12.95 1.581 
hsa-miR126* 8.503008 8.862253 9.34826 9.164389 9.749109 9.55634 9.778365 9.40407 8.97 9.62 1.572 
hsa-let-7i 8.261037 8.46942 8.945643 8.797333 9.298967 9.246797 9.441158 9.07973 8.62 9.27 1.567 
hsa-miR-191 4.511201 3.530955 4.415651 4.449697 4.363172 4.996688 5.428358 4.706812 4.23 4.87 1.566 
hsa-miR-454-3p 2.638055 3.67882 3.769802 1.958927 3.888756 3.658129 3.945975 3.11072 3.01 3.65 1.558 
hsa-miR-154 0.96864 0.203599 1.264911 1.026298 2.010604 0.563313 2.118836 1.290996 0.87 1.50 1.548 
hsa-miR-146b -0.12688 -0.18904 0.149139 0.009727 -0.05114 0.004417 1.321537 1.077401 -0.04 0.59 1.545 
hsa-miR-197 3.387481 2.977609 2.904873 2.558075 3.939771 3.213227 4.146544 2.990909 2.96 3.57 1.532 
hsa-miR-532 2.284251 1.5454 2.146553 1.970761 2.813261 1.899087 3.751636 1.939672 1.99 2.60 1.531 
hsa-miR-584 4.387312 4.405568 4.316232 4.113335 4.928368 4.834093 5.272319 4.565755 4.31 4.90 1.510 
hsa-miR-26a 4.227413 3.662418 3.794291 3.76195 4.457494 4.395531 4.704057 4.25933 3.86 4.45 1.508 
hsa-miR-424 5.227224 5.298026 6.117461 5.822627 6.159354 6.100451 6.415259 6.148446 5.62 6.21 1.505 
hsa-miR-98 5.009131 4.808316 5.96523 5.365574 5.9372 5.77703 6.067952 5.719232 5.29 5.88 1.503 
hsa-miR-602 0.935123 0.481353 1.921405 0.290319 2.180026 0.863426 1.9827 0.943806 0.91 1.49 1.500 
Table 1.2. miRNAs upregulated by 1.5 fold or greater 72 h post-KSHV infection of LEC. Raw data with normalisation applied were obtained from Dr Dimitrios 
Lagos (Lagos et al., 2010). Orange shading: scatter plots of PITA score against TargetScan 4.2 score were generated for these miRNAs. All other miRNAs lacked a 
PITA prediction when the target prediction analysis was conducted.  
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MicroRNA LEC #1 LEC #2 LEC #3 LEC #4 KLEC #1 KLEC #2 KLEC #3 KLEC #4 Av LEC Av KLEC Fold ∆ 
hsa-miR-99a 7.75816 8.19896 8.255226 8.333136 5.904055 5.91338 6.169641 5.987195 8.14 5.99 0.226 
hsa-miR-100 7.117643 7.354377 7.668636 7.654211 5.648484 5.447821 5.856828 4.915421 7.45 5.47 0.253 
hsa-miR-125b 8.369381 8.73544 8.940254 8.90634 6.897136 6.898805 6.989951 6.868966 8.74 6.91 0.282 
hsa-miR-30b 5.752814 6.040285 6.277433 6.403999 5.020121 4.041641 4.798868 3.698623 6.12 4.39 0.302 
hsa-miR-204 5.169028 5.270195 5.910926 5.449812 4.075009 3.563922 4.426569 2.893307 5.45 3.74 0.306 
hsa-miR-370 7.755948 7.689458 7.452195 7.978741 6.392429 6.209713 6.257599 5.946771 7.72 6.20 0.349 
hsa-miR-513 9.629476 9.339348 9.220378 9.884403 8.075828 7.980795 8.052207 7.949746 9.52 8.01 0.353 
hsa-miR-494 9.738636 9.73343 9.534111 10.05253 8.462424 8.291642 8.302319 8.218959 9.76 8.32 0.367 
hsa-miR-662 1.936784 1.117238 0.83947 2.334613 -0.11655 0.607197 0.23713 -0.12217 1.56 0.15 0.377 
hsa-miR-194 0.726481 1.852902 1.196585 1.946435 -0.05184 -0.44083 1.248264 -0.03137 1.43 0.18 0.421 
hsa-miR-801 4.608255 4.382871 4.324151 4.286356 3.565071 2.628404 4.032369 2.510842 4.40 3.18 0.430 
hsa-miR-30d 7.30378 7.606504 7.614802 7.784246 6.477977 6.312494 6.491982 6.309793 7.58 6.40 0.442 
hsa-miR-452 4.622719 4.552408 4.704417 4.348523 3.820566 3.076603 3.96439 2.684721 4.56 3.39 0.444 
hsa-miR-630 6.08186 5.880151 5.676642 6.027922 4.885628 4.520204 4.993346 4.658047 5.92 4.76 0.450 
hsa-miR-30a 8.711069 9.089672 9.098668 9.252089 8.006361 7.853047 8.041136 7.739246 9.04 7.91 0.458 
hsa-miR-361 5.515045 5.992441 6.13191 5.963497 4.995938 4.662561 4.980153 4.654313 5.90 4.82 0.474 
hsa-miR-30a* 4.266807 3.932265 4.182892 4.381878 3.290315 2.316618 4.139584 2.854637 4.19 3.15 0.486 
hsa-miR-221 8.128872 8.255769 8.476395 8.602289 7.348709 7.266235 7.575209 7.247093 8.37 7.36 0.498 
hsa-miR-30c 5.999949 5.952153 6.237855 6.224468 5.304869 5.059418 5.321078 4.748576 6.10 5.11 0.502 
 
Table 1.3. miRNAs downregulated by 50% or more 72 h post-KSHV infection of LEC. Raw data with normalisation applied were obtained from Dr Dimitrios 
Lagos and was generated for his paper (Lagos et al., 2010). 
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1.6 Thesis aims 
The angiogenic characteristics of KS and the targeting of endothelial cells by 
KSHV mean that changes in endothelial cells following infection may provide 
further insight into signalling networks that are important for endothelial 
regulation and function. Previous identification of the cellular miRNA expression 
signature following KSHV infection has provided an invaluable tool with which to 
begin investigating novel regulatory pathways in endothelial cells (Lagos et al., 
2010). It was hypothesised that KSHV infection of endothelial cells leads to 
alterations in the expression of miRNAs that are involved in the regulation of 
endothelial cell function, particularly angiogenesis. The aim of this thesis was to 
identify such miRNAs, determine their relevant target/s and to explore the 
functional consequences of this targeting, both in vitro and in vivo. The specific 
aims of each chapter are detailed below. 
 
Aims of Chapter 3 
 To identify miRNAs which target genes implicated in angiogenesis. 
 To select a target and it’s predicted regulatory miRNA for further 
investigation. 
 
Aims of Chapter 4 
 To determine whether the selected target from Chapter 3 is a genuine 
target of the miRNA predicted to regulate its expression. If this is 
confirmed, secondary aims would be: 
o To identify the specific target site(s) through which the miRNA 
regulates the expression of its target. 
o To investigate the relevance of the miRNA/target regulatory axis 
on endothelial cell biology in vitro.  
 
Aims of Chapter 5 
If a functioning miRNA/target pair is identified through in vitro studies in Chapter 
4, the aims of this chapter would be: 
 To confirm targeting in a suitable in vivo model. 
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 To ascertain whether overexpression and/or inhibition of the miRNA has 
an effect on endothelial cell behaviour in vivo. If a phenotype is 
characterised, a secondary aim would be: 
o To investigate whether this phenotype is due to mis-regulation of 
the target mRNA of interest or can be attributed to another target.    
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Chapter 2. Materials and Methods 
2.1 Cell Culture 
All cells were cultured using a CB 53 incubator (Binder) at 37°C with 5% CO2 in 
a humid environment. 
 
2.1.1 Lymphatic endothelial cells 
Lymphatic endothelial cells (LEC) of human dermal origin were purchased from 
Promocell. These cells were confirmed as LEC using qRT-PCR analysis and 
staining for lymphatic-specific markers including podoplanin (PDPN), lymphatic 
vessel endothelial hyaluronan receptor 1 (LYVE1) and prospero homeobox 1 
(PROX1). LEC were purchased at passage 0 then expanded and used for 
experiments between passages 2 to 8. LEC were cultured on T75 flasks (TPP, 
MIDSCI) in 10 ml of Endothelial Cell Growth Medium MV (Promocell) which was 
supplemented with 10 ng/ml of VEGFC (R&D Systems) and changed every 48 
h.  
 
LEC were split 1:3 or 1:4 when a confluency of 70-80% was reached 
(approximately 1.5-2x106 cells per T75 flask). The cells were washed with 
phosphate buffered saline (PBS) (Sigma-Aldrich) and then incubated for 3 to 4 
min at 37°C with 5 ml of 0.01% trypsin-EDTA, which was made by diluting 
0.05% trypsin-EDTA (Gibco, Life Technologies) 1:5 with PBS. Once the majority 
of cells had detached from the flask the trypsin-EDTA was quenched by the 
addition of an equal volume of LEC media. Cells were collected and then 
pelleted by centrifugation for 5 min at 1200 rpm. LEC were resuspended in LEC 
media and then seeded at a density of ~5x105 cells per T75 flask. 
 
2.1.2 Human umbilical vein endothelial cells 
HUVEC were purchased from Promocell at passage 0 then expanded and used 
for experiments between passages 2 to 8. HUVEC were cultured on T75 flasks 
in 10 ml of Endothelial Cell Growth Medium MV2 which was changed every 48 
h. HUVEC were split 1:4 using the same method as described for LEC (see 
2.1.1). 
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2.1.3 Immortalised human fibroblasts 
Human fibroblasts (HF) were previously immortalised using a retrovirus to 
introduce the catalytic subunit of human telomerase (hTERT) (Funes et al., 
2007). These immortalised human fibroblasts (HF1) were cultured on T75 flasks 
in 10 ml of Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, Life 
Technologies) containing 10% Foetal Bovine Serum (FBS) (Sigma-Aldrich).  
 
HF1 were split 1:10 every 2 to 3 days when a confluency of 80-90% was 
reached. The cells were washed with PBS and then incubated for 5-10min at 
37°C with 5 ml of 0.05% trypsin-EDTA. Once the cells had detached from the 
flask the trypsin-EDTA was quenched by the addition of an equal volume of 
DMEM. Cells were collected and then pelleted by centrifugation for 5 min at 
1200 rpm. HF1 were resuspended in DMEM media and then seeded in T75 
flasks at a density of ~1x106 per T75 flask. 
 
HF1 conditioned endothelial media was obtained by incubating cells for 48 h 
with Endothelial Cell Growth Medium MV2 and then passing the media through 
a 0.2 μm filter (Nalgene,Thermo Scientific) to remove any cell debris. The 
filtered supernatant was immediately used for the 3-D in vitro sprouting assay 
as described in 2.7.2. 
 
2.1.4 BCBL-1 cells 
BCBL-1 cells are a PEL derived cell line which are EBV-negative but are 
latently infected with a green fluorescent protein (GFP)-expressing KSHV, 
which also confers resistance to G418 (Geneticin) (Vieira et al., 2001). BCBL-1 
cells were grown in suspension in RPMI 1640 medium (Gibco, Life 
Technologies) containing 10% FBS and supplemented with 400 ng/ml of 
Geneticin (Gibco, Life Technologies). Cells were standardly grown in T75 flasks 
in 25ml of media at densities in the range of 2.5-6x105 cells/ml. Cells were split 
1:5 every 2 to 3 days by adding 5 ml of the suspension culture to 20 ml of fresh 
media.  
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2.1.5 293T cells 
293T cells were cultured on T75 flasks in 10 ml of DMEM containing 10% FBS. 
Cells were split 1:10 every 2 to 3 days when a confluency of 80-90% was 
reached using the same method as described for HF1 cells (see Section 2.1.3).  
 
2.1.6 Freezing and thawing cells 
The following procedure was used to cryogenically store all cell types used. Live 
cell pellets were resuspended in FBS containing 10% dimethyl sulphoxide 
(DMSO). The cell suspension was aliquoted into cryovials, which were insulated 
in polystyrene containers and placed at -80°C for 48 h before being transferred 
into liquid nitrogen for long term storage.  
 
Frozen cells were recovered by placing a frozen cryovial into a 37°C water bath 
until thawed. For LEC and HUVEC, the thawed cell suspension was placed into 
a T75 flask containing 10 ml of the appropriate media (pre-warmed). After 5 h 
the media was removed and 10 ml of fresh media was added. For all other 
cells, the thawed cell suspension was added to 10 ml of the appropriate pre-
warmed media and then spun at 1200rpm for 5min. The supernatant was 
removed and the cell pellet was resuspended in the appropriate media and 
placed into a T75 flask or 10 cm dish.  
 
2.2 Transfection, virus production and infection 
2.2.1 DNA transfection of 293T cells 
Cells were seeded the day before transfection, with the density of the seeding 
varying according to the experiment, as specified in the text. DNA transfection 
of 293T cells was performed using FuGENE (Roche) according to the 
manufacturer’s instructions. FuGENE is a nonliposomal transfection reagent 
comprised of a mixture of lipids and other components, which facilitates DNA 
uptake by eukaryotic cells.  Prior to transfection, the media was removed from 
all wells or plates to be transfected and cells were washed twice with pre-
warmed Opti-MEM Reduced Serum Medium (Gibco, Life Technologies). An 
overlay of 400 μl, 800 μl or 8 ml was then added to a 12-well, 6-well or 10 cm 
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plate respectively. For every 1 μg of DNA to be transfected, 3 μl of FUGENE 
was prepared and this ratio was maintained, regardless of the number of cells 
being transfected. The DNA to be transfected was suspended in double distilled 
water (ddH2O), and made up to 12.5 μl, 25 μl or 50 μl with Opti-MEM in a 1.5 ml 
Eppendorf tube, depending on whether the transfection mixture was for a 12-
well, 6-well or 10 cm plate. In a separate 1.5 ml Eppendorf tube, FuGENE was 
added dropwise to Opti-MEM to give a final volume of 12.5 μl, 25 μl or 50 μl. 
The FuGENE/Opti-MEM mix was incubated at room temperature (RT) for 5 min 
before being added to the DNA mix to give a final volume of 25 μl, 50 μl or 100 
μl. The FuGENE/DNA mix was incubated for 20-30 min at RT. 25 μl, 50 μl or 
100 μl was then added dropwise to a 12-well, 6-well or 10 cm plate respectively. 
Mastermixes of DNA and/or FuGENE were prepared when more than one well 
or plate was to be transfected. The transfection media was removed 5 h after 
DNA addition and 1 ml, 2 ml or 10 ml of the appropriate fresh cell culture media 
was added. Cells were harvested 24, 48 or 72 h post-transfection.  
 
2.2.2 Lentivirus production and infection of LEC and HUVEC 
Vesicular stomatitis virus-G (VSV-G) envelope-pseudotyped lentivirus virions 
were produced by co-transfecting 1.5 μg of pMD.G plasmid (containing the 
VSV-G envelope gene) with 2 μg of lentiviral construct (pSIN-MCS or pCSGW) 
and 1.5 μg of the packaging plasmid p8.91 into a 10 cm plate of ~70% confluent 
293T cells using the FuGENE protocol described in Section 2.2.1. Five hours 
post-transfection, the Opti-MEM media was removed and 10 ml of fresh 293T 
media was added. Virus containing supernatants were harvested 48-60 h post-
transfection, passed through a 0.45 μM filter, aliquoted and then stored at -
80°C. Some lentiviral constructs always led to the production of lentiviral 
preparations with low infectivity. In these situations the virus containing 
supernatant was concentrated 10x by spinning for 5 h at 48,000 x g and 4°C 
using a Beckman JA-25.50 rotor in an Avanti J-26 XPI Centrifuge. After 
centrifugation the supernatant was poured off and the virus containing pellet 
was resuspended in LEC, HUVEC or 293T media at a ratio of 1 ml of media to 
one 10 cm plate of 293T cells. The supernatant was then aliquoted and stored 
at -80°C. 
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Standard lentiviral infections were performed by incubating 1x105 LEC or 
HUVEC, suspended in 0.5 ml of the appropriate media, with the required 
volume of lentivirus. The virus was removed either 5 h or 16 h p.i., once the 
cells had adhered to the plate, and 1 ml of fresh media was added per well of a 
6-well plate. Cells were harvested 72 h p.i. for genomic DNA, total RNA or 
protein extraction. Infectivity of lentiviral preparations was assessed by 
quantifying the level of lentiviral packaging signal using quantitative PCR 
(qPCR) (see Section 2.3.10). Expression of the lentiviral constructs was 
determined by quantifying the level of the gene of interest cloned into the 
lentiviral backbone using quantitative reverse transcriptase-PCR (qRT-PCR) 
(see Section 2.3.13). 
 
For lentiviral infections of LEC that would subsequently be infected with KSHV, 
7x104 cells were suspended in 0.5 ml of LEC media and incubated with 0.85 ml 
of pSIN_MCS, pSIN_30b or pSIN_30c. The virus was removed 5 h p.i. and 
replaced with 1 ml of LEC media. KSHV infection was performed 48 h after 
lentiviral infection. 
 
2.2.3 KSHV production and infection of LEC 
KSHV was produced from BCBL-1 cells which were latently infected with 
recombinant GFP-expressing KSHV (Vieira et al., 2001). For KSHV production, 
BCBL-1 cells were expanded to ~2.5 L which yielded ~11 ml of concentrated 
virus. Geneticin was omitted from the media during the expansion of the BCBL-
1 cultures. Expansion was conducted by transferring 25 ml of a confluent BCBL-
1 culture to a T150 flask (TPP, MIDSCI) containing 100 ml of BCBL-1 media 
(minus Geneticin). After 72 h ~375 ml of BCBL-1 media was added to the 
culture until a volume of 500 ml was obtained and then this was split into two 
T150 flasks, each containing 250 ml. After 48 h the cultures was split into five 
T150 flasks (100 ml in each) and ~400 ml of BCBL-1 media was added to each 
flask to obtain a total volume of ~2.5 L with a cell density of 5-6x105 cells/ml. 
Lytic replication of KSHV was induced by the addition of TPA (Sigma Aldrich) at 
a final concentration of 20 ng/ml. KSHV was harvested 3 to 4 days after the 
induction of lytic replication. The ~2.5 L culture was first centrifuged at 400 x g 
and 4°C for 15 min using a Beckman JLA-10.500 rotor in an Avanti J-26 XPI 
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Centrifuge (Beckman Coulter), which pelleted the majority of the cells and cell 
debris. The supernatant containing the virus was then poured into clean 
centrifuge tubes and spun at 12,500 x g and 4°C for 3 h. The supernatant was 
then poured off and neutralised using Virkon (Antec International) whilst the 
virus-containing pellets were resuspended in 12 ml of LEC media. The LEC 
media containing KSHV was then spun at 2000 rpm and 4°C for 10 min in an 
Eppendorf desktop centrifuge and the supernatant was passed through a 0.45 
μm filter to remove all traces of cell debris before being aliquoted and stored at -
80°C. LEC media from the same batch that was used to resuspend the virus 
was also frozen at the same time to be used for uninfected cells.  
 
293T cells were used to test the infectivity of each batch of KSHV. 2.5x104 293T 
cells were seeded in one well of a 12-well plate (TPP, MIDSCI) in 1 ml of 293T 
media. After 24 h the 293T media was removed, 500 μl of KSHV preparation 
was added to the well and the plate was spun at 2500 rpm for 30 min in an 
Eppendorf desktop centrifuge. 500 μl of 293T media was then added to the well 
and the cells were left for 24 h before changing the media for 1 ml of fresh 293T 
media. 72 h p.i., cells were visualised on an Axiovert 100 microscope (Zeiss) 
using an AxioCam (Zeiss). Provided more than 50% of 293T cells were GFP 
positive, KSHV preparations were then used to infect LEC. 
 
For standard KSHV infections of LEC, 1x105 cells were seeded per well of a 6-
well plate in 1 ml of LEC media. 24 h later, the LEC media was removed, 1 ml of 
KSHV preparation or thawed LEC media was added to the well and the plate 
was spun at 2500 rpm for 30 min in an Eppendorf desktop centrifuge. After 24 h 
the media was replaced with 1 ml of fresh LEC media per well. The media was 
replaced again 48 h p.i. and cells were harvested for total RNA extraction 72 h 
p.i. Infectivity was assessed both visually, using an Axiovert 100 fluorescent 
microscope (Zeiss), and by flow cytometry using a CyAn ADP High-
Performance Flow Cytometer (Beckman Coulter).  
 
For KSHV infections of pSIN_MCS, pSIN_30b and pSIN_30c transduced LEC, 
1 ml of KSHV preparation was added to cells 48 h after infection with the 
appropriate lentivirus. The plates were then spun at 2000 rpm for 10 min in an 
Eppendorf desktop centrifuge. After 24 h the media was replaced with 1 ml of 
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fresh LEC media per well. Cells were harvested for total RNA and protein 
extraction 48 h post-KSHV infection and 96 h after lentiviral infection. 
 
2.2.4 Transfection of LEC, HUVEC, or 293T cells with miRNA 
mimics, miRNA inhibitors or siRNA 
The following synthetic small RNAs were used for these transfections:  
miRIDIAN microRNA Mimics (Dharmacon, ThermoScientific), miRIDIAN 
microRNA Hairpin Inhibitors (Dharmacon, ThermoScientific) and ON-
TARGETplus siRNA Reagents (Dharmacon, ThermoScientific). The lyophilised 
small RNAs were resuspended in 1x siRNA buffer, made up with 5x siRNA 
buffer (Dharmacon, ThermoScientific) and sterile H2O (Gibco, Life 
Technologies), to give a working concentration of 10 μM for the mimics and 
inhibitors and 20 μM for the siRNAs.  
 
For LEC and HUVEC, cells were seeded at a density of 2.5x104 cells per well of 
a 12-well plate or 5x104 cells per well of a 6-well plate. For 283T, cells were 
seeded at a density of 5x104 cells per well of a 12-well plate. 16 h later the 
media was removed and cells were washed twice with pre-warmed Opti-MEM 
before an overlay of Opti-MEM was added to each well: 400 μl for a 12-well 
plate, 800 μl for a 6-well plate. Transfections were performed using 
Oligofectamine Transfection Reagent (Invitrogen, Life Technologies) according 
to the manufacturer’s instructions. For every 0.1 nmoles of small RNA to be 
transfected, 5 μl of Oligofectamine was prepared. This ratio was maintained, 
regardless of the number of cells being transfected. The required amount of 
small RNA was made up to 87.5 μl (12-well plate) or 175 μl (6-well plate) with 
Opti-MEM in a 1.5 ml Eppendorf tube. In a separate 1.5 ml Eppendorf tube, the 
required volume of Oligofectamine was added dropwise to Opti-MEM to give a 
total volume of 12.5 μl (12-well plate) or 25 μl (6-well plate). The 
Oligofectamine/Opti-MEM mix was incubated for 10 min at RT before being 
added to the diluted small RNA to give a final volume of 100 μl (12-well plate) or 
200 μl (6-well plate). The Oligofectamine/small RNA mix was incubated at RT 
for 20 min and then added dropwise to one well of a 12-well or 6-well plate 
containing the Opti-MEM overlay. Mastermixes of small RNA and/or 
Oligofectamine were prepared when more than one well was to be transfected. 
78 
 
0.75 ml (12-well plate) or 1.5 ml (6-well plate) of the appropriate media was 
added to each well 4 h post-transfection to neutralize the transfection reagent. 
The transfection media was completely removed 24 h post-transfection and the 
cells were washed with sterile PBS before fresh media was added.  
 
LEC and HUVEC were harvested 48 h post-transfection with mimics and/or 
inhibitors for total RNA and protein extraction. 293T cells were transfected with 
luciferase reporter plasmids 48 h post-transfection with mimics (see Sections 
2.2.1 and 2.6). LEC and HUVEC were harvested at 48 h and 72 h post-
transfection with siRNA for total RNA and protein extraction. LEC and HUVEC 
were collected 48 h post-transfection with siRNA to set-up the Matrigel tube 
formation assay (see Section 2.7.1). HUVEC were collected 24 h post-
transfection with mimics or inhibitors to set-up the Matrigel 3D sprouting assay 
(see Section 2.7.2).  
 
2.3 Molecular biology techniques 
2.3.1 PCR cloning strategy 
hsa-miR-30b, hsa-miR-30c-1 and the dll4 3’UTR were cloned using the 
following polymerase chain reaction (PCR) cloning strategy. Primers were 
designed against the 5’ and 3’ ends of the required DNA fragment. All primers 
were designed to end on at least one guanine or cytosine to increase binding 
affinity. Primers were designed so that each set of forward and reverse primers 
had a similar melting temperature (TM) and a guanine/cytosine (GC) content of 
around 50%. NCBI Blast was used to check that the primers were only specific 
to the DNA sequence of interest. These primers contained different restriction 
enzyme digestion sites at their 5’ ends, along with some “junk” DNA to aid 
restriction enzyme digestion. Two different restriction enzymes were used in the 
cloning process, this aided cloning of the fragment in the correct orientation and 
minimised vector re-ligation. The restriction enzymes to be used were selected 
based on three criteria. Firstly, two restriction enzymes were chosen that would 
allow insertion of the DNA fragment into the chosen vector at the correct 
location. When cloning the hsa-miR-30b or hsa-miR-30c-1 into pSIN_MCS, a 
variety of restriction enzymes were available due to the presence of the multiple 
79 
 
cloning site (MCS), immediately downstream of the internal promoter. The MCS 
is a collection of restriction enzyme sites which was inserted into a defined 
region of the vector during vector design in order to facilitate cloning. The 
pSIN_MCS vector is based on the pCSGW vector (Godfrey et al., 2005). To 
create the pSIN_MCS vector, the GFP ORF from the pCSGW vector was 
removed with BamHI and NotI and the MCS was inserted (Vart et al., 2007). 
When cloning the dll4 3’UTR into pCSGW, there was a more limited choice of 
restriction enzymes as the 3’UTR needed to be inserted directly downstream of 
the GFP ORF. Once two restriction enzymes were selected, the second 
criterion was that the DNA to be cloned could not contain restriction sites for 
either of the proposed enzymes. To check this, the DNA sequence to be cloned 
was obtained from the NCBI GenBank depository of sequenced DNA. This 
sequence was entered into pDRAW32 (www.acaclone.com) and examined in 
order to identify all restriction enzyme sites present within the sequence. If 
either of the two selected restriction enzymes had restriction sites within the 
DNA sequence, that particular enzyme could not be used and the vector was 
re-examined for an alternative enzyme. The third criterion was only considered 
if there was more than one option with regards to restriction enzyme 
combinations. In this situation, two enzymes were chosen which had the same 
or very similar digestion conditions (i.e. buffer), in order to increase the 
efficiency of co-digestion. The primers used are shown in Table 2.1. 
 
PCR was performed with 0.25 μl of 100 μM forward and reverse primers, 10 μl 
of 5x HotStar HiFidelity PCR Buffer (Qiagen) or 5 μl of 10x PCR Buffer 
(Qiagen), 1 μl of HotStar HiFidelity DNA Polymerase (2.5 units) (Qiagen) or 
0.25 μl of HotStarTaq DNA Polymerase (1 unit) (Qiagen) and 100 ng or 500 ng 
of template DNA made up to a final volume of 50 μl with ddH2O. When using 
HotStarTaq DNA Polymerase 1 μl of 10mM deoxyribonucleotide triphosphate 
(dNTP) mix (Invitrogen) was also required as these were not included in the 
buffer. For some reactions 10 μl of Q-Solution and/or 1 μl of MgSO4 were also 
included in an attempt to optimise the PCR conditions. The PCR conditions 
used were those specified by the manufacturer’s instructions. Typically, the 
polymerase was activated by incubating the reaction mixture at 95°C for 2-15 
min and was followed by 35-40 cycles of 94°C for 1 min, 55°C for 1 min and 
72°C for 1 min. During these steps double stranded DNA is denatured, the 
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primers anneal and PCR product is synthesised by DNA polymerase mediated 
extension from the primers. The final step was a 10 min hold at 72°C which 
ensured full elongation of any remaining single stranded DNA. The cycle 
number, primer annealing temperature and the length of the extension step 
were varied to optimise the PCR program for the particular combination of 
primers and PCR target. The extension time was dependent on the length of the 
product, with 1min being allowed for every 1 kb of DNA. The initial primer 
annealing temperature was set at 4°C lower than the TM of the primer with the 
lowest TM. If no product was produced, the annealing temperature was lowered 
by 1-2°C at a time. If non-specific products were synthesised, the annealing 
temperature was increased. On some occasions temperature gradient PCR was 
used as a quick method of determining the optimum primer annealing 
temperature.  With gradient PCR the annealing temperature was increased by 
specified increments from right to left across the PCR block. Gel electrophoresis 
was then performed with all samples and the annealing temperature which 
yielded the most amount of specific product was used for subsequent PCRs, if 
required. 
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Target Vector Construct Template 
Restriction 
enzymes 
Forward primer Reverse primer PCR conditions 
hsa-miR-30b pSIN_MCS pSIN_30b HF1 genomic DNA BamHI / NotI 
CGCGGATCCAGCCTGGGC
AATATAGTGAGAC 
ATAAGAATGCGGCCGCACT
ACTCCTACTGCAACCATGC 
35 cycles of: 
94°C for 1 min 
52-61°C gradient for 1 min 
72°C for 1 min 
hsa-miR-
30c-1 
pSIN_MCS pSIN_30c HF1 genomic DNA BamHI / NotI 
CGCGGATCCAGTTGGAGGC
AATCCACAGG 
ATAAGAATGCGGCCGCGAA
AGCTCTGTGGTCACTGAGG 
35 cycles of: 
94°C for 1 min 
52-61°C gradient for 1 min 
72°C for 1 min 
dll4 3’UTR pCSGW 
pCSGW_dll4-
3’UTR 
Whole Zebrafish 
embryo cDNA from 
48 hpf 
NotI / SbfI 
ATAAGAATGCGGCCGCATT
ACAGGCTGATGTCTATGAG
GAG 
AAATATCCTGCAGGAAACA
ATCCAAGAAGACCCTGGG 
35 cycles of: 
94°C for 1 min 
50.6-60°C gradient for 1 min 
72°C for 1 min 
 
Table 2.1. PCR cloning details. The pCSGW and pSIN-MCS vectors were generated by Richard Jenner and Richard Vart Godfery et al., 2005; Vart et al., 2007). 
Red: junk DNA; green: restriction enzyme site; blue: primer sequence which is complimentary to target sequence. All primers are shown 5’ to 3’. 
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2.3.2 Restriction enzyme digestion 
Restriction enzyme digestion was performed on PCR amplified products and 
plasmid DNA prior to ligation. Restriction enzyme digestion was also used to 
confirm the presence of a cloned insert within a plasmid. All restriction enzyme 
digests were performed for 1-2 h at 37°C, except for digestions with NotI which 
required overnight digestion at 37°C. Most restriction enzyme digests were 
double-digests where both restriction enzymes were added at the same time. 
For each restriction enzyme digest, 5-10 units of each enzyme was used in a 
total volume of 20-25 μl containing the appropriate amount of 10x restriction 
enzyme buffer. The appropriate buffer was selected by consulting the enzyme 
buffer compatibility charts provided by Promega and New England Biolabs and 
determining which buffer would obtain the maximum activity for the two 
enzymes. If the two enzymes were not compatible then two single digests were 
performed with the DNA being cleaned in between using the QIAquick Gel 
Extraction Kit (see Section 2.3.4). For some restriction enzymes the appropriate 
amount of 100x bovine serum albumin (BSA) (New England Biolabs) was also 
added to the reaction mixture. Approximately 1 μg of DNA was used per 
restriction enzyme digest. If required, the restriction enzymes were heat 
inactivated at the end of the restriction digestion by incubating the reaction 
mixture at 65°C for 20 min. 
 
Following restriction enzyme digestion, plasmids required for ligation were 
treated with calf-intestinal alkaline phosphatase (CIP) (New England Biolabs) in 
order to remove the 5’ phosphate groups. This helped to prevent re-
circularisation and re-ligation of the linearized plasmid because DNA fragments 
that lack the 5' phosphoryl termini cannot self-ligate. The plasmid DNA was 
incubated with 1 μl of CIP at 37°C for 1 h before undergoing agarose gel 
purification (see Sections 2.3.3 and 2.3.4).  
 
2.3.3 Agarose gel electrophoresis 
Gel electrophoresis was used to visualise DNA and/or to purify DNA. To resolve 
DNA fragments of >200 bp, 1% agarose gels were used. These were produced 
by heating 1% weight/volume (w/v) agarose powder (Sigma-Aldrich) in 1x TAE 
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buffer (Tris-acetate 0.4 M, ethylene diamino tetraacetic acid (EDTA) 0.01 M). To 
resolve DNA fragments of <200 bp, 2-4% agarose gels were used. DNA was 
visualised through the addition of either 0.5 μg/ml of ethidium bromide (Sigma-
Aldrich) or 1 μl/ml of GelRed Nucleic Acid Stain (Biotium). Before loading, the 
DNA was mixed with DNA Loading Dye (Fermentas) to enable an estimation of 
DNA running speed. The loading dye contained Xylene Cyanol FF and 
Bromophenol blue which ran at 4160 bp and 370 bp respectively. Agarose gels 
were electrophoresed at 100 V in TAE buffer. The G:Box gel documentation 
system (Syngene) was used to visualise DNA bands. DNA ladders (Fermentas, 
ThermoScientific) of the appropriate size range were run alongside 
experimental samples to allow the size of DNA fragments to be estimated. 
 
2.3.4 Agarose gel extraction 
If the DNA fragments run on an agarose gel were going to be used for 
subsequent ligation or sequencing (PCR products or digested plasmids), 
agarose gel extraction was performed using the QIAquick Gel Extraction Kit 
(Qiagen). Gel pieces containing the required DNA band were excised with the 
help of a UVI tec BTX-20-M UV gel box and then weighed in a 1.5 ml 
Eppendorf. QG buffer was added to the gel pieces: 300 μl for every 100 mg of 
gel. The gel was dissolved in the QG buffer by incubating the Eppendorf tube at 
50°C for 10 min, vortexing occasionally. Once all the gel was in solution 
isopropanol was added: 100 μl for every 100 mg of gel. The sample was then 
loaded onto a QIAquick spin column and processed according to the 
manufacturer’s instructions. The DNA was eluted from the column in 30 μl of 
ddH2O.  
 
The QIAquick Gel Extraction Kit was also used to clean PCR products following 
restriction digest, however these products were not submitted to agarose gel 
electrophoresis because digestion had very little effect on their size and 
therefore digested and undigested DNA could not be identified using an 
agarose gel. 300 μl of QG buffer was added to the digested DNA, followed by 
100 μl of isopropanol. The sample was then loaded onto a QIAquick spin 
column and processed according to the manufacturer’s instructions. The DNA 
was eluted from the column in 30 μl of ddH2O. 
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2.3.5 Ligation 
Ligation reactions were performed in a total volume of 20 μl using 400 units (1 
μl) of T4 DNA ligase and 2 μl of 10x T4 DNA ligase buffer (New England 
Biolabs). Varying ratios of insert to plasmid DNA were used in ligation reactions, 
always keeping the insert at a higher concentration to the plasmid DNA to 
encourage ligation and prevent vector re-ligation. The ligation mixture was 
incubated either at RT for 1-2 h or at 16°C overnight in a MWG-Biotech Primus 
96 plus thermal cycler. 
 
2.3.6 Bacterial transformation 
Plasmid DNA was amplified through chemical transformation of bacteria and 
subsequent expansion of bacterial cultures. For each transformation, one vial of 
50 μl One Shot TOP10 Chemically Competent E.coli (Invitrogen, Life 
Technologies) was thawed on ice before the addition of 1-5 μl of ligation 
reaction or plasmid DNA (~100 ng). The bacteria were incubated on ice in the 
presence of the DNA for 30 min and then heat shocked at 42°C for 30 sec 
before being returned to the ice for a further 2 min. Using aseptic technique, 
250 μl of pre-warmed S.O.C media (Invitrogen, Life Technologies) was added to 
each vial of bacteria which were incubated in a bacterial shaker at 37°C and 
225 rpm for 1 h.  
 
If the bacteria had been transformed with ligation mixture, the vial was then 
spun down for 30 sec at 13,000 rpm in a Heraeus Biofuge pica centrifuge 
(Thermo Fischer Scientific) and 100 μl of the media was removed. The bacteria 
were resuspended in the remaining media (200 μl) and streaked out on Luria-
Bertani (LB) agar plates containing the appropriate antibiotic. LB agar plates 
were made by dissolving 32 g of LB Agar (Lennox L Agar) powder (Invitrogen) 
in a total volume of 1 L of ddH2O. This solution was autoclaved and allowed to 
cool slightly before the addition of the appropriate antibiotic: 100 μg/ml of 
ampicillin (Sigma-Aldrich) for pCSGW and pSIN-MCS; 50 μg/ml of kanamycin 
(Fluka BioChemika) for pEZX-MT01. Plates were incubated overnight at 37°C. 
Successfully transformed bacteria contained an antibiotic resistant cassette 
(either ampicillin or kanamycin, depending on the plasmid), and therefore 
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survived antibiotic selection and grew to form visible colonies.  Several colonies 
were then picked for subsequent expansion in 3 ml cultures of LB broth.  
 
If the bacteria had been transformed with a pure solution of plasmid DNA, the 
S.O.C. media culture was added to 5 ml of pre-warmed LB broth, containing the 
appropriate antibiotic, and incubated in a bacterial shaker at 37°C and 225 rpm 
for 1 h. This feeder culture was then expanded to 100 ml with LB broth and 
incubated overnight in a bacterial shaker at 37°C and 225 rpm. The LB broth 
was prepared by dissolving 20 g of LB Broth Base (Lennox L Broth Base) 
(Invitrogen) in a total volume of 1 L of ddH2O. This solution was autoclaved and 
allowed to cool slightly before the addition of the appropriate antibiotic: 100 
μg/ml of ampicillin (Sigma-Aldrich) for pCSGW and pSIN-MCS; 50 μg/ml of 
kanamycin (Fluka BioChemika) for pEZX-MT01. 
 
2.3.7 Plasmid purification 
Plasmid DNA was extracted from transformed bacterial cultures and purified 
using either a QIAprep Spin Miniprep kit (Qiagen) or a QIAGEN Plasmid Maxi 
kit (Qiagen), according to the manufacturer’s instructions.  
 
Minipreps were performed on 1.5 ml of bacterial cultures, which were typically 
transformed with ligation reactions during the cloning process. Obtaining 
plasmid DNA at this stage enabled tests to be carried out to check for the 
presence of a particular DNA insert. To generate a miniprep culture, a single 
bacterial colony was picked from a LB agar plate and placed into 3 ml of LB 
broth containing the appropriate antibiotic. These cultures were incubated 
overnight in a bacterial shaker at 37°C and 225 rpm. 1.5 ml of the culture was 
stored at 4°C, to be used to inoculate a maxiprep culture if required. The other 
1.5 ml of culture was spun at 1200 rpm for 1 min in a Heraceus Biofuge pica 
desktop centrifuge to pellet the bacteria. Once the supernatant had been 
removed, bacterial pellets could be processed immediately or stored at -20°C. 
To extract the plasmid DNA, the bacterial pellet was resuspended in 250 μl of 
Buffer P1 and lysed through an alkaline lysis method by the addition of 250 μl 
Buffer P2. LyseBlue (Qiagen) was included in Buffer P1 in order to ensure 
homogenous mixing (a blue precipitate appeared upon addition of Buffer P2). 
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The mixture was then neutralised through the addition of 350 μl Buffer N3, 
which caused the LyseBlue to turn colourless. The presence of a homogeneous 
solution with no traces of blue indicated that the sodium dodecyl sulphate (SDS) 
from the lysis buffer has been effectively precipitated. Buffer N3 also adjusts the 
mixture to the high-salt conditions required for effective DNA binding to the 
column. Cellular debris and genomic DNA were pelted by spinning at 13,000 
rpm for 10 min in an Eppendorf 5810R desktop centrifuge and the resulting 
clear solution containing the plasmid DNA was passed through a QIA-prep silica 
membrane column by spinning at 13,000 rpm for 1 min in a desktop centrifuge. 
The DNA was absorbed onto the silica due to the presence of high salt. Wash 
steps were performed according to the manufacturer’s protocol. Endonucleases 
were efficiently removed by a brief wash step with Buffer PB whilst salts were 
efficiently removed by a brief wash step with Buffer PE. Clean, high-quality 
plasmid DNA was then eluted in 50 μl of ddH20. Each miniprep yielded 
approximately 10 μg of plasmid DNA.  
 
Maxipreps were performed on 100 ml of bacterial culture from which bacteria 
were pelleted by spinning at 4000 rpm for 15 min at 4°C in a desktop Eppendorf 
centrifuge. Once the supernatant had been removed, bacterial pellets could be 
processed immediately or stored at -20°C. To extract the plasmid DNA, the 
bacterial pellet was resuspended in 10 ml Buffer P1 and lysed through a 
modified alkaline lysis method by the addition of 10 ml of Buffer P2. LyseBlue 
(Qiagen) was included in Buffer P1 in order to ensure homogenous mixing (a 
blue precipitate appeared upon addition of Buffer P2). After 5 min incubation at 
RT, the mixture was neutralised through the addition of 10 ml of chilled Buffer 
P3, which caused the LyseBlue to turn colourless. The presence of a 
homogeneous solution with no traces of blue indicated that the SDS from the 
lysis buffer has been effectively precipitated. The mixture was incubated on ice 
for 20 min to enhance precipitation of genomic DNA, proteins, cell debris, and 
potassium dodecyl sulphate (KDS). The mixture was centrifuged at 3,500 rpm 
for 30 min at 4°C to remove the precipitated material. The supernatant 
containing the plasmid DNA was applied to a QIAGEN-tip through a 70 μm cell 
strainer (BD Falcon), to catch any residual precipitate. The QIAGEN-tip was 
previously equilibrated by applying 10 ml of Buffer QBT. The QIAGEN-tip 
contained QIAGEN Anion-Exchange Resin, to which the plasmid DNA bound 
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under the appropriate low-salt and pH conditions. The QIAGEN-tip was washed 
twice with 20 ml of Buffer QC, a medium-salt wash which removed RNA, 
proteins, dyes and low-molecular-weight impurities. The plasmid DNA was then 
eluted in 15 ml of a high-salt buffer, Buffer QF, and precipitated and desalted 
through the addition of 10.5 ml of isopropanol (VWR). Centrifugation for 30 min 
at 4000 rpm and 4°C led to pelleting of the DNA, which was washed with 5 ml of 
70% ethanol before a final centrifugation of 10 min at 4000 rpm and 4°C. Once 
the DNA pellet had been air dried, it was resuspended in 300 μl of ddH2O. 
Maxipreps typically yielded 1-2 μg/μl of plasmid DNA. 
 
Plasmid DNA concentration was quantified by measuring the absorbance at 
260nm using a NanoDrop UV spectrophotometer (Thermo Scientific). All the 
plasmid DNA samples had a 260/280 ratio of ~1.8 indicating pure DNA. The 
260/230 ratios were all in the range of 1.8-2.2, indicating a lack of co-purified 
contaminants.  
 
2.3.8 Site directed mutagenesis 
Site directed mutagenesis was performed using the QuikChange XL Site-
Directed mutagenesis kit (Stratagene) to mutate the seed regions of miR-30b 
and miR-30c-1 and to mutate the miR-30 target site within the DLL4 3’UTR. 
Mutagenic primers were designed according to the protocol guidelines and are 
detailed in Table 2.2. Both the forward and reverse primers were designed so 
that they contained the desired mutation and would anneal to the opposite 
strands of the same DNA sequence. The primers were all within the specified 
size range of 25-45 nt, had a TM greater than or equal to 78°C, had a minimum 
GC content of 40% and terminated in one or more guanine or cytosine bases. 
The mutated bases to be incorporated into the target DNA, indicated in red in 
Table 2.2, were located in the centre of the primers with ~10-15 nt of correct 
sequence on either side.  
 
The first step was to incorporate the altered bases through PCR with the 
mutagenic primers using PfuTurbo DNA polymerase, according to 
manufacturer’s instructions. PfuTurbo replicated both plasmid strands with high 
fidelity and without displacing the mutant oligonucleotide primers. Incorporation 
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of the oligonucleotide primers therefore generated a mutated plasmid containing 
staggered nicks. PCR was performed with 125 ng of forward and reverse 
primers and 10 ng of the relevant vector (pSIN_30b, pSIN_30c or pEZX-
MT01_DLL4-3’UTR). PCR conditions were as detailed in Table 2.2. The 
parental plasmids containing the wild type miRNA target site or seed region 
were all originally isolated from E. coli, which dam methylates all DNA. 
Therefore, all un-mutated parental DNA was removed from the mixture following 
the PCR reactions by treatment with DpnI endonuclease, which is specific for 
methylated and hemi-methylated DNA. 1 μl of DpnI (10 units) was incubated 
with each PCR mixture for 1 h at 37°C.  
 
After DpnI digestion, 2 μl of each PCR reaction was used to transform XL10-
Gold*** Ultracompetent Cells (Stratagene), which have the capability to repair 
the staggered nicks in the mutated plasmids. The ultracompetent cells were 
thawed on ice and then 45 μl per transformation were transferred to a pre-
chilled 14 ml BD Falcon polypropylene round-bottom tube. Following the 
addition of 2 μl of β-mercaptoethanol (β-ME) the ultracompetent cells were 
incubated on ice for 10min and swirled every 2 min. Once the PCR mixture had 
been added the ultracompetent cells were incubated on ice for 30 min and then 
heat-shocked at 42°C for 30 sec followed by 2 min on ice. The transformed 
bacteria were plated out on agar plates containing the appropriate antibiotic for 
selection. Bacterial colonies were picked after 24 h and used to seed miniprep 
cultures. Plasmid DNA was purified from the miniprep cultures and sent for 
sequencing to confirm the presence of the mutated sites. 
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Target Plasmid name Forward primer Reverse primer PCR conditions 
miR-30 site in 
DLL4 3’UTR 
pEZX-MT01_DLL4-UTR 
GGACCTTCCTTCTGCATTGGGG
ACATTGCATCCTGGATGGG 
CCCATCCAGGATGCAATGTCCC
CAATGCAGAAGGAAGGTCC 
95°C for 1 min 
Then 18 cycles of: 
95°C for 55 sec 
60°C for 50 sec 
68°C for 8 min and 15 sec 
Then a final step at 68°C for 7 min 
Seed region of 
hsa-miR-30b 
pSIN_30b 
CCAAGTTTCAGTTCATGTCCCCA
TCCTACACTCAGCTGTAATAC 
GTATTACAGCTGAGTGTAGGAT
GGGGACATGAACTGAAACTTGG 
95°C for 1 min 
Then 18 cycles of: 
95°C for 55 sec 
60°C for 50 sec 
68°C for 10 min 
Then a final step at 68°C for 7 min 
Seed region of 
hsa-miR-30c-1 
pSIN_30c 
CCATGCTGTAGTGTGTGTCCCC
ATCCTACACTCTCAGC 
GCTGAGAGTGTAGGATGGGGAC
ACACACTACAGCATGG 
95°C for 1 min 
Then 18 cycles of: 
95°C for 55 sec 
60°C for 50 sec 
68°C for 10 min 
Then a final step at 68°C for 7 min 
 
Table 2.2. Primers and PCR conditions used for site directed mutagenesis. Red: mutated bases to be incorporated into plasmid; blue: target site/seed region 
surrounding the mutated bases. All primers are shown 5’ to 3’. 
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2.3.9 Genomic DNA extraction 
Genomic DNA was extracted from cultured cells using the QIAmp DNA Mini Kit 
(Qiagen). Cells were detached with trypsin, counted, washed with PBS and 
pelleted by centrifugation for 1 min at 5000 rpm in a table top centrifuge. A 
maximum of 5x106 cells were used per sample, according to the manufacturer’s 
instructions. Cells were resuspended in 200 μl of PBS to which 20 μl of 
Proteinase K (Qiagen) was added.  To lyse the cells, 200 μl of Buffer AL was 
added to the sample which was mixed by pulse-vortexing for 15 sec. Samples 
were incubated at 56°C for 10 min and then 200 μl of 100% ethanol was added 
and mixed by pulse-vortexing for 15 sec. These steps ensured that the lysate 
buffering conditions had been adjusted correctly to allow optimal binding of the 
DNA to the QIAamp membrane. The samples were then applied to a QIAmp 
Mini spin column which was centrifuged in a table top centrifuge at 8000 rpm for 
1 min to allow DNA absorption onto the QIAamp silica membrane. The filtrate 
was discarded and the columns were washed with 500 μl of Buffer AW1 
followed by 500 μl of Buffer AW2, both by centrifugation at 8000 rpm for 1 min. 
The use of two different wash buffers significantly improved the purity of the 
eluted DNA by ensuring complete removal of any residual contaminants without 
affecting DNA binding. The DNA was eluted in 70 μl of ddH2O by centrifugation 
at 8000 rpm for 1 min. The DNA was then separated into three aliquots of 3 μl, 
5 μl and 62 μl. The 3 μl aliquot was used to determine the concentration and 
purity of the DNA by measuring absorbance at 260 nm (A260) and 280 nm 
(A280) with a NanoDrop-1000 Spectrophotometer. All samples exhibited an 
A260/A280 ratio of ~1.8, indicating that the DNA was free of contaminants. The 
5 μl aliquot had 45 μl of ddH2O added to it to produce the 1/10 dilution required 
for qPCR (see Section 2.3.10). DNA was stored at -20°C until use. 
 
2.3.10 Quantitative polymerase chain reaction (qPCR) 
Following lentiviral infection, qPCR was performed for the glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) gene and the lentiviral packaging signal, 
in order to determine the number of lentiviral copies per cell (c/c). Genomic 
DNA was extracted 72 h p.i. as described in Section 2.3.9. The GAPDH primers 
and probe were as previously described (Bourboulia et al., 2004). The GAPDH 
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primers and probe and their concentrations used for qPCR were as follows: 
forward primer 5’-GGAGTCAACGGATTTGGTCGTA-3’, 0.7 μM; reverse primer 
5’-GGCAACAATATCCACTTTACCAGAGT-3’, 0.7 μM; TaqMan probe (Applied 
Biosystems, Life Technologies) 5’-FAM-CGCCTGGTCACCAGGGCTGC-
TAMRA-3’, 0.15 μM. The primers and probe for the lentiviral packaging signal 
were as previously described (Vart et al., 2007). The lentiviral packaging signal 
primers and probe and their concentrations used for qPCR were as follows: 
forward primer 5’-GCACGGCAAGAGGCGA-3’, 0.3 μM; reverse primer 5’-
CGCACCCATCTCTCTCCTTCTA-3’, 0.3 μM; TaqMan probe 5’-FAM-
CGGCGACTGGTGAGTACGCCAAAAAT-TAMRA-3’, 0.15 μM. Reactions were 
performed using 25 μl of ABsolute QPCR ROX Mix (ABgene, ThermoScientific) 
and 10 μl of genomic DNA at a concentration of 50-100 ng/μl, made up to a 
total volume of 50 μl using ddH2O. The qPCR conditions used were as follows: 
95°C for 15 min followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min. 
Fluorescence readings were taken at the end of the 60°C incubation. Reactions 
were run in MicroAmp® Optical 96-Well Reaction Plates (Applied Biosystems, 
Life Technologies) sealed with MicroAmp® Optical Adhesive Films (Applied 
Biosystems, Life Technologies) on an Eppendorf Mastercycler ep Realplex 
(Eppendorf). The standard used for each qPCR was a DNA mixture of 
linearized pSIN-MCS plasmid (Vart et al., 2007) and linearized pcDNA3.1/V5-
His-TOPO-GAPDH plasmid (Bourboulia et al., 2004) at a known copy number 
of 1x108 copies per 10 μl. This was serially diluted to give standards of 1x107, 
1x106, 1x105, 1x104, 1x103 and 1x102 copies per 10 μl. For each sample a neat 
and 1/10 dilution of genomic DNA was run and both samples and standards 
were run in duplicate. So at least 40 μl of each neat and dilute DNA sample and 
each standard was required. A negative control of 10 μl ddH2O was performed 
for all qPCRs for both the GAPDH and lentiviral packaging signal reaction 
mixtures. A standard curve for both GAPDH and the lentiviral packaging signal 
was used to determine how many copies of the GAPDH gene and the lentiviral 
construct was present in each sample. The number of c/c was determined by 
adjusting the number of lentiviral constructs present to the number of cells 
analysed, using GAPDH. 
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2.3.11 RNA extraction 
Before any RNA work was conducted, all surfaces, Eppendorf racks and 
pipettes were cleaned with RNaseZAP (Ambion) to remove any traces of 
RNase enzymes which could contaminate samples and lead to RNA 
degradation. Once the RNA extraction had been completed, the amount and 
purity of the RNA was determined by measuring absorbance at 260 nm (A260) 
and 280 nm (A280) with a NanoDrop-1000 Spectrophotometer. All samples 
exhibited an A260/A280 ratio of ~2.0, indicating that the RNA was pure and free 
of contaminants. RNA was stored at -80°C until use. 
 
2.3.11.1 miRNeasy Mini Kit (Qiagen) 
Total RNA was extracted from cultured cells using the miRNeasy Mini Kit 
(Qiagen) according to the manufacturer’s instructions. This kit enables 
extraction of all RNA, including the small RNA fraction (<200 bp), which is 
discarded by other RNA extraction kits. The small RNA fraction contains 
miRNAs, among other species, and therefore it was desirable to keep this RNA 
fraction. 
 
A maximum of 1x107 cells were processed per sample. When working with 
adherent cells, the media was simply removed from the cells before lysis. When 
working with cells grown in suspension or trypsinised cells, the cells were first 
pelleted by centrifugations at 1200 rpm for 5 min before the media was 
removed. To lyse the cells, 700 μl of QIAzol Lysis Reagent (Qiagen) was added 
to each sample. QIAzol Lysis Reagent is a monophasic solution of phenol and 
guanidine thiocyanate which is designed to facilitate lysis of cells or tissue, 
inhibit RNases and also to enable the removal of the majority of cellular DNA 
and proteins through organic extraction. Adherent cells were collected using a 
cell scraper whereas pelleted cells were resuspended in the QIAzol Lysis 
Reagent through repeated pipetting. This initial step caused complete disruption 
of the plasma membranes of all the cells and organelles in the sample. 
Homogenisation was then required to reduce the viscosity of the lysates 
produced by disruption. Homogenisation shears high-molecular-weight genomic 
DNA and other cellular components to create a homogeneous lysate. If the 
sample contained <3x106 cells, the lysate was homogenised by vortexing for 1 
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min. If the sample contained >3x106 cells, the lysate was passed through a 
QIAshredder spin column (Qiagen) by centrifugation at 13,000 rpm for 1 min in 
a table top centrifuge. The homogenised lysate was incubated at RT for 5 min 
before the addition of 140 μl of chloroform (Sigma-Aldrich). The sample was 
then shaken vigorously for 15 sec and incubated at RT for 2-3 min. To separate 
the sample into the aqueous and organic phases it was centrifuged for 15 min 
at 12,000 x g and 4°C. The RNA could be found in the upper aqueous phase 
whilst DNA partitioned to the interphase and proteins partitioned to the 
interphase or the lower organic phase. The upper aqueous phase was 
transferred to a new Eppendorf tube and mixed with 1.5 volume of 100% 
ethanol (typically 525 μl). This provided the appropriate binding conditions for all 
RNA molecules from 18nt upwards. The sample was then applied to an RNeasy 
Mini spin column (Qiagen) by centrifugation at 10,000 rpm for 15 sec at RT in a 
table top centrifuge, which allowed binding of the total RNA to the silica 
membrane. The column was washed with 350 μl of Buffer RWT (15sec spin at 
10,000 rpm at RT) before the addition of 80 μl of DNase I incubation mix. The 
DNase I incubation mix was prepared using an RNase-Free DNase Set 
(Qiagen) by adding 10 μl of DNase I stock solution to 70 μl of Buffer RDD. After 
15 min incubation at RT, the column was again washed with 350 μl of Buffer 
RWT. The final two washes were performed with 500 μl of Buffer RPE, the first 
at 10,000 rpm for 15 sec and then at 10,000 rpm for 2 min. The second longer 
centrifugation dried out the spin column, ensuring that no ethanol was carried 
over during RNA elution. A final centrifugation at 13,000 rpm from 1 min was 
performed without any wash buffer and with a clean collection tube. This 
eliminated the possibility of any carryover of Buffer RPE or other residual flow-
through remains. The RNA was eluted in 30 μl of RNase-free water (Qiagen) by 
centrifuging at 10,000 rpm for 1 min. 
 
2.3.11.2 TRI Reagent (Sigma-Aldrich) 
RNA extraction and purification using TRI Reagent (Sigma-Aldrich) was 
performed when obtaining RNA from zebrafish embryos. The number of 
embryos from which the RNA was harvested varied between experiments but 
was kept consistent between samples within the same experiment. Typically 
~30 embryos were collected per sample. The embryos were transferred to an 
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Eppendorf tube and a Pasteur pipette was used to remove as much fish water 
as possible. 500 μl of TRI Reagent was added to each sample and the sample 
was disrupted by repeatedly passing the solution through a 1 ml syringe and 
needle. A further 500 μl of TRI Reagent was added to prevent saturation and 
the sample was homogenised by vortexing for 1 min. They lysate was 
centrifuged at 12,000 rpm and 4°C for 10 min to remove insoluble material. The 
supernatant was transferred to a clean Eppendorf tube and 200 μl of chloroform 
was added. The sample was vortexed for 30 sec and left to incubate at RT for 5 
min before centrifuging at 12,000 rpm and 4°C for 10 min. The upper aqueous 
phase was transferred to a clean Eppendorf tube, mixed with 500 μl of 
isopropanol and incubated at RT for 5 min in order to precipitate the RNA. The 
RNA was pelleted by centrifugation at 12,000 rpm and 4°C for 10 min and then 
the pellet was washed in 1 ml of 75% ethanol. A final centrifugation for 5 min at 
7,500 rpm and 4°C occurred before the supernatant was removed and the RNA 
pellet was allowed to air-dry. The RNA was then resuspended in 40 μl of 
ddH2O. 
 
Instead of on-column DNase treatment, as in Section 2.3.11.1, 1 μl of DNase I 
(Fermentas, ThermoScientific) was added to the sample which was incubated 
at 37°C for 15 min. To inactivate the DNase, 1 μl of EDTA was added to the 
sample before precipitating the RNA overnight at -20°C using 5 μl of 4 M lithium 
chloride (LiCl) (Ambion, Life Technologies) and 150 μl of 100% ethanol. 
Following precipitation the sample was centrifuged at 12,000 rpm and 4°C for 
30 min before being air-dried and resuspended in 30 μl of ddH2O. 
 
2.3.12 cDNA synthesis 
Complimentary DNA (cDNA) synthesis was performed using 1-2000 ng of RNA, 
previously isolated by one of the methods described in Sections 2.3.11.1 or 
2.3.11.2. The RNA was first incubated at 70°C for 6 min in a MWG-Biotech 
Primus 96 plus thermal cycler with 1 μl of 100 μM oligo(dT) and 1 μl of 10 mM 
dNTP mix (Invitrogen, Life Technologies), made up to a total volume of 12 μl 
with ddH2O. This step denatured any RNA secondary structure. After incubation 
the mix was cooled on ice for 2 min to allow the oligo(dT) to anneal and then the 
following mixture was added: 4 μl of 5x first-Strand buffer (Invitrogen, Life 
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Technologies), 2 μl of 0.1M DTT (Invitrogen, Life Technologies), 1 μl of 
RNaseOUT™ Recombinant Ribonuclease Inhibitor (40 units) (Invitrogen, Life 
Technologies) and 1 μl of Superscript II Reverse Transcriptase (200 units) 
(Invitrogen Life Technologies). The Superscipt II Reverse Transcriptase is a 
modified form of the pol gene of Moloney Murine Leukaemia Virus (M-MLV-RT). 
It can be used to synthesise first-strand cDNA at higher temperatures than 
conventional M-MLV RT therefore it provides increased specificity, higher yields 
of cDNA, and more full-length product. Following gentle mixing and a brief 
centrifugation step the samples were incubated for 1h at 42°C in a MWG-
Biotech Primus 96 plus thermal cycler and then heated to 70°C for 10 min to 
inactivate the reverse transcriptase. The samples were cooled to 4°C before 
being used or stored at -20°C until required. 
 
cDNA synthesis for qRT-PCR quantification of mature miRNAs was performed 
using the TaqMan® miRNA Reverse Transcription Kit (Applied Biosystems), 
according to the manufacturer’s instructions. RNA was extracted from cells or 
tissue using the miRNeasy Mini Kit (see Section 2.3.11.1). Total RNA was 
diluted to a concentration of 2 ng/μl and 10 ng of RNA (5 μl) was used for each 
15 μl reaction. A reverse transcription master mix of the following was first 
prepared on ice: 4.16 μl of nuclease-free water, 1.5 μl of 10x reverse 
transcription buffer, 0.15 μl of 100 mM dNTPs, 0.19 μl of RNase Inhibitor (20 
units/μl) and 1 μl MultiScribe™ Reverse Transcriptase (50 units/μl). 7 μl of this 
mastermix was added to each reaction tube on ice followed by 5 μl of RNA and 
finally 3 μl of miRNA specific primers from TaqMan® MicroRNA Assays 
(Applied Biosystems). The reaction conditions were as follows: 16°C for 30 min, 
42°C for 30 min, 85°C for 5 min. Samples were then cooled to 4°C before being 
used directly or stored at -20°C until required. 
 
cDNA synthesis for qRT-PCR quantification of pre-miRNAs was performed 
using GenoExplorer™ miRNA qRT-PCR Kit (GenoSensor Corporation) 
according to the manufacturer’s instructions. RNA was extracted from cells or 
tissue using the miRNeasy Mini Kit (see Section 2.3.11.1). The first step 
involved linking an adaptor to the 5’ end of all the pre-miRNAs and miRNAs in 
the sample using a ligase. The adaptor was then polyadenlyated using poly A 
polymerase. To complete this reaction, 100 ng of total RNA was added to 3 μl of 
96 
 
Poly(A) extension mix and made up to a total volume of 10 μl with 
DNase/RNase-free water. The sample was incubated at 37°C for 30 min in a 
MWG-Biotech Primus 96 plus thermal cycler and the extension reaction was 
stopped by 5 min incubation at 95°C before cooling the sample on ice. Each 
extension reaction provided enough for five cDNA synthesis reactions. A 
universal RT Primer was used to synthesize cDNA from the tailed miRNA 
population by reverse transcriptase. 2 μl of the extended RNA was added to 8 
μl of the RT priming mix and incubated at 46°C for 10 min in a MWG-Biotech 
Primus 96 plus thermal cycler. After incubating the sample on ice for 1 min, 10 
μl of 2x RT mix was added and the sample was incubated at 42°C for 1 h in a 
MWG-Biotech Primus 96 plus thermal cycler. The sample was then incubated at 
95°C for 5 min to inactivate the reverse transcriptase before being cooled to 
4°C. The sample was then either used directly or stored at -20°C until required.  
 
2.3.13 Quantitative reverse transcriptase-polymerase chain 
reaction (qRT-PCR) 
Quantitative RT-PCR was performed using either SYBR Green (Applied 
Biosystems), TaqMan® Gene Expression Assays (Applied Biosystems) or 
TaqMan® MicroRNA Assays (Applied Biosystems), as detailed in Table 2.3. All 
qRT-PCR reactions were plated out in a PCR hood within a designated PCR 
room and all equipment and the nuclease-free water were subjected to 900 mJ 
of UV radiation in a UV Stratalinker 2400 before use. The cDNA was added in a 
separate “clean” laboratory using dedicated pipettes. All qRT-PCR reactions for 
each biological repeat were performed in either duplicate or triplicate.  
 
The primers used for qRT-PCR with SYBR Green are listed in Table 2.3. Primer 
optimisation was performed for all primers before use. The GAPDH and selectin 
E (SELE) primers were designed as previously described (Bourboulia et al., 
2004; Emuss et al., 2009). The actin b1 (actb1) primers were designed using 
Primer Express software (Applied Biosystems). The primers were used at the 
concentrations stated in Table 2.3. All qRT-PCRs were performed using 12.5 μl 
of SYBR® Green PCR Master Mix (Applied Biosystems, Life Technologies), the 
required volumes of forward and reverse primers and 1 μl of neat or diluted 
cDNA, made up to a total reaction volume of 25 μl using nuclease-free water. 
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qRT-PCRs were performed in MicroAmp® Optical 96-Well Reaction Plates 
(Applied Biosystems, Life Technologies) sealed with MicroAmp® Optical 
Adhesive Films (Applied Biosystems, Life Technologies) on an Eppendorf 
Mastercycler ep Realplex (Eppendorf).The reaction conditions were as follows: 
95°C for 10 min to activate the DNA polymerase, followed by 40 cycles of 95°C 
for 15 sec and 60°C for 1 min. Fluorescence readings were taken at the end of 
the 60°C incubation. For primer optimisation an additional dissociation step was 
added at the end of the PCR program which consisted of 95oC for 15 sec, 60oC 
for 20 sec, a 19 min 59 sec ramping step and then 95°C for 15 sec. The 
dissociation data was collected on the ramping step. Relative expression of the 
gene of interest was quantified using the comparative CT method with either 
GAPDH or actb1 being used as the housekeeping gene, as stated. 
 
qRT-PCRs using a TaqMan® Gene Expression Assay were performed in a total 
volume of 25 μl with the following reagents: 12.5 μl of TaqMan® Universal PCR 
Master Mix (Applied Biosystems, Life Technologies), 1.25 μl of the required 20x 
TaqMan® Gene Expression Assay (containing primer and probe), 1 μl of neat 
or diluted cDNA and 10.25 μl of nuclease-free water. The reactions were 
performed and analysed as described above for SYBR Green qRT-PCRs. 
 
Quantification of miRNA and human small nucleolar RNA expression was 
performed using TaqMan® MicroRNA Assays (Applied Biosystems). qRT-PCRs 
were performed in a total volume of 20 μl with the following reagents: 10 μl of 2x 
TaqMan® Universal PCR Master Mix, no AmpErase UNG (Applied Biosystems, 
Life Technologies), 1 μl of 20x TaqMan® MicroRNA Assay, 1.33 μl of miRNA 
specific cDNA and 7.67 μl of nuclease-free water. qRT-PCRs were performed in 
MicroAmp® Optical 96-Well Reaction Plates (Applied Biosystems, Life 
Technologies) sealed with MicroAmp® Optical Adhesive Films (Applied 
Biosystems, Life Technologies) on an Eppendorf Mastercycler ep Realplex 
(Eppendorf). The reaction conditions were as follows: 95°C for 10 min to 
activate the DNA polymerase, followed by 40 cycles of 95°C for 15 sec and 
60°C for 1 min. Fluorescence readings were taken at the end of the 60°C 
incubation. Relative expression of the gene of interest was quantified using the 
comparative CT method. For human miRNA quantification, small nucleolar RNA 
H/ACA box 66 (SNORA66) was used as a housekeeping gene, although RNA 
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U6 small nuclear 1 (RNU6-1) was also tested. For zebrafish miRNA 
quantification, actb1 was used as a housekeeping gene.  
 
Gene symbol 
Assay 
type 
Forward primer Reverse primer 
GAPDH 
SYBR 
green 
GGAGTCAACGGATTT
GGTCGTA – 0.3μM 
GGCAACAATATCCAC
TTTACCAGAGT-0.3μM 
actb1 
TACAGCTTCACCACC
ACAGC 0.3μM 
AAGGAAGGCTGGAAG
AGAGC 0.3μM 
SELE 
CAGCCTCAAGATCAT
CAGCA– 0.3μM 
ACAGTCTTCTGGGTG
GCAGT– 0.3μM 
DLL4 
TaqMan® 
N/A N/A 
JAG1 N/A N/A 
dll4 N/A N/A 
hsa-miR-26a N/A N/A 
hsa-miR-30b N/A N/A 
hsa-miR-30c N/A N/A 
hsa-miR-30d N/A N/A 
hsa-miR-30e N/A N/A 
let-7i N/A N/A 
hsa-miR-29c* N/A N/A 
 
Table 2.3. Real-time qRT-PCR assays and primers. N/A: not applicable, purchased TaqMan® 
assays contained primers and probe, primers shown 5’ to 3’, primer concentration used in qRT-
PCR shown.  
 
2.4 Protein analysis 
2.4.1 Western blotting 
Protein was extracted from cells using M-PER Mammalian Protein Extraction 
Reagent (Pierce, ThermoScientific) to which cOmplete ULTRA Tablets, Mini, 
EDTA-free, EASYpack Protease Inhibitor Cocktail Tablets had been added 
(Roche). The lysis buffer was either added to cell pellets (1-2x105 cells) in a 1.5 
ml Eppendorf tube, or directly to cells in 1-2 wells of a 6-well plate. For ~1x105 
cells or one well of a 6-well plate, 70 μl of lysis buffer was used. For ~2x105 
cells or for two wells of a 6-well plate, 150 μl of lysis buffer was used. When 
lysing cell pellets, the lysis buffer was mixed with the cells by repeated pipetting. 
If the lysis buffer was to be added directly to the cells in culture, the media was 
first removed and the cells were washed twice with cold PBS. The plates were 
then placed on ice, to prevent evaporation and reduce protein degradation, and 
the required quantity of lysis buffer was added. Cells were dislodged from the 
plate using a cell scraper and collected in a 1.5 ml Eppendorf tube. All cell 
lysates, whether harvested from cell pellets or directly from the plate, were 
vortexed briefly and incubated on ice for 5min before centrifugation at 13,000 
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rpm for 5-30 min at 4°C in a Heraceus Biofuge fresca desktop centrifuge to 
pellet cell debris. The supernatant containing the protein was removed and 
stored at -20°C until required.  
 
Protein concentration was measured using Pierce BCA Protein Assay Kit 
(ThermoScientific) according to the manufacturer’s instructions. Protein 
standards were produced by performing seven serial dilutions of the provided 
albumin stock (2 μg/μl) to give standards at the following concentrations: 2 
μg/μl, 1 μg/μl, 0.5 μg/μl, 0.25 μg/μl, 0.125 μg/μl, 0.0625 μg/μl, 0.03125 μg/μl 
and 0.015625 μg/μl. A sample of the ddH2O used to produce these dilutions 
was also set aside to be kept with the standards. The standards could be kept 
at 4°C for two to three weeks, or at -20°C for long term storage. All standards 
and samples were plated out in duplicate in a 96-well flat bottomed plate (TPP, 
MIDSCI). 15 μl of ddH2O was added to all the wells which would contain the 
samples of unknown concentration.  20 μl of each standard was added to the 
appropriate wells. 5 μl of each sample was added to the appropriate wells. 
Reagent A and Reagent B from the Pierce BCA Protein Assay Kit were then 
diluted at a ratio of 1:50 and 180 μl of the mixture was added to each well 
containing either standard or sample using a multichannel pipette. The plate 
was tapped gentle to agitate, covered in tin foil and incubated at 37˚C for 30 
min. The plate was allowed to cool to room temperature and then the absorption 
at 562 nm of each well was measured using the Varioskan Flash Multimode 
Reader (ThermoScientific). A standard curve was plotted using the mean 
absorption readings for the standards. A scatter graph was plotted in Excel with 
protein concentration as the dependent variable on the Y-axis and absorbance 
as the independent variable on the X-axis. A polynomial trend line (2nd order 
regression) was added and the equation of the line was displayed, of the format 
y = ax2 + bx + c. The protein concentration was represented by y, therefore the 
equation and hence the protein concentration could be solved for each protein 
sample by entering the known mean absorbance value for that sample (x). 
Because all the protein samples had been diluted 1:4 before the assay was 
performed, the calculated protein concentration then had to be multiplied by 4 to 
obtain the protein concentration of the neat sample.  
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The range of protein concentrations amongst all the samples from the same 
experiment was examined and then the same amount of protein for each 
sample (5-20 μg) was made up to the same total volume using ddH2O. The 
protein samples were then mixed with the same volume of 4x SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer, the 
composition of which is listed below. For each polyacrylamide gel, 10 μl of 
Precision Plus Protein Dual Color Standards (Bio-Rad) or 10 μl of ColorPlus 
Prestained Protein Ladder, Broad Range (10-230 kDa) (NEB) was mixed with 
the same volume of 4x SDS-PAGE sample loading buffer as the samples and 
made up to the same total volume as the samples using ddH2O. If there were 
any empty wells in the polyacrylamide gel, a suitable volume of 4x SDS-PAGE 
sample loading buffer was prepared with ddH2O so that every well in the gel 
was loaded with the same volume of solution, each containing the same 
concentration of SDS-PAGE sample loading buffer. Prior to loading, protein was 
denatured by heating at 100°C for 5 min in a heat block (Grant). The samples 
were then spun down and allowed to cool.  
 
4x SDS-PAGE sample loading buffer 
250nM Tris-HCL pH 6.8 (Sigma-Aldrich) 
8% (w/v) SDS (Sigma-Aldrich) 
10% (v/v) Glycerol (Sigma-Aldrich) 
5% (v/v) β-ME (Sigma-Aldrich) 
0.05% (w/v) Bromophenol blue (Sigma-Aldrich) 
 
Denatured protein lysates were run on 10% polyacrylamide gels which were 
composed of a 1.5 mm thick stacking gel and a 1.5 mm thick 10% resolving gel. 
The gels were made using a Mini-PROTEAN 3 comb, spacer plates, short 
plates, casting frame and casting stand (Bio-Rad). The resolving gel was made 
first, poured into the apparatus and allowed to set for 15 min. The stacking gel 
was then made, poured on top of the resolving gel and allowed to set for 15 
min. Gels were either used immediately or stored at 4°C wrapped in damp 
paper towels. The composition of each gel is listed: 
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10% Resolving gel 
4 ml ddH2O 
3.3 ml 30% (w/v) acrylamide (National Diagnostics) 
2.5 ml 1.5 M Tris pH 8.8 (Severn Biotech Ltd) 
0.1 ml 10% (w/v) SDS (Sigma-Aldrich) 
0.1 ml 10% (w/v) ammonium persulphate (APS) (Sigma-Aldrich) 
0.004 ml tetramethylethylenediamine (TEMED) (Sigma-Aldrich) 
 
5% Stacking gel 
3.4 ml ddH2O 
0.83 ml 30% (w/v) acrylamide (Sigma-Aldrich) 
0.63 ml 1 M Tris pH 6.8 (Severn Biotech Ltd) 
0.05 ml 10% (w/v) SDS (Sigma-Aldrich) 
0.05 ml 10% (w/v) APS (Sigma-Aldrich) 
0.005 ml TEMED (Sigma-Aldrich) 
 
The lysates and protein ladder were loaded into a polyacrylamide gel and the 
component proteins were separated by electrophoresis at 100 V in SDS-PAGE 
running buffer (Flowgen Bioscience). Electrophoresis was continued until the 
bromophenol blue marker ran off the bottom of the gel. Protein was transferred 
onto Immobilon-P Transfer Membrane (Millipore) at 20 V for 45 min using a 
semi-dry transfer apparatus (Bio-Rad) and transfer buffer (Flowgen Bioscience). 
Prior to transfer the membrane was activated by soaking in methanol for 5 min, 
washed in ddH2O and equilibrated in transfer buffer. All Extra ThickBlot Paper 
(Bio-Rad) used for the transfer was previously soaked in transfer buffer and the 
negative electrode of the transfer apparatus was wet with transfer buffer.  
 
Following transfer, the membrane were blocked in blocking solution [5% (w/v) 
milk powder in tris buffered saline (TBS) containing 0.1% (v/v) TWEEN® 20 
(Sigma-Aldrich) (TBST)] for 1 h at RT. The composition of the 10x TBS used to 
produce the TBST was as follows: 
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10x TBS 
40 g NaCl (Sigma-Aldrich) 
1 g KCl (Sigma-Aldrich) 
15 g Tris (Sigma-Aldrich) 
ddH2O up to a total volume of 500 ml 
Concentrated HCl was used to bring the pH to 8.0 before all H2O added 
 
After blocking, the membrane was incubated overnight on a SRT9D roller mixer 
(Stuart) at 4°C with the required primary antibody diluted in blocking solution. 
The primary antibodies used and the dilutions at which they were used are 
listed in Table 2.4. After primary antibody incubation the membrane was 
washed three times for 10 min on a SSL4 see-saw rocker (Stuart) in TBST at 
RT. The membrane was then incubated for 1 h at RT on a SRT9D roller mixer 
with the appropriate horse-radish peroxidase (HRP) conjugated secondary 
antibody diluted 1/5000 in blocking solution. The secondary antibodies used are 
listed in Table 2.5. After incubation with secondary antibody any unbound 
antibody was washed off with 3 x 10 min washes on a SSL4 see-saw rocker in 
TBST at RT. After removing excess liquid from the membrane, bound antibody 
was visualized using either Amersham ECL or Amersham ECL Plus Western 
Blotting Reagents (GEHealthcare), depending on the primary antibody, as 
indicated in Table 2.4. For ECL, Reagents 1 and 2 were mixed 1:1 and used to 
completely cover the membrane for 5min incubation at RT. For ECL Plus, 
Reagents A and B were mixed 40:1 and used to completely cover the 
membrane for a 5 min incubation at RT. Excess ECL or ECL Plus was remove 
from the membrane and the resulting chemiluminescence signal was detected 
with Amersham Hyperfilm™ ECL (GE Healthcare). After development, ECL or 
ECL Plus was washed off with 3 x 10 min washes on a SSL4 see-saw rocker in 
TBST at RT. The membrane was then incubated with Restore™ Western Blot 
Stripping Buffer (ThermoScientific) for 10 min at 37°C with shaking. The 
stripping buffer was removed with 3 x 10 min washes on a SSL4 see-saw 
rocker in TBST at RT. The membrane was then dried out, wrapped in clingfilm 
and stored at -20°C. 
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Protein Raised in Made by Cat No. Clone Dilution Reagent 
DLL4 Rabbit 
Cell Signaling 
Technology 
2589 Polyclonal  1:1000 ECL Plus 
GAPDH Mouse 
Advanced 
Immunochemical 
Inc. 
2-RGM2 6C5 1:10000 ECL 
TUBG Mouse Sigma-Aldrich T6557 GTU-88 1:5000 ECL 
TUBA Mouse Sigma-Aldrich T5168 B-5-1-2 1:8000 ECL 
 
Table 2.4. Primary antibodies used for Western blotting.  
 
Raised in Anti- Made by Cat No. Lot No. Dilution 
Goat Rabbit Dako P0448 00038290 1:5000 
Goat Mouse Dako P0447 00035941 1:5000 
 
Table 2.5. Secondary antibodies used for Western blotting. 
 
2.4.2 Flow cytometry for GFP expression 
Flow cytometry was used to evaluate the percentage of KSHV-positive cells in a 
population of LEC exposed to GFP-expressing KSHV. LEC were plated out at a 
density of 5x104 cells per well of a 6-well plate and infected with GFP-
recombinant KSHV as described in Section 2.2.3. Uninfected LEC were used as 
a control cell population. These were the same passage as the KLEC and were 
cultured alongside the KLEC in media that was frozen at the same time as the 
KSHV supernatant. 
 
Cells from each experimental condition were trypsinised, pelleted by 
centrifugation, washed in PBS, pelleted by centrifugation and resuspended in a 
minimum of 300 μl of PBS. The volume of PBS was varied in order to achieve a 
cell density within 5x105–2x106 cells per ml. The cell suspension was 
transferred to a FACS tube (BD) and placed on ice until analysis could be 
performed on a CyAn ADP High-Performance Flow Cytometer (Beckman-
Coulter). For analysis, gates were set first on live cells and then on GFP-
positive cells.  
 
2.4.3 Fluorescence-activated cell sorting 
Fluorescence-activated cell sorting (FACS) was performed on LEC infected with 
GFP-recombinant KSHV in order to separate confirmed KSHV-infected cells 
from surrounding cells based on GFP expression. LEC were plated out at a 
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density of 5x104 cells per well of a 6-well plate and infected with GFP-
recombinant KSHV as described in Section 2.2.3. Uninfected LEC of the same 
passage were cultured alongside the KLEC to use as a control. LEC and KLEC 
were trypsinised 72 h p.i, pelleted by centrifugation and resuspended in 300 μl 
of PBS. The cell suspensions were transferred to FACS tubes (BD) and placed 
on ice until FACS could be performed using a MoFlo™ XDP High-Speed Cell 
Sorter (Beckman-Coulter). A gate was first set on live cells and then two gates 
were set on GFP-positive and GFP-negative cells which was the basis of 
separation when the sort was performed. The uninfected LEC were also passed 
through the cell sorter so that all cells had experienced the same procedure. 
Once FACS had been completed the cells were pelleted through centrifugation 
and 700 μl of Qiazol (Qiagen) was added to each tube. Total RNA was then 
extracted as described in Section 2.3.11.1.  
 
2.5 Luciferase reporter assays 
Luciferase assays were performed to quantify miRNA repression of the DLL4 
3’UTR in 293T cells. The plasmids used for the luciferase assays are listed in 
Table 2.6.  
 
Plasmid Promoters Downstream of firefly 
luciferase 
Supplier 
pEZX-MT01 
firefly luciferase - 
SV40 enhancer 
Renilla luciferase – 
CMV promoter 
polyA signal GeneCopoeia 
pEZX_DLL4-3’UTR 
firefly luciferase - 
SV40 enhancer 
Renilla luciferase – 
CMV promoter 
DLL4 3’UTR and polyA 
signal 
GeneCopoeia 
pEZX_DLL4-3’UTR-mut 
firefly luciferase - 
SV40 enhancer 
Renilla luciferase – 
CMV promoter 
DLL4 3’UTR containing 
mutated miR-30 target site 
and polyA signal 
GeneCopoeia 
but altered by 
site-directed 
mutagenesis 
 
Table 2.6. Plasmids used for luciferase reporter assays.  
 
To investigate miRNA activity, 293T cells were seeded at a density of 5x104 
cells per well of a 12-well plate. 16 h later the cells were transfected with non-
targeting control (NTC) mimic, miR-30b mimic, miR-30c mimic or a combination 
of miR-30b and miR-30c, at a total concentration of 100nM, as detailed in 
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Section 2.2.4. 48 h post-mimic transfection each well of cells was transfected 
with 100ng of reporter plasmid (pEZX-MT01, pEZX_DLL4-3’UTR or 
pEZX_DLL4-3’UTR_mut), as detailed in Section 2.2.1. The pEZX-MT01 and 
pEZX_DLL4-3’UTR plasmids were purchased from GeneCopoeia. The 
pEZX_DLL4-3’UTR_mut plasmid was created by site-directed mutagenesis of 
the pEZX_DLL4-3’UTR plasmid, as detailed in Section 2.3.8.  
 
Cells were harvested 24 h post-transfection with the reporter plasmids. Cells 
were washed with PBS and lysed in 250 μl of 1x Passive Lysis Buffer (PLB) 
which was formed by diluting 5x PLB (Promega) in ddH2O. The PLB was added 
to each well of the 12-well plate and then the plate was shaken on a SSL4 see-
saw rocker at 50 rpm for 15 min at RT. The samples were pipetted up and down 
to lyse any remaining cells and then either stored at -20°C in a 1.5 ml 
Eppendorf tubes or placed on ice before analysis. To pellet any insoluble 
elements the samples were spun at for 30sec at 13,000 rpm and 4°C in a 
Heraceus Biofuge Fresca desktop centrifuge. According to the manufacturer’s 
instructions, this is not necessary for use with the Dual-Luciferase Reporter 
Assay System (Promega). However, it is necessary if the protein concentration 
of the samples is to be subsequently determined or if the samples may be used 
for Western blotting, therefore this step was always performed. The Fluoroskan 
Ascent FL luminometer and fluorometer (Thermo Scientific) was first prepared 
by washing the dispensers with 2 ml of ddH2O, 2 ml of 70% ethanol and then 
another 2 ml of ddH2O. It was then primed with 0.8 ml of Luciferase Assay 
Reagent II (LAR II) (Promega) and Stop & Glo® Reagent (Promega). LARII was 
prepared by resuspending 1 vial of lyophilised Luciferase Assay Substrate 
(Promega) with 10ml of Luciferase Assay Buffer II (Promega) and could be 
stored like this at -80°C. Stop & Glo® Reagent was prepared by adding 1 
volume of 50x Stop & Glo® Substrate to 50 volumes of Stop & Glo® Buffer. 10 μl 
of each sample was assayed in triplicate in a 96-well white Sterilin* Microtiter 
Plates (Thermo Scientific). The Fluoroskan Ascent FL dispensed 50 μl of LAR II 
into the designated wells of the 96-well plate and then after a 2 sec pre-
measurement delay, recorded the luminescent signal over the course of 10 sec. 
Luminescence was recorded as relative light units (RLU). This luminescent 
signal was generated by the activity of the firefly (Photinus pyralis) luciferase. 
Subsequently, 50 μl of Stop & Glo® Reagent was then dispensed into each well 
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to simultaneously quench the firefly luciferase reaction and provide a substrate 
for the Renilla (Renilla reniformis or sea pansy) luciferase. Again, after a 2 sec 
pre-measurement delay, the luminescent signal was recorded over the course 
of 10 sec. The Fluoroskan Ascent FL was then thoroughly cleaned by washing 
the dispensers with 2 ml of ddH2O, 2 ml of 70% ethanol and then another 2 ml 
of ddH2O. 
 
Before examining the results, firefly luciferase RLU was normalised to Renilla 
luciferase RLU to control for variations in cell number, transfection efficiencies 
and pipetting errors between samples.  
 
2.6 Functional in vitro assays 
2.6.1 Matrigel tube formation assay 
BD Matrigel™ Basement Membrane Matrix Growth Factor Reduced (BD 
Biosystems) was thawed overnight at 4°C, aliquoted into appropriate volumes 
and stored at -20°C. The day before setting up the tube formation assay, the 
required amount of Matrigel was thawed overnight at 4°C. Throughout the 
preparation of the plate the Matrigel was kept on ice. 80 μl of Matrigel was 
added to the appropriate number of wells of a pre-chilled 96-well flat bottomed 
plate (TPP, MIDSCI) using pre-chilled pipette tips. The pipette was not fully 
ejected to avoid the creation of bubbles and the plate was kept flat at all times. 
The plate was then incubated at 37°C for 30 min to allow the Matrigel to set.  
 
LEC and HUVEC were trypsinised as detailed in Section 2.1.1 and 
resuspended in the appropriate media. For some experiments, cells were 
transfected with NTC or DLL4 siRNA 48 h prior to the tube formation assay. On 
these occasions LEC and HUVEC were plated out at a density of 5x104 cells 
per well of a 6-well plate and transfected at a concentration of 100 nM, as 
detailed in Section 2.2.4. When optimising the tube formation assay, LEC and 
HUVEC were resuspended at a density of 5,000, 7,500 and 10,000 cells per 
100 μl of media. For subsequent tube formation assays, LEC were resuspended 
at a density of 7,000, 10,000 and 12,500 cells per 100 μl of media whereas 
HUVEC were resuspended at a density of 2,500, 5,000 and 7,500 cells per 100 
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μl of media. For each cell density and cell treatment, 100 μl of cells was added 
per well of the 96-well plate containing Matrigel in triplicate. The plate was 
returned to the CB 53 incubator (Binder) at standard cell culture conditions for 
24 h. The cells were photographed at various time points on an Axiovert 100 
microscope (Zeiss) using an AxioCam (Zeiss) and the images were acquired 
using AxioVision software (Zeiss).  
 
2.6.2 Spheroid-based in vitro angiogenesis assay 
HUVEC were trypsinised, as detailed in Section 2.1.1, and resuspended in 
HUVEC media at a density of 2.5x104 cells per ml. The HUVEC media 
contained 20 μl of sterile 0.25% w/v methylcellulose (Sigma-Aldrich) per 2 ml. 
For some experiments, HUVEC were transfected with miRNA mimics or 
inhibitors 24 h prior to the 3D sprouting assay. On these occasions HUVEC 
were plated out at a density of 5x104 cells per well of a 6-well plate and 
transfected at a concentration of 100 nM, as detailed in Section 2.2.4. For each 
treatment condition, 2 ml of cells were plated out in Nunc® 60-well 
MicroWell® MiniTrays (Sigma-Aldrich) with 20 μl of cells (500 cells) added to 
each well. This would lead to the formation of 100 spheroids per condition. The 
mini-trays were then inverted and placed in a CB 53 incubator (Binder) at 
standard cell cultures conditions for 24 h.  
   
BD Matrigel™ Basement Membrane Matrix (BD Biosystems) was thawed 
overnight at 4°C, aliquoted into appropriate volumes and stored at -20°C. The 
day before setting up the 3D sprouting assay, the required amount of Matrigel 
was thawed overnight at 4°C. Throughout the preparation of the plate the 
Matrigel was kept on ice. The mini-trays were examined to check for spheroid 
formation and then the spheroids from each experimental condition were 
collected using a p1000 pipette tip and very gently pipetted into a 15 ml falcon 
tube (BD Biosciences). The spheroids were centrifuged at 1000 rpm for 1 min in 
an Eppendorf table-top centrifuge and the majority of the media was removed 
(leaving ~10-50 μl of media above the spheroids).  The falcon tubes were 
placed on ice and the spheroids from each experimental condition were gently 
resuspended in 200 μl of Matrigel using pre-chilled pipette tips.  Each Matrigel 
sample was added to one well of a 12-well flat bottomed plate (TPP, MIDSCI) 
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using pre-chilled pipette tips. The Matrigel formed a blob in the centre of the 
well and was prevented from spreading across the well as this was found to be 
detrimental to the assay as it encouraged the spheroids to cluster around the 
edges of the plate. The plate was then incubated at 37°C for 15 min to allow the 
Matrigel to set. 1 ml of conditioned HUVEC media was then added to each well 
of the 12-well plate. The HUVEC media had been conditioned by 48 h 
incubation with HF1 cells, as detailed in Section 2.1.3. The plate was then 
placed in a CB 53 incubator (Binder) at standard cell culture conditions for up to 
5 days. The spheroids were photographed using an Axiovert 100 microscope 
(Zeiss) using an AxioCam (Zeiss) and the images were acquired using 
AxioVision software (Zeiss). To calculate the average sprouts per spheroid, 
sprouts were counted using Adobe Photoshop CS4. Only 60 spheroids were 
analysed per condition due to disruption and loss of spheroids during collection 
and resuspension. Average sprout length was measured using the segmented 
lines tool in Image J (NIH). Five sprouts were measured per spheroid (n=20). 
 
2.7 In vivo angiogenesis studies using Danio rerio 
(zebrafish) embryos and larvae 
2.7.1 Culture of zebrafish embryos and larvae 
Zebrafish embryos were obtained by natural spawning of adult zebrafish. The 
transgenic lines Tg(kdrl:EGFP) (Beis et al., 2005) and Tg(fli1a:EGFP) (Lawson 
and Weinstein, 2002) lines were used to monitor blood vessel development. 
Embryos were raised and maintained at 28.5°C in system water and staged as 
described in Section 11 (Development Staging Series) of Chapter 3 of The 
Zebrafish Book: A guide for the laboratory use of zebrafish Danio (Brachydanio) 
rerio (Westerfield, 2000). The various developmental stages are detailed in 
table 2.7.  
 
2.7.2 Microinjection of zebrafish embryos 
Antisense morpholinos (MOs) (GeneTools), miRIDIAN microRNA mimics 
(Dharmacon, Thermo Scientific) and pCSGW_dll4-3’UTR reporter plasmid were 
injected into 1- to 4- cell stage embryos using a Picospritzer III microinjector 
109 
 
(Parker). The MOs used in this work are listed in Table 2.8. dll4-TPmiR-30 was 
designed so that the 3’ end binds to the miR-30 target site within the dll4 3’UTR 
whilst the 5’ region binds to the downstream flanking sequence, as described 
(Choi et al., 2007). dll4-TPcontrol was designed so that it binds to another 
unrelated region of the dll4 3’UTR (596-620 nt), which is not predicted to 
contain any other miRNA binding sites, as described (Choi et al., 2007). 
Lyophilised MOs and miRNA mimics were resuspended in sterile ddH2O to give 
a stock solution of 50 μg/μl and 10 μg/μl respectively. 10 μl working solutions of 
MOs and miRNA mimics were prepared by added 1 μl of 0.5% Phenol Red 
(Sigma-Aldrich) to the required volume of stock solution and ddH2O. For most 
experiments 1 nl of MO or miRNA mimic was injected per embryo because this 
is volume is ~1/10 of the total cell volume. Therefore if 5 ng of MO was to be 
injected per embryo, a working solution of 5μg/μl (5 ng/nl) was produced. 
Injection volumes of up to 2 nl could be tolerated and were used to inject a large 
quantity of MO or for co-injections. Phenol red is a non-toxic dye which enabled 
visualisation of the injection solution to aid needle loading and so that 
successful injections could be confirmed. Stock and working solutions were 
stored at -20°C and were heated to 65°C once thawed in order to eliminate 
secondary structures and duplexes. 
 
Egg laying was controlled by regulating the light/dark intervals of the fish. The 
night before laying was to be initiated, two stacked plastic boxes were placed in 
the bottom of the relevant tank. The top box contained marbles on a fine wire 
mesh; the bottom box was empty.  Normally the fish would eat their own eggs 
after laying as they are a rich source of protein and this behaviour reduces the 
energy loss experienced in egg production and breeding behaviour by cycling 
the protein within the tank. When the plastic boxes were placed in the tank the 
eggs fell between the marbles, through the wire mesh and into the bottom box, 
thereby escaping predation. Fish would lay shortly after the lights were turned 
on and the plastic boxes were then removed. The newly fertilised eggs were 
collected with a net, washed in system water and placed in petri dishes 
containing system water and methylene blue (Sigma-Aldrich). The methylene 
blue killed any fungi that would otherwise harm the embryos. 
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Glass microinjection needles were first broken using tweezers and then back-
loaded with 3μl of the appropriate working solution. The needles often had to be 
flicked in order to move the fluid down to the tip. The loaded needle was then 
secured to the microinjector. In order to calibrate the microinjector, injections 
were first performed into a petri dish containing oil and the resulting bubble of 
injection solution was measured using a Nikon SMZ1500 Stereo Microscope 
and an eye-piece containing a graticule ruler. At 11.25x magnification, a bubble 
of 1nl has a diameter of ~14.2 graticule units. Therefore the length of the gas 
pulse controlling the microinjection was altered until a bubble of this diameter 
was achieved.  Generally the gas pulse was between 20 and 35 msec long. 
Once the needle had been calibrated, the embryos were transferred into an 
empty petri dish containing a glass slide and most of the water was removed. 
The embryos were then lined up against the edge of the glass slide. The needle 
was pushed through the chorion of each embryo and the required volume of 
injection solution was injected inside. The embryos were then collected, placed 
in a petri dish containing system water plus methylene blue and incubated at 
28.5°C. 
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Period Stage 
Hours post-
fertilisation (hpf) 
Developmental landmarks 
Zygote (0-0.75 hpf) 1-cell 0 
Cytoplasm streams toward animal 
pole to form blastodisc 
Cleavage (0.75-2.2 hpf) 2-cell 0.75 Partial cleavage 
 4-cell 1 2 X 2 array of blastomeres 
 8-cell 1.25 2 X 4 array of blastomeres 
 16-cell 1.5 4 X 4 array of blastomeres 
 32-cell 1.75 4 X 8 array of blastomeres 
 64-cell 2 3 regular tiers of blastomeres 
Blastula (2.25-5.25 hpf) 128-cell 2.25 
5 blastomere tiers; cleavage planes 
irregular 
 256-cell 2.5 7 blastomere tiers 
 512-cell 2.75 
9 blastomere tiers; yolk syncytial 
layer (YSL) forms 
 1k-cell 3 
11 blastomere tiers; single row of 
YSL nuclei; asynchronous cell cycle 
 High 3.33 
Greater than 11 blastomere tiers; 
blastodisc flattening begins; YSL 
nuclei in two rows 
 Oblong 3.66 
Blastodisc flattening; multiple rows of 
YSL nuclei 
 Sphere 4 
Spherical shape; flat border between 
blastodisc and yolk 
 Dome 4.33 
Yolk cell bulging toward animal pole 
as epiboly begins 
 30%-epiboly 4.66 
Blastoderm an inverted cup of 
uniform thickness 
Gastrula (5.25-10 hpf) 50%-epiboly 5.25 
Blastoderm remains of uniform 
thickness 
 Germ-ring 5.66 
Germ ring visible from animal pole; 
50%-epiboly 
 Shield 6 
Embryonic shield visible from animal 
pole; 50%-epiboly 
 75%-epiboly 8 
Dorsal side distinctly thicker; epiblast, 
hypoblast, evacuation zone visible 
 90%-epiboly 9 
Axis and neural plate; brain and 
notochord rudiments 
 Bud 10 
Tail bud prominent; early polster; 
100%-epiboly 
Segmentation (10-24 hpf) 1-4 somites 10.33 First somite furrow 
 5-9 somites 11.66 
Polster prominent; optic vesicle, 
Kupffer's vesicle, neural kee 
 10-13 somites 14 Pronephros forms 
 14-19 somites 16 
EL (embryo length) = 0.9 mm; otic 
placode, brain neuromeres 
 20-25 somites 19 
EL = 1.4 mm; lens, otic vesicle, 
hindbrain neuromeres 
 26+ somites 22 
EL = 1.6 mm; blood islands, otoliths, 
midbrain-hindbrain boundary 
Pharyngula (24-48 hpf) Prim-5 24 
EL = 1.9 mm; early pigmentation, 
heartbeat 
 Prim-15 30 
EL = 2.5 mm; early touch reflex, 
retina pigmented 
 Prim-25 36 
EL = 2.7 mm; early motility, tail 
pigmentation 
 High-pec 42 
EL = 2.9 mm; rudiments of pectoral 
fins 
Hatching (48-72 hpf) Long-pec 48 
EL = 3.1 mm; elongated pectoral fin 
buds 
 Pec-fin 60 EL = 3.3 mm; pectoral fin blades 
Larval 
Protruding-
mouth 
72 3.5 mm total body length 
Table 2.7. Zebrafish Developmental Staging Series. Adapted from 
www.zfin.org/zf_info/zfbook/stages/index.html. Percentage-epiboly indicates the fraction of the 
yolk cell that the blastoderm covers. Somites are undifferentiated mesodermal components of 
early trunk or tail segments or metameres which are derived from paraxial mesoderm. 
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Morpholino 
(MO) 
Sequence (5’ to 3’) Targets 
Injected per 
embryo (ng) 
Reference 
MO1-dll4 
GTTCGAGCTTACCGG
CCACCCAAAG 
Splice blocking 5 and 6 
(Siekmann 
and Lawson, 
2007) 
MO4-dll4 
TGATCTCTGATTGCT
TACGTTCTTC 
Exon 4/intron 4 splice-donor 
site 
6 and 8 
(Hogan et al., 
2009b) 
dll4-TP
miR-30
 
TGTAAACAATCCAGA
AAAAAAGATT 
miR-30 target site within dll4 
3’UTR 
5 and 10 N/A 
dll4-TP
control
 
ATAGCACTCTATTTAA
CTCTTTTAA 
Random site within dll4 3’UTR 
which does not contain any 
miRNA target sites 
5 and 10 N/A 
MO2-kdr 
TATGCTCTATTAGAT
GCCTGTTTAA 
5’UTR of kdr 4.5 
(Bahary et al., 
2007) 
MO2-kdrl 
CCGAATGATACTCCG
TATGTCACTT 
 4.5 
(Bahary et al., 
2007) 
 
Table 2.8. Morpholinos used for in vivo angiogenesis studies in zebrafish embryos. dll4-
TP
miR-30
 and dll4-TP
control
 were designed in-house as described (Choi et al., 2007).  
 
2.7.3 Zebrafish whole mount in situ hybridisation 
Before whole mount in situ hybridisation could be performed, zebrafish embryos 
had to be fixed. Embryos up to 15 somites could be fixed in their chorions 
however older embryos were dechorionated before fixing. This was to aid 
examination of the older embryos, as if they were fixed in their chorions they 
would have been fixed curled up rather than straighten out. Dechorionation was 
performed manually using two pairs of tweezers under a Nikon E1500 
dissecting scope. The chorion was pinched with one pair of tweezers and pulled 
apart with the other pair, taking care not to puncture the yolk sac or damage the 
tail of the embryo.  
 
All embryos of the same stage and experimental condition were collected and 
transferred to a 1.5 ml Eppendorf tube using a Pasteur pipette (Sterilin). The 
majority of the water was removed from the tube, leaving ~50 μl. The embryos 
were then covered with 4% paraformaldehyde (PFA) in PBS and incubated at 
4°C overnight to allow fixation to occur. The PFA was made by adding 10 ml of 
16% PFA (Sigma-Aldrich) to 4ml of sterile 10x PBS (Sigma-Aldrich) and 26 ml 
of ddH2O. The PFA was then removed using a Pasteur pipette and the embryos 
were washed three times for 5 min with PBS + 0.1% Tween® 20 (Sigma-Aldrich) 
(PBST). Enough PBST was added to each tube to completely cover the 
embryos (0.5-1 ml). At this stage, embryos of 15 somites or younger could be 
dechorionated, also using tweezers. The fixed embryos were then dehydrated 
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by two 5min washes with 50% ethanol/50% PBST and two 5 min washes with 
100% ethanol. For each wash 0.5-1 ml of solution was added to each 
Eppendorf tube in order to completely cover the embryos. The last ethanol 
wash was removed with a Pasteur pipette and 0.5 ml of fresh ethanol was 
added to each Eppendorf tube before the embryos were stored at -20°C. A 
minimum of overnight storage at -20°C was required before the in situ 
hybridisation could be performed, however longer -20°C storage was found to 
improve the quality of the staining.  
 
On day one of the in situ hybridisation procedure the embryos were first 
rehydrated by two 5 min washes with 50% ethanol/50% PBST and four 5 min 
washes with 100% PBST. For each wash 0.5-1 ml of solution was added to 
each Eppendorf tube in order to completely cover the embryos. Embryos older 
than 24 hpf were then treated with Proteinase K (Sigma-Aldrich) for 3-20 min, 
depending on stage and potency of enzyme, which varies from batch to batch. 
A 20 mg/ml stock solution of Proteinase K was thawed on ice and then added to 
PBST to produce a 10 µg/ml working solution. This was used to completely 
cover the relevant embryos for the required time period. Removal of the 
Proteinase K was begun 30 sec prior to the end of the required time period so 
that all Proteinase K had been removed within the required time. If embryos 
were incubated in Proteinase K for too long damage and disintegration could 
occur. Any residual Proteinase K was removed by two washes in PBST. The 
embryos were then re-fixed by incubation with 4% PFA in PBST for 20 min at 
RT. The PFA was removed with a Pasteur pipette and two quick washes with 
PBST were performed before five 5 min washes with PBST to remove any 
residual PFA. The embryos from each experimental condition and/or time point 
were then split into several different Eppendorf tubes, one per probe. This was 
done over a light box so that the embryos could be easily visualised.  
 
Hybe solution was removed from storage at -20°C and warmed up slightly on 
ice to reduce pipetting errors. The recipe for the Hybe solution is shown below. 
The embryos were then washed with 50% Hybe solution/50% PBST for 5 min 
before being prehybridised in 200 μl of 100% Hybe solution for 1 h at 65°C. A 
heat block was used for this incubation step and it was turned on its side so that 
the embryos were spread out along each Eppendorf tube. To generate the 
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probes, a PCR fragment spanning ~1 kb was used as a template. This had 
been amplified from 24 hpf embryo cDNA. Digoxigenin (DIG)-labelled antisense 
RNA probes were transcribed from linearized templates using T3, T7 or Sp6 
RNA polymerases (Roche). The probes were thawed on ice and then 1:200 
dilutions were made up using Hybe solution. The diluted probe was heated to 
65°C for 15 min to destroy any secondary structures. The 100% Hybe solution 
was then removed from the embryos and 200 μl of diluted probe was added to 
each Eppendorf tube. The embryos were then incubated overnight at 65°C on a 
heat block which was turned on its side.  
 
Hybe Solution - pH 6.0 
Formamide (Sigma-Aldrich)     25 ml 
20x Standard saline citrate (SSC) (Sigma-Aldrich)  12.5 ml 
tRNA (50 mg/ml) (Sigma-Aldrich)     0.5 ml 
Heparin (100 mg/ml) (Sigma-Aldrich)    25 μl 
Citric acid (1 M) (Sigma-Aldrich)     460 μl 
Tween® 20 (Sigma-Aldrich)     250 μl 
ddH2O        11.5 ml 
 
On day two of the in situ hybridisation procedure the diluted probe was removed 
from the embryos and stored in Eppendorf tubes at -20°C as it could be reused 
twice. The embryos were then returned to the heat block and pre-warmed 100% 
Hybe minus solution was added to each Eppendorf tube, enough to cover the 
embryos. Hybe minus solution is Hybe solution lacking the heparin and tRNA. 
Hybe minus solution was added to the bottom of a 24- or 48-well in situ 
hybridisation plate (Intavis Bioanalytical Instruments AG) and the plate was 
placed on a light box. Embryos labelled with each probe and from each 
experimental condition or time point were then added to separate wells of the 
plate using a Pasteur pipette. The plate was then placed in the BiolaneTM HTI in 
situ hybridisation machine (Intavis Bioanalytical Instruments AG) and connected 
to the dispensing and extraction tubes. The in situ hybridisation protocol was 
then started, which is detailed in Table 2.9. All the solutions had to be made up 
in advance from stock solutions and incubated at the required temperature so 
that they were already equilibrated before entering the in situ hybridisation 
machine. The recipes for 10x maleic acid buffer (MAB) and MAB block are 
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shown below. Before each step, whilst the machine was pumping out the 
previous wash from the plate, the bottles of solution had to be switched to 
provide the machine with the correct solution for the next wash or incubation.  
 
10x Maleic acid buffer (MAB)   
0.1 M Maleic Acid (Sigma-Aldrich)  
0.15 M NaCl (Sigma-Aldrich)   
Adjust pH to 7.5 using NaOH (Sigma-Aldrich)   
 
MAB block 
Blocking reagent (Boehringer Mannheim, Roche) 0.8 g 
1x MAB       up to 40 ml 
Heat to ~80° until granules disappear 
 
Step/Solution 
Volume of 
solution 
(ml) 
Time per 
wash 
(min) 
Washes 
Total length 
of step 
(min) 
Temp 
(°C) 
Pump out      
75% Hybe minus / 25% 2x SSC 50 10 1 10 65 
50% Hybe minus / 50% 2x SSC 50 10 1 10 65 
25% Hybe minus / 75% 2x SSC 50 10 1 10 65 
100% 2x SSC 50 10 1 10 65 
100% 0.2x SSC 200 15 4 60 65 
25% MABT / 75% 0.2x SSC 50 10 1 10 21 
50% MABT / 50% 0.2x SSC 50 10 1 10 21 
75% MABT / 25% 0.2x SSC 50 10 1 10 21 
100% MABT 50 10 1 10 21 
MAB block 40 60 1 60 21 
Anti-DIG antibody 40* 600 1 600 4 
100% MABT 400 15 8 120 21 
Hold (does not pump out)      
 
Table 2.9. Incubations and washes performed by in situ hybridisation machine. Volume of 
solution indicates the total volume of solution required for that step in the procedure for a 24-
well plate. Volumes are doubled for a 48-well plate. Standard saline citrate (SSC); Maleic acid 
buffer (MAB); 1x MAB plus 0.1% Tween
® 
20 (MABT); 1x MAB plus Boehringer block (MAB 
block). *Final volume in plate was 40 ml to achieve antibody dilution of 1:5000 however the 
machine was provided with 10 μl of anti-DIG antibody in 10ml of MAB block and separately 
provided with 30 ml of MAB Block which it cools to 4°C before addition to plate. 
 
 
On the third day of the in situ hybridisation procedure, the in situ hybridisation 
machine was provided with AP buffer (developing buffer) and the developing 
procedure was run on the machine (three washes of 5 min). The recipe for AP 
buffer is shown below.  
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AP buffer     
24-well plate  48-well plate 
1 M TrisHCl (pH9.5) (Sigma-Aldrich) 20 ml   40 ml 
5 M NaCl (Sigma-Aldrich)   4 ml   8 ml 
1 M MgCl2 (Sigma-Aldrich)   10 ml   20 ml 
Tween® 20 (Sigma-Aldrich)  1 ml   2 ml 
ddH2O     165 ml  330 ml 
 
The embryos were then removed from the in situ hybridisation machine and 
transferred from the in situ hybridisation plate into a sterile 24-well flat bottomed 
plate (Corning) with the aid of a light box. Any remaining AP buffer was 
removed from each well and the embryos were covered with 0.5-1 ml of staining 
buffer. Staining buffer was prepared by mixing AP buffer and BM Purple 
(Roche) in a 1:1 ratio. The plate was wrapped in foil and placed on a Gyro 
rocker STR (Stuart® Scientific) for between 10 min and 24 h, depending on the 
probe and the strength of the signal. Embryos were frequently examined under 
a Nikon E1500 dissecting scope to check the extent of the staining so that it 
could be stopped before it reached saturation. To stop the staining reaction 
temporarily, the staining buffer was removed and the embryos were washed 
three times for 5 min in PBST plus 20 mM EDTA. To permanently stop the 
staining reaction, the staining buffer was removed and the embryos were 
washed two times for 5 min with PBST. The embryos were then re-fixed in 4% 
PFA for 20 min at RT or overnight. Once fixed, the embryos were washed three 
times for 5 min in PBST.  
 
If the embryos were 24 hpf or older they had to be bleached before being 
examined or photographed as the pigment would obscure the in situ 
hybridisation staining. Bleaching solution was prepared by mixing hydrogen 
peroxide (H2O2) with 50% formamide (see below for recipes). 1 ml of bleaching 
solution was added to each subset of embryos and then they were incubated on 
the light box until the pigment was removed: ~5min for 24 hpf; 10 min for 30 hpf; 
15-20 min for 48 hpf; 30-35 min for 3-5 dpf.  
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50% formamide    Bleaching solution 
Formamide (Sigma-Aldrich) 4 ml ddH2O   5.67 ml 
20x SSC (Sigma-Aldrich)  2 ml H2O2 (Sigma-Aldrich) 3.33 ml 
1x PBS (Sigma-Aldrich)  2 ml 50% formamide  1 ml 
 
The bleached embryos were washed three times for 5 min in PBST and then all 
embryos were resuspended in 50% glycerol (in PBS) for 10 min before 1 ml of 
fresh 50% glycerol was added to each Eppendorf tubes. Embryos were stored 
at 4°C until photographed but at RT for long term storage. Images of in situ 
hybridisations were taken using a Nikon 1200F camera on a Nikon E1500 
dissecting scope and acquired using ACT-1 software (Nikon). Embryos were 
orientated with the anterior to the left and posterior to the right. 5x magnification 
was used to photograph the whole embryo whereas 11.25x magnification was 
used to photograph specific areas. Figures were generated using Adobe 
Photoshop CS4. 
 
2.7.4 Imaging and quantification of live zebrafish embryos 
Brightfield images of whole embryos within the chorion were taken using a 
Nikon 1200F camera on a Nikon E1500 dissecting scope and acquired using 
ACT-1 software (Nikon).  
 
Fluorescent images of Tg(kdrl:EGFP) and Tg(fli1a:EGFP) embryos were taken 
using a Zeiss Axiocam on a Zeiss AxioVision SteREO Lumar V12 dissecting 
microscope and acquired using AxioVision v4.8 software. 1-phenyl 2-thiourea 
(PFU) (Sigma-Aldrich) was added to the water of Tg(kdrl:EGFP) or 
Tg(fli1a:EGFP) embryos at 24 hpf if they were to be used for live imaging. PTU 
inhibited melanogenesis by blocking all tyrosinase-dependent steps in the 
melanin pathway and therefore prevented pigmentation of the embryos which 
would obscure imaging or hinder identification of phenotypes. PTU treatment 
was initiated before pigmentation began because it does not remove already 
formed pigment. Before imaging and/or quantification, the embryos were 
dechorionated and placed in 3% methylcellulose (Sigma-Aldrich) within the dip 
of a depression slide. To stop embryos from moving during imaging and/or 
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quantification, a few drops of 5 g/L tricaine mesylate (MS-222) (Sigma-Aldrich) 
was added to the water in the petri dish to give a final concentration of 0.01-
0.05%. If this was done, the embryos were transferred to a new petri dish with 
fresh water after imaging. MS-222 is a muscle relaxant that operates by 
preventing action potentials. x45 magnification was used to photograph whole 
embryos and x120 magnification was used to obtain detailed photographs of the 
DA, ISVs and other specific areas. Images were cropped and arrowheads were 
added using Adobe Photoshop CS4. The n numbers for all quantification 
experiments are displayed in Table 2.10.  
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Figure Microinjection group n number 
Figure 5.9A NIC 30/32 
 0.2 ng NTC mimic 24/25 
 0.5 ng NTC mimic 33/34 
 0.05 ng miR-30b mimic 36/40 
 0.1 ng miR-30b mimic 42/48 
 0.2 ng miR-30b mimic 80/99 
 0.1 ng miR-30c mimic 56/60 
 0.2 ng miR-30c mimic 34/40 
 0.4 ng miR-30c mimic 74/83 
Figure 5.9B NIC 24/31 
 0.2 ng NTC mimic 22/23 
 0.5 ng NTC mimic 35/36 
 0.05 ng miR-30b mimic 37/39 
 0.1 ng miR-30b mimic 41/43 
 0.2 ng miR-30b mimic 34/52 
 0.1 ng miR-30c mimic 47/49 
 0.2 ng miR-30c mimic 26/29 
 0.4 ng miR-30c mimic 46/55 
Figure 5.11C NIC 66/71 
 NTC mimic 27/27 
 TP alone 50/52 
 miR-30b mimic 36/41 
 miR-30c mimic 29/31 
 NTC mimic + TP 59/63 
 miR-30b mimic + TP 27/31 
 miR-30c mimic + TP 47/53 
Figure 5.13B uninjected 60/60 
 kdr MO 41/41 
 kdrl MO 40/40 
 kdrl MO + kdr MO 40/40 
 control TP 50/50 
 control TP + kdr MO 49/49 
 miR-30 TP 35/35 
 miR-30 TP + kdr MO 37/37 
 
Table 2.10. List of n numbers for the microinjection groups quantified in Figures 5.9A, 
5.9B and 5.11C. For each microinjection group the n value is given as counted embryos/total 
embryos. This reflects the fact that embryos with severe morphological defects which prevented 
ISV phenotyping were not counted. NIC: non-injected control; NTC: non-targeting control; MO: 
morpholino; TP: target protector. 
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2.8 Bioinformatics analysis 
Processing and statistical analysis of the KLEC GEM data was performed by 
Stephen Henderson using the Bioconductor packages (Gentleman et al., 2004) 
(affy (Irizarry et al., 2003) and limma (Smyth, 2004)) for the R programming 
language.  
 
2.8.1 Data mining of DLL4 and miR-30 expression from TGCA 
GEM and RNAseq data for analysis of the correlation between DLL4 and miR-
30 in tumours compared to normal tissue were obtained from The Cancer 
Genome Atlas (www.cancergenome.nih.gov) data portal (www.tcga-
data.nci.nih.gov) by Gemma Bridge and analysed by Stephen Henderson. As 
data for each sample were individually processed rather than normalised as a 
batch, and since data from different platforms and data-types were analysed, 
both the miRNA and gene expression data were scaled (i.e. between 0 and 1) 
and centred (i.e. about 0) before merging. A full list of the sample numbers, 
data-types and platforms are shown in Table 2.11. 
 
Tumour type 
Number of 
samples 
mRNA 
data-type 
mRNA 
expression 
platform 
miRNA 
data-type 
miRNA 
expression 
platform 
Breast invasive 
carcinoma 
326 GEM AgilentG4502A RNAseq 
Illumina-
GAmiRNAseq 
Colon 
adenocarcinoma 
147 GEM AgilentG4502A RNAseq 
Illumina-
GAmiRNAseq 
Gioblastoma 
multiforme 
498 GEM AgilentG4502A GEM 
Agilent 
8x15H-
miRNA 
Renal clear cell 
carcinoma 
62 GEM AgilentG4502A RNAseq 
Illumina-
GAmiRNAseq 
Lung 
adenocarcinoma 
32 GEM AgilentG4502A RNAseq 
Illumina-
GAmiRNAseq 
Rectum 
adenocarcinoma 
63 GEM AgilentG4502A RNAseq 
Illumina-
GAmiRNAseq 
Ovarian serous 
cystadenocarcinoma 
462 GEM AgilentG4502A RNAseq 
Illumina-
HimiRNAseq 
 
Table. 2.11. Sample numbers, data-types and platforms for tumours analysed for Figure 
3.5. All data for both tumour and normal samples were obtained from The Cancer Genome 
Atlas (www.cancergenome.nih.gov) data portal (www.tcga-data.nci.nih.gov). 
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2.9 Statistical analysis 
Standard error of the mean (SEM) was used to determine the confidence limits 
for all experiments which had been performed in replicate. SEM is a method 
used to estimate the standard deviation (SD) of a sampling distribution. SEM 
was calculated by dividing the SD (σ) by the square root of the number of 
samples (N):  
SEM = _σ_ 
           √N 
  
SD is the square root of the variance (σ2). The variance is a measure of how 
spread out a set of values is and therefore SD indicates how much variability 
there is about the mean and can be used as a measure of variation between 
sample values.  
σ = √σ2  σ2 = ∑ (X – μ)2 
                                      N 
(Where X is a sample value and μ is the mean of the sample values). 
 
To determine whether the difference between two experimental conditions was 
significant (with the exception of the analysis of zebrafish phenotypes) p values 
were calculated using a two-sided unpaired Student's t test for samples with 
equal variance (homoscedastic). The difference was considered significant if 
p<0.05. 
 
For some experiments which have only been repeated once, SD was used to 
evaluate the technical error of that particular experiment. Where this has 
occurred it has been explained in the figure legend.  
 
To determine the statistical significance between the indicated zebrafish 
phenotypes in Fig. 5.13, each observation of no phenotype, moderate 
phenotype and severe phenotype was given the value 0, 1 and 2 respectively 
and then a Wilcoxon rank-sum test was performed.   
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Chapter 3. Evaluation of the predicted targets of 
miRNAs altered upon KSHV infection LEC.  
3.1. Aims 
The aims of this chapter were: 
i. To investigate the predicted targets of miRNAs that are upregulated or 
downregulated upon Kaposi sarcoma-associated herpesvirus (KSHV) 
infection of lymphatic endothelial cells (LEC) using TargetScan 4.2 and 
PITA prediction algorithms.  
ii. To compare any predicted targets to a list of pro- and anti-angiogenic 
genes and also to angiogenic factors which are known to be regulated 
following KSHV infection of LEC.  
iii. To select a predicted miRNA/target pair of interest based on opposite 
changes of expression in KSHV-infected LEC (KLEC) and/or due to the 
importance of the target to endothelial cell biology.  
iv. To confirm the upregulation or downregulation of the chosen miRNA and 
its predicted target in KLEC using qRT-PCR.  
 
3.2. Target prediction of miRNAs upregulated or 
downregulated in KLEC 
Microarray data had been previously generated in this laboratory to measure 
the expression of cellular miRNAs in LEC and in KLEC (Lagos et al., 2010). 
These data had been analysed to determine miRNA expression levels 72h post-
infection (p.i.) (Lagos et al., 2010). Those miRNAs which were upregulated by 
1.5-fold or greater (Table 1.2), or with at least a 50% reduction in expression 
(Table 1.3), were taken forward for further investigation in this work. Two target 
prediction algorithms, TargetScan 4.2 (Grimson et al., 2007; Lewis et al., 2003; 
Lewis et al., 2005) and PITA (Kertesz et al., 2007) were used to predict 
potential targets of these miRNAs. The two chosen target prediction algorithms 
are based on different criteria and hence generate varying lists of predicted 
targets.  
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TargetScan 4.2 only displays conserved target sites (Lewis et al., 2003) and 
only considers the 3’UTR of target mRNAs, excluding target sites within 
5’UTRS, ORFs or within 15nt of the stop codon (Grimson et al., 2007). It 
produces a Total Context Score for each mRNA/miRNA pair which is the sum of 
the context scores for all the target sites specific to that particular miRNA. The 
context score of a specific site combines scores for the following features: type 
of target site, additional pairing to the 3’ region of the miRNA, local AU 
composition and position of the target site within the 3’UTR (Grimson et al., 
2007). The four types of target site, listed in order of efficacy, are 6mer, 7mer-
A1, 7mer-m8 and 8mer. The 6mer is the perfect 6nt match to the miRNA seed, 
miRNA nucleotides 2-7 (Lewis et al., 2005). The 7mer-A1 contains the seed 
match augmented by an adenine at target position 1 (Lewis et al., 2005). The 
7mer-m8 is the best 7mer site and contains the seed match augmented by a 
match to miRNA nucleotide 8 (Brennecke et al., 2005; Krek, 2005; Lewis et al., 
2003; Lewis et al., 2005). The best site, an 8mer, comprises the seed match 
flanked by both the adenine at position 1 and the match at position 8 (Lewis et 
al., 2005). Additional Watson-Crick pairing at the 3’ end of the miRNA, 
particularly nucleotides 13-16, was found to be an effective determinant, 
especially for 7mer-m8 sites. Therefore a score for 3’ binding is calculated that 
is equal to the greatest number of contiguously paired bases but weighted 
towards pairing at nucleotides 13-16 (Grimson et al., 2007). When comparing 
functional and non-functional target sites, it was found that the nucleotides 
flanking functional sites were highly enriched for adenine and uracil, therefore a 
score for local AU composition is calculated with a higher score indicating 
greater local AU composition in the region flanking the target site (Grimson et 
al., 2007). Target sites located near either end of a 3’UTR were found to be 
more effective than those near the centre and site-conservation analysis 
revealed that more sites were selectively maintained near the end of 3’UTRs 
than in the central region. Therefore the score for target site position is based 
on the distance in nucleotides between the site and the nearest end of the 
3’UTR (Grimson et al., 2007).  
 
The PITA algorithm is very different in that it focuses on target site accessibility 
and the binding energy of miRNA-target duplexes, rather than considering 
target site location and sequence-based criteria. This model was based on the 
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finding that mutations which diminished target site accessibility significantly 
reduced miRNA-mediate translational repression to an extent that was 
comparable with mutations that disrupted sequence complementarity (Kertesz 
et al., 2007). Therefore the PITA algorithm calculates ∆∆G for each target site, 
which is the difference between the free energy gained by the binding of the 
miRNA to the target (∆Gduplex) and the free energy lost by separating the target 
site nucleotides (∆Gopen) (Kertesz et al., 2007). To assign an overall miRNA-
mRNA target score, the algorithm computes the statistical weight of all 
configurations in which exactly one of the sites is bound by the miRNA. For 
negative values of ΔΔG, the summation formula is -log (Σ(e-ΔΔGi)). The PITA 
algorithm allows you to dictate the minimum seed size you wish to consider 
(6mer, 7mer or 8mer), permits you to allow G:U wobble and single mismatches 
within the seed region and to alter the minimum seed conservation required. 
 
Even with stringent search requirements the target prediction results returned 
by TargetScan and PITA were excessive, therefore initial analysis focussed on 
those targets that were predicted by both algorithms (Fig. A1 and A2). To 
increase the chance of overlap between these two algorithms the PITA target 
predictions were performed with the broadest search criteria. Therefore 6mer 
seeds were considered, G:U wobbles and single mismatches within the seed 
region were permitted and minimum seed conservation was used. For some 
miRNAs a PITA score could not be calculated and hence these miRNAs were 
discounted from further analysis (highlighted in white in Tables 1.2 and 1.3). 
Predicted targets were considered to be of potential interest if they possessed 
target prediction scores which fell below one or both of the threshold scores 
which are indicated by the dotted red lines in Figures A1 and A2. The threshold 
score for TargetScan was set as a Total Context Score of -0.4 as previous 
experience in the laboratory had indicated that this was a suitable threshold for 
this algorithm. The threshold score for PITA was set as an overall miRNA-
mRNA target score of -10. The ΔΔG value calculated by PITA is an energetic 
score, therefore the lower its value, the stronger the binding between a miRNA 
and the given target site is expected to be. The creators of the PITA algorithm 
suggest that target sites with ΔΔG values below -10 are likely to be functional at 
endogenous miRNA expression levels. Each miRNA may only have one target 
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site within each target mRNA therefore an overall miRNA-mRNA target score of 
-10 seemed appropriate as a threshold score. 
 
The specific aim of this project was to identify miRNAs which target genes 
implicated in angiogenesis, therefore a list of genes that are involved in the 
regulation of angiogenesis and vascular integrity was compiled (Table A1). This 
list was based on a list of angiogenic genes as defined by Vart et al., 2007. 
Additional genes were added to this list due to recent reports of pro- or anti-
angiogenic functions, based on the Gene Ontology (GO) biological process 
terms. The predicted targets generated by both TargetScan and PITA were 
compared to this list in order to identify any targets which play a role in 
angiogenesis (Table A2 and A3). A target was of particular interest if it had a 
good PITA score (-10 or less) and/or was predicted by TargetScan, particularly 
if it displayed the opposite expression pattern from the miRNA in KLEC, as 
determined by Vart et al., 2007 (Fig. 1.1).  
 
For example, when the predicted targets of upregulated miRNAs were 
examined, phosphatase and tensin homologue (PTEN) stood out as a strong 
predicted target of miR-26a due to the low PITA and TargetScan 4.2 Scores 
and the fact that PTEN is downregulated in KLEC (Table A2, Fig. 1.1 and 3.1A). 
The TargetScan 4.2 and PITA scores for PTEN were also much more 
favourable than those of any previously reported miR-26a targets: SMAD family 
member 1 (SMAD1) (Luzi et al., 2008), enhancer of zeste homolog 2 (EZH2) 
(Wong and Tellam, 2008), cyclin-E2 (CCNE2) (Kota et al., 2009) and cyclin-D2 
(CCND2) (Kota et al., 2009) (Fig. 3.1B). PTEN is a well-documented tumour 
suppressor gene and therefore its expression is not restricted to endothelial 
cells (Keniry and Parson, 2008). However, PTEN has been shown to have an 
anti-angiogenic effect because it is an antagonist of the phosphatidylinositol 3-
kinase (PI3K) pathway, which is the major signalling route of pro-angiogenic 
factors (Jiang and Liu, 2009). My target prediction strategy was validated when 
miR-26a targeting of PTEN was confirmed, and the miR-26a/PTEN axis 
implicated in gliomagenesis (Huse et al., 2009). 
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Figure 3.1. hsa-miR-26a is predicted to target PTEN. TargetScan Version 4.2 Total Context 
Scores plotted against PITA ddGSum scores for hsa-miR-26a. (A) Potential targets of interest 
are shown as red squares and have been named. The red lines indicate threshold scores; 
targets which fall below both these thresholds are of particular interest. Targets with either a 
favourable TargetScan Version 4.2 Total Context Score or a favourable PITA ddSum score 
have also been labelled. (B) PTEN is indicated by a red circle, genes known to be targeted by 
hsa-miR-26a at the time of conducting the target prediction analysis are marked with orange 
circles. 
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3.3 The miR-30 family is predicted to target DLL4 
The target prediction analysis described in Section 3.2 revealed that hsa-miR-
30a, -30b, -30c and -30d, all members of the miR-30 family, were predicted to 
target DLL4. These miR-30 family members were all downregulated by 0.5 fold 
or less in KLEC (Table 1.3), whilst DLL4 is one of the most significantly 
upregulated genes in KLEC (Fig. 1.1) (Emuss et al., 2009). The miRNA-mRNA 
binding between miR-30 and DLL4 was predicted by both PITA and 
TargetScan, with an almost favourable TargetScan 4.2 Total Context Score of -
0.38 (Table A2). DLL4 is not the most promising miR-30 target out of those 
upregulated in KLEC, especially when compared to known targets (Fig. 3.2A). 
However, when the reverse analysis was performed, searching for miRNAs 
predicted to target DLL4, the miR-30 family was found to be the best scoring 
miRNA for this 3’UTR (Fig. 3.2B).  
 
The predicted target site within the DLL4 3’UTR is an 8mer which is the best 
possible binding site: complete complementarity with the seed region of the 
miRNA plus additional complementarity at position 8 and an adenine at position 
1 (Fig. 3.3A). The target site is located towards the beginning of the 3’UTR at 
positions 59-66. This is another positive factor as target sites located near either 
end of the 3’UTR have been found to be the most effective (Grimson et al., 
2007). All miRNAs of the miR-30 family share an identical seed, however their 
sequences vary outside of the seed region which was reflected in variations in 
predicted 3’ complementary binding (Fig. 3.3A). TargetScan takes conservation 
into consideration when calculating the Total Context Score and the miR-30 
target site is absolutely conserved within the DLL4 3’UTR across 24 species, 
suggesting an essential function for this predicted miRNA-mRNA interaction 
(Fig. 3.3B). 
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Figure 3.2. The miR-30 family is predicted to target DLL4. (A) Predicted targets of hsa-miR-
30a, -30b, -30c and -30d. TargetScan Version 4.2 Total Context Scores are plotted against 
PITA ddGSum scores for the indicated miRNAs. DLL4 is indicated by a red circle and label, 
genes known from the literature to be targeted by miR-30 members at the time of conducting 
the target prediction analysis are marked with orange circles and labelled. (B) MiRNAs 
predicted to target DLL4. TargetScan Version 4.2 Total Context Scores are plotted against PITA 
ddGSum scores. All five members of the miR-30 family are indicated by red triangles and 
labelled.  
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Figure 3.3. Graphical representation of the miR-30 target site within the DLL4 3’UTR. (A) 
Complementarity between miR-30 family members and the DLL4 3’UTR. Black lines indicate 
canonical Watson and Crick base-pairing, grey lines indicate G:U wobbles. The predicted target 
site within the DLL4 3’UTR, positions 59-66 is shown in red; miR-30 seed region is shown in 
green. (B) Alignment demonstrating conservation of the miR-30 target site (red) and 
surrounding sequence within the DLL4 3’UTR across 24 species. Positions 53-66 of the 3’UTR 
are shown. 
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3.4 miR-30 and DLL4 expression inversely correlate in 
cancer 
miRNAs are known to target Notch components during tumour development, 
but a function for this cross-talk in tumourigenesis is unclear (Wang et al., 
2010). Downregulation of the miR-30 family is associated with enhanced 
tumourigenesis in anaplastic thyroid carcinoma and breast cancer (Braun et al., 
2010; Yu et al., 2010). However, an association between DLL4 and miR-30 
expression has not been described. Expression data from The Cancer Genome 
Atlas (www.cancergenome.nih.gov) was analysed, with a specific focus on 
angiogenic solid tumours. A significant negative correlation between one or 
more miR-30 family members and DLL4 expression was found in breast 
adenocarcinoma, ovarian serious cystadenocarcinoma and the highly 
angiogenic renal clear cell carcinoma (Fig. 3.4). Most of the other tumours 
analysed also displayed a negative correlation, although non-significant (Fig. 
3.4). These results provided additional evidence to support the hypothesis that 
miR-30 targets DLL4 and suggested that this interaction could be functionally 
relevant during human cancer development. 
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Figure 3.4. DLL4 and miR-30 expression inversely correlate in human tumour samples. 
Heatmap table displaying the correlation coefficient R between expression of DLL4 and each 
member of the miR-30 family in the indicated tumour types. GEM and RNAseq data was 
obtained from The Cancer Genome Atlas (www.cancergenome.nih.gov) data portal (tcga-
data.nci.nih.gov), as described in Section 2.8.1 of Chapter 2. Due to the large difference in the 
number of replicates for each tumour type, the significance of R was calculated for each miR-30 
vs. DLL4 combination. The values and fill-in colour indicate the degree of negative correlation. 
Non-significant correlations are greyed out; significant correlations are marked with an asterisk 
*, p<0.05; **, p<0.01. Tumour types included are breast invasive carcinoma (BRCA), colon 
adenocarcinoma (COAD), glioblastoma multiforme (GBM), renal clear cell carcinoma (RCC), 
lung adenocarcinoma (LUAD), rectum adenocarcinoma (READ) and ovarian serous 
cystadenocarcinoma (OV). Data was selected and obtained by Gemma Bridge. Bioinformatic 
analysis and heatmap were completed by Stephen Henderson.  
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3.5 Confirmation of miR-30b and -30c downregulation in 
LEC  
From expression microarray data previously generated in our laboratory (Lagos 
et al., 2010), it was known that miR-30a, -30b, -30c and -30d are downregulated 
in KLEC 72h p.i. When all the probes for members of the miR-30 family were 
examined individually, the probes corresponding to miR-30b and miR-30c were 
found to be significantly suppressed whilst downregulation in KLEC was a trend 
displayed by most members of the miR-30 family (Fig. 3.5A). To validate these 
microarray data, new KSHV infections were performed in human dermal LEC 
and miR-30b and miR-30c expression was quantified 72h p.i. using qRT-PCR 
(Fig. 3.5B). Both miR-30b and miR-30c were significantly repressed in KLEC by 
~45% whereas expression of let-7i, an unrelated miRNA, was not significantly 
altered (Fig. 3.5B). Fluorescence-activated cell sorting (FACS) was performed 
on KLEC to separate infected cells from non-infected cells, based on GFP 
expression. The expression of miR-30b and miR-30c was examined in the two 
cell populations but was not found to be significantly different; therefore future 
analysis of KLEC was performed with the mixed cell population.    
 
The mature miR-30c miRNA detected by the microarray can be produced from 
two distinct precursor hairpins (pre-miR-30c-1 and -2). This is because there 
are two pri-miRNA transcripts from which the pre-miRNAs are derived 
(Kozomara and Griffiths-Jones, 2011). These in turn are transcribed from two 
genomic locations: human chromosome 1 for miR-30c-1 and human 
chromosome 6 for miR-30c-2. Therefore, the observed downregulation of miR-
30c could have been due to a reduction in just one or both sources of miR-30c. 
To investigate this, qRT-PCR was performed using primers and probes specific 
to pre-miR-30c-1 and -2. Expression of both precursor hairpins was found to be 
reduced in KLEC 72h p.i., although pre-miR-30c-1 was only downregulated by 
~45% compared to the ~70% reduction in pre-miR-30c-2 (Fig. 3.5C). 
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Figure 3.5. The miR-30 family is downregulated in KLEC. (A) Heatmap representing relative 
changes in expression of hsa-miR-30 family members in LEC 72 h post-KSHV infection. Red 
and yellow denote low and high expression respectively. Probes for hsa-miR-30b and hsa-miR-
30c showed significant changes in expression (**, Q<0.01; ***, Q<0.001). Original GEM data 
from Lagos et al., 2010. Heatmap generated by Stephen Henderson. (B) Confirmation of 
downregulation of miR-30b and -30c in KLEC 72 h p.i., as quantified by qRT-PCR (means + 
SEM, n=4). Expression is relative to LEC. **, p<0.01. (C) pre-miR-30c-1 and pre-miR-30c-2 are 
both downregulated in KLEC 72 h p.i., as quantified by qRT-PCR (means + SEM, n=3). 
Expression is relative to LEC. **, p<0.01; ***, p<0.001.  
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3.6 Confirmation of DLL4 upregulation in human dermal 
LEC 
Previous work in our laboratory showing upregulation of DLL4 and JAG1 in 
KLEC had been performed in LEC derived from adult lymph nodes (Emuss et 
al., 2009), however the work described here was performed using human 
dermal LEC. It was therefore necessary to confirm that the alterations in Notch 
signalling components were also observed in this cell type. Uninfected human 
dermal LEC displayed the expected cobble-stone morphology of LEC (Fig. 
3.6A) whereas KSHV-infected human dermal LEC developed the typical 
spindle-shape morphology (Fig. 3.6B). This morphological change is most likely 
due to cytoskeletal rearrangements induced by nuclear factor of kappa light 
polypeptide gene enhancer in B-cells (NF-κB) which is activated by vFLIP 
(Grossmann et al., 2006). The recombinant strain of KSHV used for these 
infections (rKSHV.152), contains the GFP gene within its genome (Vieira et al., 
2001). Therefore, KSHV infection was also confirmed by GFP expression (Fig. 
3.6B). Significant upregulation of DLL4 and JAG1 was observed in KSHV-
infected human dermal LEC when compared to uninfected human dermal LEC 
(Fig. 3.6C). This verified that human dermal LEC were suitable for future 
investigations into miRNA regulation of DLL4 following KSHV infection.  
135 
 
 
Figure 3.6. Characterisation of KSHV infection in human dermal LEC. (A) Phase contrast 
image of human dermal LEC taken 72 h after cells had been plated. Photograph taken at 10x 
magnification on an Axiovert 100 microscope (Zeiss) using an AxioCam (Zeiss). (B) Upper 
panel: phase contrast image of human dermal LEC 72 h post-KSHV infection. Photograph taken 
at 10x magnification on an Axiovert 100 microscope (Zeiss) using an AxioCam (Zeiss). Lower 
panel: fluorescent image of the same field of view as in the upper panel, showing GFP 
expression. Photograph taken at 10x magnification on an Axiovert 100 microscope (Zeiss) using 
an AxioCam (Zeiss). (C) Upregulation of DLL4 and JAG1 mRNA 72 h following KSHV infection 
of human dermal LEC, as quantified by qRT-PCR (means + SEM, n=3). Expression is relative to 
uninfected human dermal LEC. ***, p<0.001. 
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3.7 Discussion 
The target prediction analyses presented here highlight the inherent difficulties 
of identifying functional miRNA-mRNA regulation. Depending on the particular 
algorithm used, and the stringency of the filters, each miRNA has hundreds to 
thousands of predicted targets. One method to refine a list of potential targets is 
to look at the overlap between the results of two or more algorithms, as adopted 
here. The advantages of this approach are that it reduces the targets of interest 
to a manageable number whilst also focusing on those that are most likely to be 
genuine targets.  
 
For this study TargetScan 4.2 and PITA were used as they incorporate a range 
of different parameters when producing a final target prediction score (Grimson 
et al., 2007; Kertesz et al., 2007; Lewis et al., 2003; Lewis et al., 2005). 
TargetScan considers target site conservation with an emphasis on the extent 
of seed match, 3’ complementarity and impact of target site position, whereas 
PITA allows the cut-off level for cross-species conservation to be reduced whilst 
focusing on target site accessibility. Only two prediction algorithms were 
selected for the cross-comparison of predicted targets as we decided that 
including a third algorithm would lead to excessive numbers of genuine targets 
being discarded. TargetScan was of particular interest because, along with 
PicTar, it performed best in a test of target prediction algorithms (Baek et al., 
2008). miR-223 was knocked out in mouse neutrophils and changes in protein 
expression were examined using stable isotope labelling with amino acids in 
cell culture (SILAC). Perturbations in endogenous targeting were then 
compared to target predictions from miRBase Targets (Griffiths-Jones et al., 
2008), miRanda (Betel et al., 2008; John et al., 2004), PicTar (Krek, 2005; Lall 
et al., 2006), PITA and TargetScan 4.2.  
 
However, as TargetScan heavily weights perfect seed pairing, PITA is 
preferential for allowing identification of non-canonical sites, such as those 
containing G:U wobbles or with imperfect seeds (Thomas et al., 2010). Since 
these target analyses were completed, the task of miRNA target prediction has 
been further complicated by the discovery of non-canonical 3’-supplementary, 
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3’-complementary (Bartel, 2009) and centred miRNA target sites (Shin et al., 
2010) and the suggestion that miRNAs can also ORFs (Duursma et al., 2008).   
 
The cross-comparison between miRNAs differentially expression in KLEC with 
angiogenic genes which are simultaneously upregulated or downregulated 
revealed an extensive network of predicted interactions. However, it was 
notable that many miRNA upregulated in KLEC are predicted to target genes 
that are also upregulated and vice versa. This does not necessarily mean that 
these miRNAs do not regulate expression of these genes. It could imply that in 
this system, other viral-induced signalling pathways predominate. Yet, amongst 
both the targets of upregulated and downregulated groups of miRNAs, specific 
genes stood out due to strong predictive scores and opposing changes in 
expression of target and miRNA. Several genes were also predicted to be 
targets of multiple similarly expressed miRNAs. For example, the pro-
angiogenic gene fibroblast growth factor receptor 2 (FGFR2) is upregulated in 
KLEC (Fig. 1.1) (Vart et al., 2007) and is predicted by both PITA and 
TargetScan to be a target of miR-494 and miR-513, both of which are 
downregulated in KLEC (Table 1.3). Conversely, N(alpha)-acetyltransferase 15 
(NAA15), previously known as NMDA receptor-regulated protein 1 (NARG1), is 
downregulated in KLEC (Vart et al., 2007) and is predicted by both PITA and 
TargetScan to be a target of several upregulated miRNAs: miR-148a, miR-26a, 
miR-329, miR-503 and miR-582. NAA15 has been reported to maintain 
endothelial homeostasis by preventing retinal neovascularisation and to 
enhance the ubiquitination of hypoxia-inducible factor 1 alpha subunit (HIF1A), 
which is upregulated in KLEC (Fig. 1.1) (Gendron et al., 2001; Gendron et al., 
2006; Jeong et al., 2002). Therefore, co-ordinated upregulation of miRNAs that 
target NAA15 could be responsible for the subsequent downregulation of this 
potent anti-angiogenic gene and hence contribute to the pro-angiogenic 
environment of KSHV infected endothelial cells. Further examination of the 
target prediction analyses could reveal other interesting targets for future 
investigation. 
 
The outcome of the target prediction analyses described in Section 3.2 was to 
uncover the predicted targeting of DLL4 by the miR-30 family. Further 
examination of this prediction revealed a potential 8mer miR-30 target site 
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located in a beneficial position within the DLL4 3’UTR. DLL4 was of particular 
interest as a target gene because it is overexpressed in human tumours, often 
in association with markers of inflammation, hypoxia and angiogenesis (Jubb et 
al., 2009; Jubb et al., 2010; Patel et al., 2005; Patel et al., 2006). Blockade of 
DLL4 signalling suppresses experimental tumour growth by inducing non-
productive, deregulated angiogenesis (Haller et al., 2010; Hoey et al., 2009; 
Noguera-Troise et al., 2006; Oishi et al., 2010; Ridgway et al., 2006). This 
discovery has subsequently led to a Phase I trial of a DLL4 blocking antibody 
(www.clinicaltrials.gov). However, as long term treatment of rats with such an 
antibody led to the development of vascular neoplasms (Yan et al., 2010), there 
is a potential need for more subtle mechanisms to moderately reduce DLL4 
expression or signalling. Regulation of expression using exogenous miRNAs 
could be investigated as a potential solution. 
 
The miR-30 family contains five members: miR-30a, miR-30b, miR-30c, miR-
30d and miR-30e. Four of these family members demonstrate some level of 
downregulation in KLEC (miR-30a-d). This group of related miRNAs are 
encoded by six genes spread across three chromosomes. pre-miR-30a and 
pre-miR-30c-2 are transcribed individually from chromosome 6, pre-miR-30b 
and pre-miR-30d are clustered together as a pri-miRNA transcript on 
chromosome 8 and pre-miR-30c-1 and pre-miR-30e are also clustered on 
chromosome 1. All members of the family share the same seed sequence and 
there is very little variation in the remaining sequence of the mature miRNAs. 
Therefore, the entire family share common predicted targets. This level of 
redundancy suggests that this miRNA family possesses a critical function, 
potentially the regulation of a key mediator of angiogenesis. 
 
The potential link between miR-30 and DLL4 was highlighted partly because of 
the inverse expression of these genes in KLEC, according to microarray 
expression data. The Notch ligand DLL4 is one of the most significantly 
upregulated genes in KLEC of lymph node origin (Emuss et al., 2009), and this 
was independently confirmed here in human dermal LEC. Whilst four of the 
miR-30 members show some level of downregulation, probes for miR-30b and 
miR-30c were found to be significantly downregulated in KLEC and this was 
confirmed in three independent infections by qRT-PCR. Additionally, 
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downregulation of miR-30c was shown to be due to a reduction in both pre-miR-
30c-1 and pre-miR-30c-2. A putative promoter for pri-miR-30a has been 
identified (Fujita and Iba, 2008) and NF-κB binding has been shown to mediate 
lipopolysaccharide (LPS) induced upregulation of miR-30b (Zhou et al., 2009; 
Zhou et al., 2010). However, when the regions upstream of the various pri-miR-
30 transcripts were investigated, a common transcription factor binding site 
could not be identified. Given the multitude of genomic locations, it is possible 
that the altered expression of miR-30 family members following KSHV infection 
is due to regulation at the level of pri-miRNA processing. 
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Chapter 4. miR-30b and miR-30c target DLL4  
4.1. Aims 
Having identified DLL4 as a predicted target of the miR-30 family, the aims of 
this chapter were: 
i. To investigate whether functional targeting of DLL4 by miR-30 occurs in 
vitro by overexpressing miR-30 using miRNA mimics and lentiviral 
constructs and inhibiting endogenous miR-30 using miRNA inhibitors. 
ii. If miR-30 does regulate DLL4 expression, to identify the specific target 
site(s) through which miR-30 acts by employing a luciferase reporter 
assay to examine miR-30 binding to the DLL4 3’UTR. 
iii. To elucidate whether miR-30 targeting of DLL4 can influence endothelial 
cell behaviour in vitro using a tube formation assay.  
 
4.2. Cloning hsa-miR-30b and hsa-miR-30c-1 
To confirm the targeting of DLL4 by miR-30b and miR-30c, these two miRNAs 
would need to be overexpressed in vitro. For short-term expression, synthetic 
miRNA mimics from Dharmacon (ThermoScientific) was employed. However, to 
obtain long-term stable expression, miR-30b and miR-30c-1 were also cloned 
into the pSIN-MCS vector which would allow expression using a lentiviral 
system, as described in Section 2.2.2. Primers were designed which were 
complementary to either end of a ~500-600bp region surrounding the mature 
hsa-miR-30b and hsa-miR-30c-1 sequences (Table 2.1). These regions were 
smaller than the predicted pri-miRNAs for hsa-miR-30b and hsa-miR-30c-1, but 
would fully encompass the pre-miRNA sequences. This method has previously 
been shown in our laboratory to allow effective expression and processing of 
human miRNAs (Hansen et al., 2010; Lagos et al., 2010).  
 
Genomic DNA was extracted from LEC and used as a template to perform 
gradient PCR, as detailed in Table 2.1. The PCR samples were then run on an 
agarose gel using electrophoresis in order to visualise any products (Fig. 4.1A). 
The expected PCR product containing pre-miR-30b was 624bp and a band 
between 500 and 750bp was generated at all the annealing temperatures used, 
although more product was synthesised at annealing temperatures of 55-58°C 
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(Fig. 4.1A, upper panel). Some smaller, non-specific bands were also visualised 
at lower annealing temperatures and primer dimers appeared to have occurred 
at all annealing temperatures, indicating that these PCR reactions/primers were 
not efficient. The expected PCR product containing pre-miR-30c-1 was 564bp 
and a very strong band between 500 and 750bp was generated at all the 
annealing temperatures used, indicating very efficient PCR reactions with these 
primers (Fig. 4.1A, lower panel). All the DNA bands of the correct size were 
excised from the gels, extracted and pooled to produce a more concentrated 
PCR product for both miR-30b and miR-30c-1.   
 
The PCR products and the pSIN-MCS plasmid were then digested with BamHI 
and NotI restriction enzymes to generate the required sticky ends before ligation 
overnight at 16°C using T4 DNA ligase. Ligation reactions were performed at 
two ratios of vector to insert; 1:8 and 2:10. Following transformation and growth 
on ampicillin-containing agar plates, colonies were picked and grown up 
overnight as mini cultures. For pre-miR-30b both the 1:8 and 2:10 ligations 
generated colonies whereas only the 1:8 ligation was successful for pre-miR-
30c-1. DNA was extracted from half of the mini cultures and a diagnostic digest 
was performed with BamHI and NotI restriction enzymes. When gel 
electrophoresis was performed with the digested products, minipreps C-P for 
miR-30b and minipreps B, C and G for miR-30c-1, all displayed inserts of the 
expected size (Fig 4.1B). Sequencing revealed that miR-30b miniprep M and 
miR-30c-1 miniprep G contained the correct insert without any mutations and 
therefore the remainder of these cultures were used to seed maxi cultures to 
produce DNA maxipreps.  
 
  
142 
 
 
Figure 4.1. Cloning hsa-miR-30b and hsa-miR-30c-1 into a lentiviral vector. (A) Gel 
electrophoresis of miR-30b and miR-30c-1 PCRs.  Correct bands for both products shown 
between 500 and 750bp. Ladder: lanes containing Generuler 1kb DNA Ladder (Fermentas). 
250, 500 and 750bp bands are indicated. Images were taken using G:Box gel documentation 
system (Syngene) at 100ms exposure. (B) Gel electrophoresis of miR-30b and miR-30c-1 
minipreps following digestion with BamHI and NotI restriction enzymes. miR-30b minipreps 
labelled A-H were picked from the 1:8 ligation agar plate. miR-30b minipreps labelled I-P were 
picked from the 2:10 ligation agar plate. Ladder: lanes containing Generuler 1kb DNA Ladder 
(Fermentas). 250, 500 and 750bp bands are indicated. Images were taken using G:Box gel 
documentation system (Syngene) at 100ms exposure. 
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4.3. miRNA expression from pSIN_miR-30b and 
pSIN_miR-30  
Before using pSIN_30b and pSIN_30c to generate lentiviruses it was necessary 
to confirm that the cloned miRNAs were expressed from these plasmids. 1x105 
293T cells were transfected with either 500ng or 1000ng of pSIN_MCS, 
pSIN_30b or pSIN_30c and total RNA was harvested 48 h later. Both miRNAs 
were found to be expressed from the relevant plasmid; however miR-30c 
expression was ~4x higher than miR-30b expression at both concentrations 
(Fig. 4.2A). It was therefore decided that the miR-30b lentivirus but not the miR-
30c lentivirus would be concentrated.  
 
Lentiviruses encoding empty vector, GFP, hsa-miR-30b and hsa-miR-30c were 
produced in 293T cells after transfection with the relevant pSIN vector, the 
packaging plasmid pCMV-8.91 and the envelope plasmid pMD.G. The infectivity 
of the lentiviral preparations was determined by qPCR for the lentiviral 
packaging signal. 1x105 LEC were initially infected with 1 ml of each lentivirus 
and a successful infection was deemed to have occurred when the pSIN_GFP 
infected cells were 100% GFP-positive at 72 h p.i. (Fig. 4.2B). Both genomic 
DNA and total RNA were harvested at 72 h p.i. and qPCR analysis revealed 
that 1 ml of lentivirus yielded ~250 lentiviral copies per cell (c/c) for pSIN_30c 
but only 40 c/c for pSIN-30b (Fig. 4.2C). Despite the greater infectivity of 
pSIN_30c, the upregulation of miR-30c was only slightly higher than that of 
miR-30b, 19-fold compared to 12-fold (Fig. 4.2D). It was decided that matching 
miRNA expression between the two lentiviruses was more important than 
matching copy number and therefore volumes of pSIN_30c lentivirus were 
titrated to ascertain a volume which would also achieve 12-fold upregulation of 
miR-30c. This was found to be 500 μl (Fig. 4.3A). For all remaining lentiviral 
experiments 1 ml of concentrated pSIN_30b and 500 μl of unconcentrated 
pSIN_MCS and pSIN_30c were used. 
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Figure 4.2. Optimising miRNA expression from pSIN_30b and pSIN_30c. (A) Expression of 
miR-30b and miR-30c in 293T cells 48 h following transfection with the either 500 ng or 1000 ng 
of the indicated plasmid, as quantified by qRT-PCR. Expression is relative to pSIN_MCS 
transfected cells (SEM is not shown as n=1). (B) Top panel: phase contrast image of LEC 72 h 
p.i. with pSIN_GFP. Bottom panel: fluorescent image of the same field of view as in the upper 
panel showing GFP expression. Photographs taken at 10x magnification on an Axiovert 100 
microscope (Zeiss) using an AxioCam (Zeiss). (C) Lentiviral titre in LEC 72 h p.i. with 1 ml of the 
indicated lentivirus, as measured by qPCR (means + SEM, n=2 therefore SEM has only been 
included to give an approximate indication of reproducibility). (D) Overexpression of miR-30b 
and -30c in LEC 72 h p.i. with the relevant lentivirus, as quantified by qRT-PCR (means + SEM, 
n=2 therefore SEM has only been included to give an approximate indication of reproducibility). 
Expression is relative to pSIN_MCS infected LEC. *, p<0.05. 
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Figure 4.3 Titration of pSIN_miR-30c lentivirus in LEC.  (A) miR-30c expression increases 
with increasing volume of pSIN_30c lentivirus, as quantified by qRT-PCR. Expression is relative 
to LEC infected with the equivalent volume of empty vector, pSIN_MCS (SEM is not shown as 
n=1). (B) Downregulation of DLL4 mRNA and upregulation of miR-30c in LEC both correlate 
with lentiviral copy number, as quantified by qRT-PCR. Expression is relative to LEC infected 
with the equivalent copy number of empty vector, pSIN_MCS (SEM is not shown as n=1). 
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4.4. DLL4 is downregulated by miR-30b and miR-30c 
To ascertain whether DLL4 was a genuine target of miR-30b and -30c, these 
two miRNAs needed to be overexpressed in LEC. Initially Dharmacon 
miRIDIAN microRNA mimics (ThermoScientific) were used to achieve this goal. 
Oligofectamine was used for delivery of the non-targeting control (NTC), miR-
30b and -30c mimics. To determine the most suitable concentration of mimic to 
use in LEC a titration experiment was performed and selectin E (SELE) and 
DLL4 mRNA were quantified by qRT-PCR. A mimic concentration of 100nM 
was chosen because at this concentration ~40% reduction in DLL4 expression 
was observed for both miR-30b and -30c whilst expression of SELE, an 
unrelated mRNA, was unchanged (Fig 4.4A). Using 200nM of mimics did not 
suppress DLL4 expression further and caused significant cell death due to the 
required increase in transfection reagent (Fig. 4.4A). 
 
When the mimic transfections were repeated using 100nM, DLL4 mRNA and 
protein levels were significantly reduced by 40-50% in LEC expressing either 
mimic (Fig. 4.5A and B). This effect was not seen with the miR-29c* mimic, 
which is a miRNA that is not predicted to target DLL4 (Fig. 4.5A). Expression of 
an unrelated mRNA (SELE) was unchanged, suggesting that the suppression of 
DLL4 mRNA does not reflect a non-specific effect of these mimics on global 
mRNA levels (Khan et al., 2009). The effect of the miR-30 mimics on DLL4 
mRNA expression was noted to be dose dependent as significant suppression 
was first observed at 20-40nM and increased as the mimic concentration was 
increased to 100nM (Fig. 4.4B).  
 
Co-transfection of miR-30b and -30c, at an equivalent total concentration, did 
not increase DLL4 repression, suggesting that there are no additive or 
synergistic effects between these miR-30 family members (Fig. 4.4B). This 
finding concurred with the target prediction studies, which indicated only one 
miR-30 target site in the DLL4 3’UTR (Fig. 3.3A). 
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Figure 4.4. The effect of miR-30 mimic concentration on DLL4 expression in LEC. (A) 
DLL4 and SELE mRNA expression in LEC 48 h following transfection with the indicated 
concentrations of miRNA mimic (nM), as quantified by qRT-PCR. Expression is relative to LEC 
transfected with the equivalent concentration of NTC mimic (SEM is not shown as n=1). (B) 
Downregulation of DLL4 mRNA in LEC increases with increasing concentration of transfected 
mimic (nM), as quantified by qRT-PCR (means + SEM, n=3). Expression is relative to LEC 
transfected with the equivalent concentration of NTC mimic. *, p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 4.5. Overexpression of miR-30 causes downregulation of DLL4 in LEC. (A) DLL4 
and SELE mRNA expression in LEC transfected with NTC, miR-29c*, miR-30b or -30c mimics, 
as quantified by qRT-PCR (means + SEM, n=4). Expression is relative to NTC-transfected LEC. 
***, p<0.001. (B) DLL4 protein expression in LEC transfected with miR-30b or -30c mimics 
measured by Western blotting and normalised to GAPDH expression. Upper panel: 
representative western blot. Values beneath blot denote intensity of antibody ECL signal relative 
to NTC mimic. Molecular weight markers are represented to the right. Lower panel: intensity of 
antibody ECL signal relative to NTC-transfected LEC (means + SEM, n=3). **, p<0.01. (C) DLL4 
mRNA expression in LEC infected with miR-30b or -30c expressing lentiviruses, as quantified 
by qRT-PCR (means + SEM, n=4). Expression is relative to empty vector, pSIN_MCS. **, 
p<0.01. (D) Representative Western blot showing DLL4 protein levels in LEC infected with miR-
30b or -30c expressing lentiviruses. Values beneath blot denote intensity of antibody ECL signal 
relative to empty vector, pSIN. Molecular weight markers are represented to the right.   
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Transduction of LEC with pSIN_30b and pSIN_30c through infection with the 
relevant lentivirus also suppressed DLL4 mRNA and protein (Fig. 4.5C and D). 
Although the observed downregulation was more variable with the lentiviruses, 
a greater degree of suppression was achieved, sometimes as high as 70-85% 
(Fig. 4.5D). 
 
KSHV infection of endothelial cells results in transcriptional reprogramming from 
a LEC to a BEC phenotype and vice versa (Hong et al., 2004; Wang et al., 
2004). Therefore, the effect of miR-30 overexpression in human umbilican vein 
endothelial cells (HUVEC) was then examined to determine whether the 
suppression of DLL4 was specific to lymphatic endothelial cells or also relevant 
in blood vascular endothelial cells. Transfection of HUVEC with miR-30b and -
30 mimics at 100nM led to a significant reduction in DLL4 mRNA and protein 48 
h post-transfection (Fig. 4.6A and B). This effect was also dose dependent in 
HUVEC as DLL4 suppression increased as the mimic concentration was 
increased from 100nM to 200nM (Fig. 4.7A and B). HUVEC transduced with 
pSIN_30b and pSIN_30c displayed a significant downregulation of DLL4 mRNA 
and protein when compared to pSIN_MCS or pSIN_GFP transduced cells (Fig. 
4.6C and D). This effect was not seen in HUVEC overexpressing miR-132, a 
miRNA which is not predicted to target DLL4 (Fig. 4.6C and D). DLL4 mRNA 
suppression was also not observed in HUVEC expressing mutant miR-30b or -
30c (pSIN_30b-m and pSIN_30c-m) (Fig. 4.6C). These constructs contain a 
mutation within the predicted miRNA seed, as described in Section 2.3.8, which 
should prevent miR-30 from binding to target mRNAs. 
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Figure 4.6. Overexpression of miR-30 causes downregulation of DLL4 in HUVEC. (A & C) 
DLL4 mRNA expression in HUVEC transfected with NTC, miR-30b or -30c mimics (A) or 
infected with the indicated lentiviruses (C), as quantified by qRT-PCR. Means + SEM, n=4 (A) or 
n=6 (C). Expression is relative to NTC (A) or empty vector, pSIN_MCS (C). (B) DLL4 protein 
expression in HUVEC transfected with miR-30b or -30c mimics measured by Western blotting 
and normalised to α-tubulin expression. Upper panel: representative Western blot. Values 
beneath blot denote intensity of antibody ECL signal relative to NTC mimic. Molecular weight 
markers are represented to the right. Lower panel: intensity of antibody ECL signal relative to 
NTC-transfected HUVEC (means + SEM, n=3). (D) Representative Western blot showing DLL4 
protein levels in HUVEC infected with GFP, miR-30b, -30c or -132 expressing lentiviruses. 
Values beneath blot denote intensity of antibody ECL signal relative to pSIN_GFP-infected 
cells. Molecular weight markers are represented to the right.*, p<0.05; **, p<0.01; ***, p<0.001. 
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Figure 4.7. The effect of miR-30 mimic concentration on DLL4 expression in HUVEC. (A) 
DLL4 mRNA expression in HUVEC transfected with NTC, miR-30b or -30c mimics at the 
indicated concentrations, as quantified by qRT-PCR. Expression is relative to HUVEC 
transfected with the equivalent concentration of NTC mimic (SEM is not shown as n=1). (B) 
DLL4 protein expression in HUVEC transfected with NTC, miR-30b or -30c mimics at the 
indicated concentrations, as measured by Western blotting. Values beneath blot denote 
intensity of antibody ECL signal relative to NTC mimic at the equivalent concentration. 
Molecular weight markers are represented to the right. 
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4.5. Endogenous miR-30 regulates DLL4 expression 
Overexpression of miR-30b and -30 in endothelial cells, using both miRNA 
mimics and lentiviral infection, had proven that DLL4 could be targeted by the 
miR-30 miRNA family. However, these experiments only revealed that miR-30b 
and -30 could suppress DLL4 expression when expressed at supra-
physiological levels. To ascertain whether regulation of DLL4 by miR-30 occurs 
endogenously in endothelial cells, LEC were transfected with Dharmacon 
miRIDIAN microRNA hairpin inhibitors (ThermoScientific) at a concentration of 
100nM, again using Oligofectamine as the delivery agent.  
 
miRNA inhibitors are synthetic RNA oligonucleotides which are complementary 
to a particular mature miRNA of interest. The first generation of miRNA 
inhibitors contained 2’-O-methyl modifications, which promoted rapid and stable 
hybridisation to single-strand RNA and protected the oligoribonucleotides from 
degradation (Hutvágner et al., 2004; Meister et al., 2004). These inhibitors were 
shown to successfully interact with the miRNA-RISC nucleoprotein and block 
target mRNA degradation (Hutvágner et al., 2004; Meister et al., 2004). The 
miRIDIAN hairpin inhibitors contain additional proprietary chemical 
modifications and secondary structural elements flanking the anti-sense miRNA 
sequence. These modifications have improved the ability of the inhibitors to 
bind to and sequester the required miRNA and allow the inhibition to be 
maintained for longer.  
 
When LEC were transfected with the hairpin inhibitor against miR-30b, a slight 
but non-significant increase in DLL4 protein levels was observed 42 h post-
transfection (Fig. 4.8A and B). When LEC were transfected with the inhibitor 
against miR-30c, a larger and significant increase of DLL4 protein levels was 
observed (Fig. 4.8A and B). This modest effect was to be expected as each 
inhibitor would only block the action of one member of the miR-30 family. 
Interestingly, when mRNA levels were quantified by qRT-PCR, an increase in 
DLL4 mRNA was only observed at 72 h post-transfection (Fig 4.8C). This would 
suggest that miR-30b and -30 are primarily acting through translation inhibition, 
with mRNA degradation occurring as a secondary consequence. 
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Figure 4.8. Inhibition of miR-30 causes upregulation of DLL4 in LEC. (A) DLL4 protein 
expression in LEC transfected with NTC, miR-30b or -30c inhibitors measured by Western 
blotting and normalised to GAPDH expression. Intensity of antibody ECL signal relative to NTC-
transfected LEC (means + SEM, n=3). *, p<0.05. (B) Representative Western blot showing 
DLL4 protein levels in LEC transfected with NTC, miR-30b or -30c inhibitors. Values beneath 
blot denote intensity of antibody ECL signal relative to NTC mimic. Molecular weight markers 
are represented to the right. (C) DLL4 mRNA expression in LEC transfected with NTC, miR-30b 
or -30c inhibitors, as quantified by qRT-PCR (means + SEM, n=2). Expression is relative to NTC 
transfected LEC. *, p<0.05. 
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4.6. DLL4 silencing occurs via a miR-30 target site 
within the 3’UTR 
The loss of DLL4 suppression seen when the seed region of miR-30b and -30c 
were mutated had confirmed that this region of the miRNAs is required for DLL4 
targeting (Fig. 4.6C). However, this experiment did not elucidate the exact 
region of the DLL4 transcript which is subject to miR-30-binding. To confirm that 
miR-30b and miR-30c specifically target the DLL4 3’UTR, a reporter plasmid 
was used which contained the Firefly luciferase coding sequence upstream of 
the DLL4 3’UTR (pEZX_DLL4-3’UTR), under the control of the SV40 enhancer. 
The plasmid also contained the Renilla luciferase coding sequence under the 
control of a separate promoter (CMV). Therefore, minor variations in 
transfection efficiency and cell density between samples could be controlled for 
by normalising firefly luciferase RLU to Renilla luciferase RLU. This construct 
was expressed in 293T cells in the presence of miR-30b- or -30c mimics and a 
50% reduction in luciferase activity was observed when compared to NTC 
mimic-transfected cells (Fig. 4.9A). The control plasmid (pEZX-MT01) 
maintained luciferase activity in the presence of exogenous miR-30, suggesting 
the changes in activity were due to the action of miR-30 on the DLL4 3’UTR. To 
identify the exact site of miR-30 binding the predicted miR-30 target site in the 
DLL4 3’UTR was mutated (see Section 2.3.8) to prevent miRNA association 
(pEZX_DLL4-3’UTR-mut). Luciferase activity was significantly increased to 
near-baseline levels in cells transfected with the mutant plasmid (Fig. 4.9A), 
confirming that miR-30 silencing occurs via the predicted target site.  
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Figure 4.9. Confirmation of predicted miR-30 target site within the DLL4 3’UTR (A) 
Reporter assay indicating the response of wildtype or mutant (mut) DLL4 3’UTR to miR-30b and 
-30c mimics in 293T cells (means + SEM, n=3). Firefly expression was normalised to Renilla 
expression to give the relative light units (RLU), which are shown relative to NTC mimic. pEZX-
MT01 is a control reporter, lacking a 3’UTR sequence but containing the Firefly and Renilla 
luciferase genes. Related statistically significant values are indicated by horizontal bars *, 
p<0.05; **, p<0.01; ***, p<0.001.  
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4.7. Overexpression of miR-30 attenuates upregulation 
of DLL4 in KLEC  
The link between miR-30 and DLL4 was first identified in KLEC due to the 
downregulation of miR-30 and upregulation of DLL4 in these cells. This 
induction of DLL4 in KLEC is well characterised and has been attributed to the 
viral gene viral G-protein coupled receptor (vGPCR) acting through an 
extracellular-signal-regulated kinase (ERK)-dependent mechanism (Emuss et 
al., 2009). It was hypothesised that suppression of the miR-30 family in KLEC 
could contribute to the observed increase in DLL4 mRNA and protein levels. To 
test this theory, LEC were infected with pSIN_MCS, pSIN_30b or pSIN_30c and 
then after 48 h half the cells were also infected with KSHV. All cells were 
harvested 96 h post-lentivirus infection (48 h post-KSHV infection). DLL4 mRNA 
expression was increased 3-fold in pSIN_MCS infected KLEC compared to 
pSIN_MCS infected LEC (Fig. 4.10A), which was comparable to previously 
reported levels of DLL4 induction (Emuss et al., 2009). However, this induction 
was attenuated to 2-fold in KLEC expressing exogenous miR-30 (Fig. 4.10A). 
This was also reflected at the protein level where KSHV infection induced a 5-
fold increase in DLL4 that was reduced to 4-fold in pSIN_30c transduced cells 
(Fig. 4.10B).  
 
Having determined that miR-30 suppression can modulate DLL4 induction in 
KLEC, miR-30b and -30c expression was quantified in LEC transduced with the 
KSHV gene vGPCR, to ascertain whether vGPCR expression results in 
downregulation of these two miRNAs. Expression of vGPCR did not influence 
miR-30b or miR-30c levels in LEC, either 24 h, 48 h or 72 h post-transduction 
(Fig. 4.11A). Therefore vGPCR-induced upregulation of DLL4 does not occur by 
way of the regulation of the miR-30 family.  
 
It has previously been reported that miR-30b and miR-30d are upregulated in 
response to hypoxia (Herbert et al., 2007; Hua et al., 2006; Kulshreshtha et al., 
2007). However, these findings are all based on microarrays and have not been 
confirmed using qRT-PCR. In addition, another family member, miR-30e, is 
reported to be downregulated in hypoxic conditions (Herbert et al., 2007).  
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Figure 4.10. Changes in DLL4 expression upon overexpression of miR-30 in KLEC. (A) 
DLL4 mRNA expression in LEC or KLEC infected with miR-30b- and miR-30c-expressing 
lentiviruses, as measured by qRT-PCR (means + SEM, n=3). Expression is relative to LEC 
infected with empty vector, pSIN_MCS. Related statistically significant values are indicated by 
horizontal bars (*, p<0.05). (B) DLL4 protein expression in LEC measured by Western blotting. 
Values beneath blot denote intensity of DLL4 antibody ECL Plus signal normalised to GAPDH 
antibody ECL signal and relative to KSHV-/pSIN_MCS+. Molecular weight markers are 
represented to the right. Western blotting was performed by Dimitra Georgopoulou.  
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Figure 4.11. The effect of vGPCR expression and hypoxia on miR-30b and -30 levels. (A) 
miR-30b and miR-30c expression in LEC transduced with vGPCR at the indicated time points, 
as quantified by qRT-PCR (means + SEM, n=2). Expression is relative to empty vector, 
pSIN_MCS. (B) miR-30b, miR-30c and DLL4 mRNA expression in LEC grown at 1% oxygen for 
24 h, as quantified by qRT-PCR (means + SEM, n=2). Expression is relative to LEC grown at 
20% oxygen for the same time period. (*, p<0.05; ***, p<0.001). 
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Given the important influence hypoxia has on angiogenesis, and to clarify 
whether the miR-30 family is regulated by hypoxia, miR-30b and -30c 
expression was quantified in hypoxic LEC. A slight increase in both miR-30b 
and miR-30c was observed in LEC exposed to 1% oxygen, but this increase 
was only significant for miR-30b (Fig. 4.11B). DLL4 is known to be upregulated 
by hypoxia in endothelial cells (Diez et al., 2007) and an increase of 2.5-fold 
was observed in LEC exposed to 1% oxygen (Fig. 4.11B). If the miR-30 family 
were involved in the induction of DLL4 during hypoxic conditions a reduction in 
miR-30b and -30c expression would be seen, which was not observed (Fig. 
4.11B). 
 
4.8. miR-30b promotes sprouting angiogenesis in vitro 
To investigate the effect of miR-30 overexpression on endothelial cell function 
the Matrigel tube formation assay was first employed. Previous work had shown 
that overexpression of DLL4 in HUVEC using a retroviral vector impaired the 
ability of the cells to form the characteristic network of orderly branching 
cordlike structures when plated onto the surface of Matrigel (Williams et al., 
2006). Compared to the HUVEC infected with GFP-expressing retrovirus, the 
DLL4 overexpressing HUVEC formed fewer cord-like structures and the 
network was often incomplete (Williams et al., 2006). I hypothesised that in the 
reverse scenario, when DLL4 was downregulated by exogenous miR-30, an 
increase in network formation would be observed.  
 
Before embarking on the complete experiment, the assay conditions were 
optimised. Both HUVEC and LEC were plated on complete Matrigel in a 96-well 
plate at densities of 5000, 7500 and 10,000 cells per well and 24 h later the 
wells were photographed in order to examine network formation. Cord-like 
structures were observed at all three cell densities for both cell types (Fig. 4.12); 
however, LEC required 10,000 cells per well to obtain a complete network of 
branching cords, whereas network formation was evident for the HUVEC at 
5000 cells per well (Fig. 4.12). 10,000 cells per well was an excessive number 
for the HUVEC, as at this cell density single cells began to cluster around the 
branch points of the network, without being incorporated into the cords (Fig. 
4.12).  
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Figure 4.12. Optimising cell 
densities for Matrigel tube 
formation assay.  Representative 
images of a tube formation assay 
performed with LEC and HUVEC. 
Photos taken at 5x and 10x 
magnification, 24 h after cells 
were plated on Matrigel. Values 
indicate number of cells per well of 
a 96-well plate. 
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It was therefore decided that in order to be able to properly assess the effect of 
any agents on network formation, the LEC would be plated out at 7500, 10,000 
and 12,500 cells per well whilst the HUVEC would be plated out at 2500, 5000 
and 7500 cells per well. 
 
The aim of the Matrigel tube formation assay experiment was to assess the 
effect of miR-30-induced DLL4 downregulation on endothelial cell function. A 
siRNA against DLL4 was used as a positive control for DLL4 knockdown. The 
ON-TARGETplus siRNA for DLL4 was obtained from Dharmacon 
(ThermoScientific) and transfected into LEC and HUVEC at a final 
concentration of 100nM using Oligofectamine as the delivery reagent.  This 
resulted in a ~70% reduction in DLL4 mRNA in LEC 48 h post-transfection 
when compared to NTC-transfected cells and a ~40% reduction in HUVEC at 
the same time point (Fig. 4.13A). The observed downregulation of DLL4 mRNA 
was concordant with a ~60% reduction in DLL4 protein levels at the same time 
point (Fig. 4.13B). The downregulation of DLL4 mRNA and protein was still 
evident at 72 h post-transfection and DLL4 protein reduction in HUVEC actually 
increased to 80% (Fig. 4.13A and B). This was beneficial for the purposes of the 
Matrigel tube formation assay, as it meant the cells could be given suitable 
recovery period before being plated on the Matrigel, whilst still maintaining 
DLL4 knockdown.  
 
LEC and HUVEC were transfected with NTC and DLL4 siRNA at a 
concentration of 100nM and then trypsinised and counted 48 h post-
transfection. The cells were plated on Matrigel at the cell densities determined 
during assay optimisation and 20 h later the wells were photographed to assess 
network formation (Fig. 4.14). For both LEC and HUVEC, at all three cell 
densities, DLL4 knockdown prevented tube formation (Fig. 4.14). It is probable 
that the effect of the Oligofectamine and exogenous small RNA had a negative 
impact on tube formation, as NTC-transfected LEC and HUVEC displayed 
impaired tube formation at cell densities which were previously compatible to 
network formation (10,000 and 5000 cells per well respectively).  
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Figure 4.13. Confirmation of DLL4 knockdown using siRNA in endothelial cells. (A) 
Downregulation of DLL4 mRNA in LEC and HUVEC, 48 h and 72 h following transfection with 
NTC and DLL4 siRNA, as quantified by qRT-PCR. Expression is relative to cells transfected 
with NTC mimic (SEM is not shown as n=1). (B) Downregulation of DLL4 protein in LEC and 
HUVEC, 48 h and 72 h following transfection with NTC and DLL4 siRNA, as quantified by 
Western blotting. Values beneath blot denote intensity of DLL4 antibody ECL Plus signal 
normalised to GAPDH antibody ECL signal and relative to NTC mimic. Molecular weight 
markers are shown to the right. 
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                     Figure 4.14. Knockdown of 
DLL4 inhibits tube formation in 
endothelial cells. Representative 
images of a tube formation assay 
performed with LEC and HUVEC 
48 h post-transfection with NTC 
and DLL4 siRNA. Photos taken at 
5x magnification, 20 h after cells 
were plated on Matrigel. Values 
indicate number of cells per well of 
a 96-well plate.                                                                                                                                                                                                      
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However, at the highest cell densities, the NTC-transfected cells displayed clear 
cord-like structures, whereas the siRNA-transfected cells had only managed to 
gather in small clusters (Fig. 4.14). From discussions with Professor Adrian 
Harris (University of Oxford) and further examination of the literature it was 
determined that, whilst overexpression of DLL4 in endothelial cells impairs tube 
formation (Williams et al., 2006), a decrease in the basal level of DLL4 also 
decreased network formation (Patel et al., 2005). These contradictory 
observations are due to the different roles of DLL4 at varying expression levels. 
When overexpressed, DLL4 inhibits the proliferative and migratory responses to 
VEGF-A by downregulating VEGFR2 expression (Williams et al., 2006); a 
downregulation of DLL4 inhibits basal endothelial cell proliferation (Patel et al., 
2005). 
 
Further discussions with Professor Adrian Harris revealed it would be better to 
use a spheroid-based in vitro angiogenesis assay to assess the effect of miR-30 
on endothelial cell function. The Matrigel tube formation assay depends on 
endothelial cell migration, as cells migrate into cord-like structures. This is 
similar to the formation of the primary vessels during developmental 
vasculogenesis in zebrafish embryos when angioblasts migrate towards the 
midline of the embryo where they coalesce to form a vascular cord (Ellertsdóttir 
et al., 2010). The spheroid-based cellular angiogenesis assay more closely 
resembles sprouting angiogenesis as endothelial cells sprout from the spheroid 
to form vessel-like structures (Alajati et al., 2008).  
 
HUVEC were transfected with NTC or miR-30b mimics and 24 h post-
transfection they were collected and induced to form spheroids by suspension 
in hanging droplets for 24 h. These spheroids were then collected, embedded in 
Matrigel and monitored for up to 5 days. Spheroids comprised of miR-30b 
overexpressing HUVEC displayed an increased propensity to form sprouts, as 
can be seen from the representative photographs (Fig 4.15; left-hand panels) 
and the quantification of sprouts per spheroid (Fig. 4.15; middle panels). This 
phenotype was maintained for 5 days, at which point the sprouts began to 
regress. Furthermore, the sprouts from the miR-30b-expressing spheroids were 
significantly longer (Fig 4.15; right-hand panels). These studies demonstrated 
that miR-30 overexpression in endothelial cells increases their angiogenic 
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potential. DLL4 mRNA suppression was confirmed by qRT-PCR in a small 
sample of miR-30-transfected HUVEC which were isolated prior to spheroid 
formation (data not shown). 
 
Having optimised the spheroid-based cellular angiogenesis assay, it seemed 
appropriate to also investigate sprouting angiogenesis upon KSHV infection of 
HUVEC, which has not yet been reported (Fig. 4.16).  HUVEC were infected 
with KSHV during spheroid formation and then the spheroids were embedded in 
Matrigel and monitored for 96 h. At all three time points, KSHV-infected HUVEC 
generated significantly more sprouts per spheroid, which were of a longer 
length than those from uninfected spheroids (Fig. 4.16). The difference in sprout 
frequency was most clearly seen at 24 h. By 96 h, the sprouts from both 
spheroids had started to regress, so the overall sprouts numbers were 
decreased (Fig. 4.16). However, the KSHV-infected HUVEC sprouts were still 
significantly longer (Fig. 4.16). These findings concur with previous work, in 
which KLEC were shown to possess an increased propensity to form capillary-
like sprouts when compared with uninfected LEC, in the presence of both 
VEGFA or VEGFC (Cheng et al., 2011). The HUVEC used in this work were 
grown in media containing VEGF and 3D tubular sprouts were also observed 
(Fig. 4.16).  
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Figure 4.15. Overexpression of 
miR-30b promotes sprouting 
angiogenesis in vitro.  
Left-hand panels: representative 
photographs at indicated time 
points of HUVEC spheroids 
embedded in Matrigel. HUVEC 
were transfected with indicated 
mimic before being induced to 
form spheroids. Middle panels: 
quantification of total sprouts per 
spheroid (y-axis) at indicated time 
points (n=60). Box plot indicates 
inter-quartile range, whiskers 
indicate total range, black line 
denotes median. Sprouts were 
counted using Adobe Photoshop 
CS2. The difference between 
NTC-transfected and miR-30-
transfected spheroids was 
significant (***, p<0.001). Right-
hand panels: quantification of 
average sprout length in μm (y-
axis) (means + SEM, n=20). 
Average sprout length was 
measured using the segmented 
line tool in Image J (NIH). Five 
sprouts were measured per 
spheroid. The difference between 
NTC-transfected and miR-30b 
transfected cells was significant 
(***, p<0.001). 
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Figure 4.16. KSHV infection of 
HUVEC promotes sprouting 
angiogenesis in vitro. Left-hand 
panels: representative 
photographs at indicated time 
points of uninfected and KSHV-
infected HUVEC spheroids 
embedded in Matrigel. HUVEC 
were infected with KSHV before 
being induced to form spheroids. 
Middle panels: quantification of 
total sprouts per spheroid (y-axis) 
at indicated time points (n=35-50). 
Box plot indicates inter-quartile 
range, whiskers indicate total 
range, black line denotes median. 
Sprouts were counted using 
Adobe Photoshop CS2. The 
difference between non-infected 
and KSHV-infected spheroids was 
significant (**, p<0.01; ***, 
p<0.001). Right-hand panels: 
quantification of average sprout 
length in μm (y-axis) (means + 
SEM, n=20-45). Average sprout 
length was measured using the 
segmented line tool in Image J 
(NIH). Five sprouts were 
measured per spheroid. The 
difference between NTC-
transfected and miR-30b 
transfected cells was significant 
(**, p<0.001; ***, p<0.001).  
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4.9. Discussion 
DLL4 mRNA was downregulated by 50 to 70% in LEC or HUVEC, when 
transfected with miR-30 mimics or transduced with pre-miR-30b or -30c; this led 
to a similar reduction in DLL4 protein levels. This level of repression is 
comparable to other validated miRNA targets. During development DLL4 
haploinsufficiency results in embryonic lethality (Gale et al., 2004), indicating 
that the developing vasculature is sensitive to minor alterations in DLL4 dosage. 
Therefore, a reduction in DLL4 of the magnitude described would be expected 
to have a significant impact on endothelial cell behaviour during development 
and in other biological systems.  
 
DLL4 protein was upregulated by 1.5 to 2-fold in LEC transfected with hairpin 
inhibitors of miR-30b or miR-30c. This indicates that endogenous miR-30 
actively regulates DLL4 in endothelial cells, as inhibition of miR-30 family 
members would release DLL4 mRNA from miR-30-directed RISC targeting, 
thereby preventing translation inhibition and mRNA degradation. The protein 
increase is fairly modest, which is expected if DLL4 were regulated by all 
members of the miR-30 family, as each inhibitor should only block one family 
member. This theory could be tested by simultaneously transfecting inhibitors of 
two or more miR-30 family members and examining DLL4 protein expression. If 
this level of redundancy exits, it would highlight the importance of sensitive 
regulation of DLL4 expression. 
 
Exogenous miR-30 suppressed luciferase activity, and hence expression, when 
the Firefly luciferase coding sequence was expressed upstream of the DLL4 
3’UTR. Disruption of the predicted miR-30 target site within the DLL4 3’UTR 
using site directed mutagenesis almost abolished miR-30-directed silencing of 
this luciferase reporter. These data confirm that the miR-30 family is able to 
direct miRISC to the DLL4 3’UTR and instigate target suppression via binding to 
one particular target site. When miR-30b and -30c were co-expressed at an 
equivalent total concentration, luciferase activity was not suppressed further, 
indicating that both these family members act through the same target site(s). 
However, mutation of the predicted miR-30 target site did not entirely rescue the 
repression of luciferase activity. It is possible that a residual level of targeting 
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occurred through this site due to the extensive 3’ complementarity exhibited by 
miR-30b and miR-30c. Alternatively, the miR-30 family may also act through a 
non-canonical target site within the DLL4 3’UTR. Both “seedless” and “centred” 
miRNA target sites have been identified (Lal et al., 2009; Shin et al., 2010). 
More recently, differential CLIP-seq has revealed that for one particular miRNA, 
miR-155, 40% of miRNA-dependent Argonaute binding occurs at sites 
containing at least one seed mismatch and that these non-canonical sites 
enable modest regulation of gene expression (Loeb et al., 2012). The DLL4 
3’UTR does not contain a centred site for miR-30, which is defined as 11 
contiguous nucleotides that pair to positions 4-14 or 5-15 of the miRNA. 
However, it does contain four predicted non-canonical sites: one 8mer, one 
7mer and two 6mer sites, each containing one nucleotide mismatch or G:U 
wobble. One or several of these non-canonical sites could account for the low 
level of residual luciferase suppression observed following mutation of the 
canonical 8mer target site. This could be investigated by disrupting each of the 
non-canonical sites in the pEZX_DLL4-3’UTR-mut background using site-
directed mutagenesis. If mutation of one or more of these sites completely 
removes luciferase suppression in the presence of exogenous miR-30, it would 
confirm the role of non-canonical targeting of DLL4 by miR-30.  
 
Overexpression of miR-30b or miR-30c attenuated KSHV-induced DLL4 
upregulation in vitro. However, as overexpression of vGPCR did not 
downregulate miR-30b or miR-30c, the suppression of the miR-30 family in 
KLEC cannot be attributed to the reported viral signalling pathway which leads 
to DLL4 upregulation (Emuss et al., 2009). It is possible that viral induced 
downregulation of miR-30 is a secondary mechanism by which DLL4 is 
upregulated, independent of the action of vGPCR. To confirm this, miR-30 
levels would need to be returned to baseline in KLEC, which proved technically 
challenging using lentiviral delivery. A small degree of miR-30 overexpression 
was always observed (~10 fold compared to KLEC/pSIN); hence the 
attenuation of DLL4 could simply reflect the ability of miR-30 to regulate DLL4, 
even in a system where it is upregulated. 
 
The current literature confers contradictory information with regards to the 
regulation of the miR-30 family in response to hypoxia. miR-30b is reported to 
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be upregulated in hypoxic conditions, whereas miR-30e is downregulated 
(Herbert et al., 2007; Hua et al., 2006; Kulshreshtha et al., 2007). Given that all 
miR-30 family members share common targets, it might be expected for them to 
be regulated in a co-ordinated manner by hypoxia, as is seen following KSHV 
infection of LEC. In all studies where miR-30 expression was reported to 
change following hypoxia, expression was assessed by miRNA microarray, but 
not confirmed by qRT-PCR. Using qRT-PCR, I found that exposure of LEC to 
hypoxic conditions only increased miR-30b and miR-30c levels by 1.25-1.5 fold, 
and this minor increase was only significant for miR-30c. This suggests that 
hypoxic signalling does not have a major impact on miR-30 expression, and that 
changes in miR-30 expression do not contribute to the induction of DLL4 
following hypoxia, which was previously attributed to HIF1A-mediated activation 
of the DLL4 promoter (Diez et al., 2007).  
 
A putative promoter of pri-miR-30a has been identified (Fujita and Iba, 2008). 
Studies have also shown the promoters of pri-miRNA transcripts are usually 
found within 1000bp upstream of the transcription start site. Therefore the 
putative promoters or upstream regions of pri-miR-30a, pri-miR-30b/pri-miR-30d 
(clustered miRNAs), pri-miR-30c-1/pri-miR-30e (clustered miRNAs) and pri-
miR-30c-2 were analysed using MAPPER to identify potential transcription 
factor binding sites (Marinescu et al., 2005). Whilst several transcription factor 
binding sites were predicted, a transcription factor binding site common to all 
the members of the family could not be identified. It is therefore possible that 
the altered expression of miR-30 family members following KSHV infection is 
due to regulation at the level of pri-miRNA or pre-miRNA processing, rather 
than transcriptional regulation.  
 
Several different proteins have been identified that influence the processing of 
either one specific miRNA or a group of similarly regulated miRNAs. The most 
extensively studied of these is the RNA-binding protein Lin28 which regulates 
the production of the Let-7 family of miRNAs, particularly during development 
(Viswanathan and Daley, 2010). Lin28 binds to conserved nucleotides in the 
loop region of pri-let7 which prevents Drosha processing of the pri-miRNA 
(Newman et al., 2008). The miR-30 family pri-miRNAs and/or pre-miRNAs may 
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also contain a conserved RNA-binding protein sequence which allows collective 
regulation of the family.  
 
Not all miRNA regulation by RNA-binding proteins is inhibitory: SMAD proteins 
bind to a conserved sequence found within ~20 pri-miRNAs to promote Drosha 
processing in response to transforming growth factor β (TGFβ)/bone 
morphogenetic protein (BMP) signalling (Davis et al., 2010). In addition to 
directly binding to precursor miRNAs, some proteins regulate miRNA maturation 
indirectly. Cellular tumour antigen p53 (p53) interacts with the Drosha 
processing complex to enhance the maturation of a group of “growth-
suppressive” miRNAs (Suzuki et al., 2009). Ataxia-telangiectasia mutated 
(ATM) induces the biogenesis of approximately one-fourth of miRNAs by 
phosphorylating the KH-type splicing regulatory protein (KSRP), leading to 
enhanced interaction between KSRP and pri-miRNAs (Zhang et al., 2011). 
KSRP is a component of both the Drosha and Dicer complexes and binds to the 
terminal loop of pri-miRNAs to promote their cleavage (Trabucchi et al., 2009). 
Interestingly, miR-30a, miR-30c and miR-30d expression was reduced when 
KSRP was knocked-down in HeLa cells and these miRNAs are induced in ATM 
+/+ cells in response to DNA damage, but not in ATM -/- cells (Trabucchi et al., 
2009; Zhang et al., 2011). However, a KSRP-based mechanism could not 
account for the upregulation of miR-30b in KLEC and a common regulatory 
pathway for all miR-30 family members has yet to be identified. 
 
Overexpression of miR-30b in HUVEC promoted sprouting from Matrigel-
embedded spheroids. The sprouts which developed from the miR-30-
transfected spheroids were also of a greater length, compared to the NTC-
transfected spheroids. This is consistent with the known role of DLL4 during 
angiogenesis. DLL4 is thought to control angiogenic sprouting, in part through 
the regulation of VEGF signalling and tip cell specification. Therefore, the 
increased sprouting observed from miR-30b expressing spheroids is most likely 
due to the concomitant decrease in DLL4 in these cells. To confirm this, I 
attempted to express a DLL4 construct lacking the 3’UTR in HUVEC using 
lentiviral infection. This construct would be immune to miR-30b targeting and 
therefore sufficient DLL4 expression would be maintained in these cells to 
regulate tip cell specification. However, I was not able to develop a transfection 
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protocol that was compatible with lentiviral infection, in order to carry out this 
experiment. Recently, in vitro target protectors have been developed that 
enable inhibition of miRNA interaction with a specific target. This technique 
would allow future investigations into the mechanism behind the increased 
sprouting observed in miR-30b expressing HUVEC. Inhibition of DLL4 targeting 
by miR-30 would be expected to rescue the pro-angiogenic phenotype.  
 
The spheroid assay was also used to investigate in vitro sprouting upon KSHV 
infection of HUVEC. KSHV-positive spheroids displayed significantly more 
sprouts, which were of a longer length than those from uninfected spheroids. 
These findings highlight the complex signalling milieu at work in KSHV-infected 
endothelial cells. Although DLL4 is upregulated upon KSHV infection, which 
would be expected to inhibit sprouting angiogenesis, a multitude of other pro-
angiogenic factors are also upregulated and appear to increase the angiogenic 
potential of KSHV-infected HUVEC (Vart et al., 2007). 
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Chapter 5. miR-30-mediated regulation of dll4 
affects endothelial cell behaviour during 
zebrafish development.  
5.1. Aims 
The work described in Chapter 4 showed that DLL4 expression is actively 
suppressed by miR-30 in endothelial cells and that upregulation of miR-30 in 
these cells increases their angiogenic potential in vitro. However, regulation in 
the in vitro context does not always directly translate to the in vivo setting. 
Therefore, the aims of this final chapter were: 
i. To ascertain whether active regulation of DLL4 by miR-30 occurs in vivo. 
This will be achieved by both overexpressing miR-30 in zebrafish 
embryos using microinjection of miRNA mimics and disrupting 
endogenous miR-30/dll4 targeting using target protector morpholinos 
(TPs). The subsequent expression of zebrafish dll4 will be monitored 
using qRT-PCR and in situ hybridisation.  
ii. To document any changes in the expression of selected vascular 
markers upon both miR-30 overexpression and the inhibition of miR-
30/dll4 targeting. 
iii. To characterise the effects of miR-30 overexpression and TP injection on 
vasculogenesis and sprouting angiogenesis by imaging vascular 
development in transgenic zebrafish embryos with GFP-expressing 
endothelial cells. 
iv. If a phenotype is observed upon miR-30 overexpression, to attempt to 
rescue this phenotype using co-injection of the TP. 
 
The zebrafish embryo was selected as a suitable in vivo model because the 
developing zebrafish vasculature is an established model of angiogenic 
processes (Ny et al., 2006). Because manipulation of miR-30 expression could 
potentially interfere with normal vascular development, it was of great benefit 
that zebrafish embryos can develop normally for several days with a perturbed 
or absent circulatory system. This is because they receive enough oxygen via 
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passive diffusion from their surroundings (Ellertsdóttir et al., 2010; Ny et al., 
2006).  
 
Given the potential applications of miR-30 in human medicine, a model system 
was required which did not differ entirely from the human organism. It was 
therefore ideal that most human genes have orthologues in zebrafish (Gates et 
al., 1999) and that human and zebrafish organs share many molecular, 
physiological and anatomical similarities (Ny et al., 2006). Importantly, both 
DLL4 and miR-30 homologues are known to be expressed during zebrafish 
development (Chen et al., 2005; Leslie et al., 2007; Wienholds et al., 2005) and 
dll4 knockdown has been well characterised in zebrafish embryos (Hogan et al., 
2009b; Leslie et al., 2007; Siekmann and Lawson, 2007). Targeted knockdown 
of dll4 and other genes in the developing embryos is easily achieved by the 
injection of MOs into the embryo at the 1-4 cell stage (Nasevicius and Ekker, 
2000). Morpholino injection has also been adapted to block miRNA binding to 
specific target mRNAs (Choi et al., 2007), which is an invaluable tool for 
dissecting the biological roles of particular miRNA-target interactions. Previous 
work had shown that miRNA mimics can be injected into zebrafish embryos and 
that this achieves functional targeting (Deacon et al., 2010; Zeng et al., 2009). 
 
5.2. Characterisation of dll4 and miR-30 expression 
during zebrafish development 
During zebrafish development, dll4 mRNA has been detected by RT-PCR from 
8 hpf (Leslie et al., 2007). This semi-quantative analysis showed a clear 
increase in expression at 12 hpf and further slight increases at 18, 30, 50 and 
72 hpf. To detect changes in miR-30 expression with a quantitative method, 
total RNA was extracted from ~30 embryos at more frequent intervals up to 48 
hpf and qRT-PCR analysis was performed (Fig. 5.1A). Expression is shown 
relative to the 6 hpf time point.   
 
This analysis revealed robust dll4 induction from 12 hpf onwards (Fig 5.1A). 
Interestingly, there was a stepwise decrease in dll4 expression between 18 hpf 
and 24 hpf. During this temporal window, angiogenic sprouts from the DA are 
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first initiated and progress towards the dorsal roof of the neural tube to form the 
ISVs (Isogai et al., 2003). Given that dll4 is known to dampen angiogenic 
sprouting, a slight decrease in dll4 expression at this point might release the 
endothelial cells of the DA from this negative regulation, allowing sprouting to 
occur.   
 
Homologues of miR-30b and miR-30c have been detected in both the 
developing embryo and the adult zebrafish (Wienholds et al., 2005). When the 
RNA samples described above were used to perform miRNA qRT-PCR, miR-
30b, -30c, -30d and 30e were found to be expressed, with an overall trend of 
increasing expression from 6 hpf to 48 hpf (Fig. 5.1B). During the angiogenic 
sprouting window (18-24 hpf), the expression of miR-30 steadily increased (Fig. 
5.1B). Although this experiment was only repeated once, the decrease in dll4 
expression and increase in miR-30 expression during the period of 
angiogenesis was of particular interest. These temporally coincident changes in 
dll4 and miR-30 could indicate a functional interaction that may contribute to the 
tight control of Dll4 expression during zebrafish vascular development. 
Decreased dll4 expression immediately prior to and during sprouting of the ISVs 
could be partly due to increased miR-30-directed miRISC targeting.  
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Figure 5.1. Expression of dll4 and the miR-30 family during zebrafish development. (A) 
dll4 mRNA expression in zebrafish embryos at the indicated stage of development, as 
measured by qRT-PCR. Expression is relative to 6 hpf. RNA was extracted from ~30 embryos 
for each developmental stage (SEM is not shown as n=1). (B) Expression of miR-30b, miR-30c, 
miR-30d and miR-30e in zebrafish embryos at the indicated stage of development, as 
measured by qRT-PCR. Expression is relative to 6 hpf. RNA was extracted from ~30 embryos 
for each developmental stage (SEM is not shown as n=1). RNA extraction was performed by 
Rui Monteiro. qRT-PCR was performed by Gemma Bridge. 
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5.3. Optimisation of miR-30 mimic microinjections 
Having identified a potential functional interaction between miR-30 and dll4 
during zebrafish development, miR-30 overexpression was adopted to 
investigate this relationship. Examination of the literature revealed that miRNA 
mimics had previously been injected at 3ng per embryo for overexpression 
studies (Zeng et al., 2009). Therefore, microinjections of 2.5ng/embryo and 
5ng/embryo were tested for NTC, miR-30b and miR-30c mimics. By 24 hpf the 
embryos injected with 5ng of NTC mimic displayed slightly abnormal anatomical 
features, including an oversized yolk sac extension. However, the embryos 
injected with 5ng of miR-30b or miR-30c mimic were severely abnormal with 
extensive necrosis and embryonic death. This quantity of mimic was therefore 
discounted from future studies. The embryos injected with 2.5ng of mimic were 
imaged at 24 hpf (Fig. 5.2). For this quick examination of anatomical features, 
the embryos were not dechorionated or sedated with muscle relaxant. 
Therefore, the tails of the wildtype (WT) and NTC-injected embryos were 
moving during the imaging process and hence are slightly blurry in the images 
(Fig 5.2). This highlights one of the first developmental abnormalities of the 
miR-30 injected embryos: the tails were either missing entirely (Fig. 5.2; red 
arrowheads), severely stunted (Fig. 5.2; black arrowheads) or short and curved 
(Fig. 5.2; grey arrowheads). None of the miR-30 injected embryos had mobile 
tails.  
 
The only obvious abnormal feature of the NTC-injected embryos was an 
oversized yolk sac extension (Fig. 5.2; black arrow). The miR-30-injected 
embryos also displayed this feature to a greater extent but in addition these 
embryos were generally stunted with small heads and often exhibited necrosis 
in the head region (Fig 5.2; red arrow). Necrosis of the head is a common 
feature when MOs are injected at high concentrations. The fact that both NTC- 
and miR-30-injected embryos displayed large yolk sac extensions would 
suggest that this is a side-effect of high miRNA mimic concentrations. Indeed, 
qRT-PCR analysis of total RNA from embryos injected with 2.5ng of miR-30 
mimic revealed that miR-30 expression was over 200 fold higher than in 
uninjected controls (Fig. 5.3A). However, the extensive abnormalities shown in 
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the miR-30-injected embryos alone would suggest that this miRNA is capable of 
targeting one or many factors that are crucial for normal zebrafish development.  
 
Due to the severe abnormalities displayed upon injection of large quantities of 
miR-30 mimic, the amount of microinjected mimic was titrated to an amount 
where overall embryo morphology was normal (Fig. 5.2B) and miR-30 
expression was detectable at a level that is within the physiological range for 
zebrafish miRNAs (Fig. 5.3A). This was 0.05ng/embryo for miR-30b and 
0.1ng/embryo for miR-30c. An upregulation of 20-25 fold was considered to be 
compatible with normal variations in zebrafish miRNA expression, as changes 
of this magnitude are seen for various different miRNAs during zebrafish 
development (Chen et al., 2005).  
 
Extraction of total RNA from whole embryos also allowed dll4 levels to be 
quantified by qRT-PCR in embryos injected with each quantity of miRNA mimic 
(Fig. 5.3B). dll4 expression titrated with levels of miR-30, displaying the 
expected inverse correlation (Fig. 5.3B). dll4 mRNA was suppressed by 40-50% 
in embryos injected with 2.5ng of miR-30 mimic when compared to NTC; 
however a 20-30% suppression was still observed in the lowest mimic 
concentrations chosen for further studies (Fig. 5.3B). Downregulation of dll4 
expression in the DA and ISVs was confirmed by in situ hybridisation when the 
mimics were injected at 0.05ng/embryo and 0.1ng/embryo for miR-30b and 
miR-30c respectively (Fig. 5.3C). Ten miR-30b-injected embryos were 
examined by in situ hybridisation. Eight of these displayed repressed dll4 
expression, whilst the remaining two embryos showed wildtype dll4 levels. 
Similarly, for the miR-30c-injected embryos, dll4 levels were reduced in 11 
embryos with only one embryo exhibiting normal dll4 expression (Fig. 5.3C).  
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Figure 5.2. Testing miR-30 mimics in zebrafish embryos. (A) Images of wildtype (WT) 
zebrafish embryos or embryos injected with 2.5ng of the indicated miRNA mimic at 24 hpf. Red 
arrowheads indicate missing tails; black arrowheads indicate stunted tails; grey arrowheads 
indicate short, curved tails. Red arrows indicate head necrosis; black arrows indicate oversized 
yolk sac extensions. Magnification: 2.5x. (B) Representative images of a wildtype (WT) 
zebrafish embryo or embryos injected with the indicated quantity of miRNA mimic at 27 hpf. In 
situ hybridisations were performed on the embryos to assess dll4 expression; however the 
images are shown here to examine overall embryo morphology. Microinjections were performed 
by Rui Monteiro and Gemma Bridge. In situ hybridisations were performed by Gemma Bridge. 
Images were taken by Gemma Bridge.  
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Figure 5.3. dll4 mRNA is suppressed in zebrafish embryos following miR-30 mimic 
injection. (A and B) Expression of miR-30 (A) and dll4 mRNA (B) in whole zebrafish embryos 
following microinjection of the indicated amount of miRNA mimics, as measured by qRT-PCR. 
Expression is relative to uninjected control embryos. Error bars indicate SD of qRT-PCR 
experiment which was performed in triplicate. n=1 but RNA was collected from 20-30 embryos 
per condition. (C) Representative in situ hybridization showing dll4 mRNA expression in the 
developing vasculature of wildtype (WT) embryos and embryos injected with 0.2ng (NTC), 
0.05ng (miR-30b) and 0.1ng (miR-30c) miRNA mimics. Values indicate the number of embryos 
with the predominant, displayed phenotype versus the total number of embryos assayed. Dorsal 
aorta (DA) and intersegmental vessels (ISV) are labelled. Microinjections were performed by 
Rui Monteiro and Gemma Bridge. RNA extraction, qRT-PCR and in situ hybridization were 
performed by Gemma Bridge. Images were taken by Rui Monteiro. 
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5.4. The effects of miR-30 overexpression on other 
vascular markers 
The primary focus of this chapter of work was the effect of miR-30 regulation on 
dll4 expression in vivo and the subsequent functional consequences with regard 
to ISV sprouting. However, given the severe anatomical abnormalities observed 
at high levels of miR-30 overexpression (Fig. 5.2), I also decided to assess the 
expression of other vascular markers following miR-30 overexpression by in situ 
hybridisation.     
 
Knockdown of Dll4 was used as a positive control. To achieve Dll4 knockdown, 
two previously published dll4 MOs were tested: MO1-dll4 (Siekmann and 
Lawson, 2007) and MO4-dll4 (Hogan et al., 2009b). The sequences of these 
MOs are given in Table 2.8. The MOs were injected into Tg(kdrl:EGFP) 
embryos at levels previously used in publication and the trunk vasculature was 
imaged 48 hpf (Fig. 5.4A). The genetic marker kdrl is only expressed in blood 
endothelial cells; therefore, the kdrl promoter specifically drives EGFP 
expression in blood endothelial cells alone, allowing easy visualisation on a 
fluorescent microscope. Embryos injected with either MO1-dll4 or MO4-dll4, 
also known as dll4 morphants (Nasevicius and Ekker, 2000), displayed ISV 
hyperbranching as expected (Fig. 5.4A; red arrowheads), but this phenotype 
was much more pronounced in the embryos injected with MO4-dll4. Because 
miR-30 acts to downregulate dll4 but does not entirely eliminate its expression, 
it was not expected that miR-30 microinjection would cause extremely 
excessive hyperbranching. Therefore, MO1-dll4 was chosen as a positive 
control for Dll4 knockdown. Misplicing of dll4 mRNA in the embryos injected 
with MO1-dll4 was confirmed by RT-PCR (Fig. 5.4B). Increased dll4 mRNA 
expression was observed in dll4 morphants (Fig. 5.5A). This was expected 
because the dll4 MO blocks dll4 mRNA splicing leading to the accumulation dll4 
mRNA (Siekmann and Lawson, 2007). 
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Figure 5.4. Testing dll4 morpholinos in zebrafish embryos. (A) Trunk vasculature in 
uninjected Tg(kdrl:EGFP) embryos or embryos injected with the indicated morpholino at 48 hpf. 
Red arrowheads denote extra sprouts from the ISVs. Microinjections were performed by Rui 
Monteiro and Gemma Bridge. Fluorescent images were taken by Rui Monteiro with the 
assistance of Gemma Bridge. (B) RT-PCR for dll4 and ef1a using RNA extracted at 24 hpf from 
wildtype (WT) embryos or embryos injected with the indicated morpholino type and quantity. 
The dll4 primers used were as described in (Siekmann and Lawson, 2007). Microinjections 
were performed by Rui Monteiro and Gemma Bridge. RNA extractions were performed by 
Gemma Bridge. RT-PCR was performed by Rui Monteiro. 
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Notch signalling is known to be required for haematopoietic stem cell (HSC) 
emergence, for example the expression of runt-related transcription factor 1 
(runx1) is absent in embryos treated with the Notch inhibitor DAPT or in the 
Notch signalling mutant mindbomb (Burns et al., 2005; Gering and Patient, 
2005). The transcription factor runx1 is a marker of HSCs in zebrafish (Zhang et 
al., 2013). It was therefore of interest whether runx1 expression is also absent 
or reduced upon miR-30 overexpression, potentially due to a reduction in DLL4-
mediated Notch signalling.  
 
Through a process called endothelial haematopoietic transition (EHT), zebrafish 
HSCs are generated from the ventral wall of the DA (Zhang et al., 2013). During 
this process, single endothelial cells move from the DA wall into the sub-aortic 
space at around 30 hpf and from there into the blood circulation via the PCV. 
The endothelial cells are derived from the haemogenic endothelium, a 
specialised population of endothelial cells that have the potential to generate 
HSCs (Zhang et al., 2013). The haemogenic endothelium can be identified by 
runx1 expression, as seen by the dots of staining along the ventral wall of the 
DA in WT embryos (Fig. 5.5B, left-hand panels). In the dll4 morphants, runx1 
expression was almost entirely absent in the DA due to a lack of runx1 positive 
cells (Fig. 5.5B, left-hand panels). A lack of runx1 positive HSC progenitors due 
to dll4 knockdown has not yet been reported and suggests that Dll4 could be 
involved in the specification or maintenance of the haemogenic endothelium. 
The neural expression of runx1 in the dll4 morphants was normal (Fig. 5.5B, 
right-hand panels).  
 
Staining for runx1 mRNA was reduced in the DA and neural tissue of miR-30b 
and miR-30c injected embryos when compared to WT or NTC injected embryos 
(Fig. 5.6A). However, the decreased intensity of staining in the DA was due to 
reduced expression, not a decreased number of runx1 positive cells as seen 
with the dll4 MO. I would hypothesise that the reduction in Notch signalling in 
the miR-30 overexpressing embryos was not sufficient to impair HSC 
emergence. The decrease in runx1 expression in this scenario could be due to 
direct targeting of runx1 by miR-30. In addition to decreased runx1 expression, 
the miR-30 overexpressing embryos also displayed aberrant runx1 neural 
patterning (Fig. 5.6A, right-hand panels). 
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Figure 5.5. Expression of dll4, runx1 and dab2 mRNA in dll4 MO-injected zebrafish 
embryos. 
(A, B and C) Representative in situ hybridization showing expression of dll4 (A), runx1 (B) and 
dab2 (C) mRNA at 27 hpf in the vasculature of wildtype (WT) embryos and embryos injected 
with 5ng of dll4 morpholino (dll4 MO). Values indicate the number of embryos with the 
predominant, displayed phenotype versus the total number of embryos assayed. Asterisk and 
brackets denote cardinal vein bifurcation. Dorsal aorta (DA); intersegmental vessels (ISV); 
haematopoeitic stem cell (HSC); posterior cardinal vein (PCV);  anterior cardinal vein (PCV); 
Duct of Cuvier (DC). Microinjections were performed by Rui Monteiro and Gemma Bridge. In 
situ hybridisations were performed and imaged by Gemma Bridge. 
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The next gene tested was the venous marker disabled homolog 2 (dab2). DLL4 
signalling is known to promote arterial specification, therefore it was 
hypothesised that dab2 staining would be increased in miR-30-injected embryos 
due to increased venous specification upon dll4 downregulation. The WT 
embryos had a strong band of staining which denotes the PCV and a very weak 
line of DA staining just above (Fig. 5.5C, left-hand panels). The cardinal vein 
was also labelled where it bifurcates just before reaching the head (Fig. 5.5C, 
right-hand panels). Each cardinal vein empties into a large sinus called the Duct 
of Cuvier (DC), which fans out across the yolk sac, whilst the remaining anterior 
cardinal veins (ACV) proceed down into the head of the embryos. dab2 
expression was unaffected in the trunk region of the dll4 morphants but clearly 
downregulated in miR-30b and miR-30c injected embryos (Fig. 5.5C and 5.6B, 
left-hand panels). miR-30 overexpression also caused a wider gap to develop 
between the bifurcating cardinal veins in the head region (Fig. 5.6B, right-hand 
panels).  
 
The third VEGFR receptor, flt4, is also a venous marker and staining in the WT 
embryos followed a very similar pattern to dab2 (Fig. 5.7). The PCV is clearly 
visible in the trunk (Fig. 5.7, left-hand panels), as is the bifurcation of the 
cardinal vein in the head (Fig. 5.7, right-hand panels). Unfortunately, due to 
experimental restrictions, flt4 in situ hybridisation was not performed in the dll4 
morphants. The NTC-injected embryos displayed normal, WT expression of flt4 
(Fig. 5.7). However, flt4 expression was clearly reduced in the trunk of miR-30-
injected embryos (Fig. 5.7, left-hand panels). When the embryos were 
visualised from above, it became apparent that miR-30 overexpression is 
affecting angioblast migration and/or specification in relation to formation of the 
PCV. In the majority of miR-30 overexpressing embryos, two parallel lines of 
venous endothelial cells could be seen in the trunk, rather than the single line 
that denotes the PCV (Fig. 5.7, right-hand panels). The gap between the two 
bifurcations of the cardinal vein was also wider and in some embryos the DCs 
appeared disorganised and spread out (Fig. 5.7, right-hand panels). 
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Figure 5.6. Expression of runx1 and dab2 mRNA in zebrafish embryos injected with NTC 
and miR-30 mimics. (A and B) Representative in situ hybridization showing expression of 
runx1 (A) and dab2 (B) mRNA at 27 hpf in the vasculature of wildtype (WT) embryos and 
embryos injected with 0.2ng (NTC), 0.05ng (miR-30b) and 0.1ng (miR-30c) miRNA mimics. 
Values indicate the number of embryos with the predominant, displayed phenotype versus the 
total number of embryos assayed. Asterisk and brackets denote cardinal vein bifurcation. Dorsal 
aorta (DA); intersegmental vessels (ISV); haematopoeitic stem cell (HSC); posterior cardinal 
vein (PCV); anterior cardinal vein (ACV); Duct of Cuvier (DC). Microinjections were performed 
by Rui Monteiro. In situ hybridisations were performed and imaged by Gemma Bridge. 
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Figure 5.7. Expression of flt4 mRNA in zebrafish embryos injected with NTC and miR-30 
mimics. (A) Representative in situ hybridization showing expression of flt4 mRNA at 26 hpf in 
the vasculature of wildtype (WT) embryos and embryos injected with 0.2ng (NTC), 0.05ng (miR-
30b) and 0.1ng (miR-30c) miRNA mimics. Values indicate the number of embryos with the 
predominant, displayed phenotype versus the total number of embryos assayed. Asterisk and 
brackets denote cardinal vein bifurcation. Posterior cardinal vein (PCV); anterior cardinal vein 
(ACV); Duct of Cuvier (DC). Microinjections were performed by Rui Monteiro and Gemma 
Bridge. In situ hybridisations were performed and imaged by Gemma Bridge. 
 
 
188 
 
5.5. Exogenous expression of miR-30 induces aberrant 
intersegmental vessel development and branching in 
zebrafish 
Having confirmed suitable miR-30 expression and dll4 downregulation upon 
microinjection of a viable quantity of miR-30 mimic, experiments were 
undertaken to investigate the effect of miR-30 overexpression on vascular 
development. The miR-30 mimics and the chosen dll4 MO were injected into 
Tg(kdrl:EGFP) embryos and vascular development was examined at 25 and 72 
hpf by fluorescent microscopy (Fig. 5.8A).  
 
At 25 hpf, embryos injected with both dll4 MO and miR-30 mimic possessed 
ISVs at a more advanced stage of sprouting than the uninjected control (Fig 
5.8.A). Some of the endothelial cells from these ISVs displayed a vessel-free 
hyper-migratory phenotype, whereby they had separated from the sprouting 
vessel and moved dorsally leading to premature DLAV formation (Fig 5.8.A; 
yellow arrowheads). At the time of investigation this phenotype had not been 
reported; however, it was recently also observed by Biyashev et al. upon dll4 
knockdown, although at the later time point of 30 hpf (Biyashev et al., 2011). 
With increasing amounts of miR-30 mimic, a higher percentage of embryos 
displayed advanced sprouting and a greater proportion of these exhibited 
premature DLAV formation and hyper-migratory behaviour (severe advanced 
ISVs) (Fig 5.9A). Upon injection of 0.05ng miR-30b mimic, ~60% of embryos 
displayed advanced ISVs (21/36), with ~15% of embryos exhibiting the more 
severe phenotype (5/36) (Fig 5.9A). When miR-30b mimic was increased to 
0.2ng, ~90% of embryos displayed some form of abnormal ISVs (71/80) and the 
incidence of severe hyper-migratory endothelial cells had increased to ~70% 
(58/80) (Fig 5.9A). Only 10% of embryos injected with the highest amount of 
NTC mimic possessed abnormal ISVs (3/24) and none of these displayed the 
hyper-migratory phenotype, confirming that the results reported were not a non-
specific effect of miRNA mimic injection (Fig 5.9A). 
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Figure 5.8. Overexpression of miR-30b and miR-30c in zebrafish embryos phenocopies 
dll4 knockdown. (A) Trunk vasculature in uninjected Tg(kdrl:EGFP) embryos or embryos 
injected with the indicated MO or miRNA mimic. Left panels: advanced sprouting and aberrant 
endothelial cell migration (yellow arrowheads) at 25 hpf. Right panels: increased branching of 
the ISVs (red arrowheads) at 72 hpf. (B) DA diameter in embryos injected with dll4 MO or miR-
30 mimic relative to uninjected embryos (means + SEM, n=3). Six DA measurements were 
made per embryo using Adobe Photoshop CS4. Differences between uninjected embryos and 
embryos injected with dll4 MO or miR-30 mimics were significant. ***, p<0.001. Microinjections 
were performed by Rui Monteiro and Gemma Bridge. Images were taken by Rui Monteiro with 
the assistance of Gemma Bridge. DA measurements were made by Rui Monteiro. 
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A novel observation at 25 hpf was that the diameter of the DA was significantly 
reduced in dll4 morphants and in miR-30–overexpressing embryos compared 
with WT embryos (Fig. 5.8B). This phenotype has previously been reported 
following Dll4 knockdown in mice and the opposite effect has also been 
observed upon Dll4 overexpression in mouse embryos (Duarte et al., 2004; 
Gale et al., 2004). This concurs with studies showing that DLL4 up-regulation in 
tumours correlates with increased vessel maturation and size (Li et al., 2007; 
Patel et al., 2006; Trindade et al., 2008).  
  
Excessive ISV branching was observed in embryos expressing miR-30b and 
miR-30c mimics at 72 hpf (Fig. 5.8A; red arrowheads). This hyperbranching was 
comparable to that caused by dll4 MO injection (Fig. 5.8A; red arrowheads) and 
to the branching induced by dll4 knockdown in a previous report (Leslie et al., 
2007). This phenotype titrated with increasing amounts of miR-30: the higher 
the amount of mimic injected, the greater the number of branches from the ISVs 
(Fig. 5.9B). Approximately 50% of embryos injected with 0.05ng of miR-30b 
mimic presented extra ISV branches at 72 hpf (19/37) (Fig 5.9B). This 
increased to 85% with 0.2ng of mimic (29/34), with the addition of ~40% of 
embryos that showed 3-5 extra branches (13/34) (Fig. 5.9B). Again, the NTC 
mimic had a very mild effect on ISV branching (Fig 5.9B).  
 
Overall this work showed that miR-30 overexpression in the developing 
zebrafish embryo phenocopies dll4 knockdown at both 25 and 72 hpf.  
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Figure 5.9. Quantification of zebrafish embryo phenotypes following titration of miR-30 
mimics. (A and B) Quantification of ISV sprouting defects at 24 hpf (A) and 72 hpf (B) in non-
injected control (NIC) Tg(kdrl:EGFP) embryos or embryos injected with the indicated mimic 
Values denote the quantity of mimic injected per embryo in ng. Embryos with severe 
morphological defects which prevented ISV phenotyping were discounted. n values per group 
ranged from 25-100 and are given in Table  2.10. Mild advanced ISVs: embryos with ISVs that 
have reached a more dorsal position in the trunk compared to wildtype embryos at the same 
time point. Severe advanced ISVs: as described for mild advanced ISVs but with the addition of 
premature DLAV formation and/or vessel-free, hyper-migratory endothelial cells. Microinjections 
were performed by Rui Monteiro. ISV phenotyping was performed by Gemma Bridge.  
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5.6. The hyperbranching phenotype induced by miR-30 
overexpression occurs due to dll4 targeting 
The work described in Section 5.5 had shown that overexpression of miR-30 in 
zebrafish embryos induces excessive ISV branching and therefore phenocopies 
dll4 knockdown. However, at this stage it could not be concluded that the 
hyperbranching phenotype was due to miR-30-induced dll4 suppression, 
because miRNAs can potentially target hundreds of mRNA transcripts. 
Downregulation of another, as yet unknown target could be causing the 
observed vascular phenotype. To dissect the specific role of dll4 targeting in this 
setting, a target protector morpholino (TP) was employed.  
 
A TP is a 25nt long morpholino which is designed to bind to a region of mRNA 
containing a specific miRNA target site. The TP is not only complementary to 
the miRNA target site, but also to flanking sequences in the 3’UTR, whilst the 
miRNA is only complementary to the target site and possibly a few downstream 
nucleotides. Therefore, the TP exhibits preferential binding and sterically blocks 
the miRNA from accessing the target site. This technique was first devised by 
Choi et al. to investigate the role of miR-430 during zebrafish development 
(Choi et al., 2007). A TP can be used to disrupt the interaction between a 
miRNA and one specific target, without affecting any other miRNA-target 
interactions. A TP was designed with a 3’ end that bound to the miR-30 target 
site within the dll4 3’UTR whilst the 5’ region bound to the downstream flanking 
sequence (dll4-TPmiR-30; Table 2.8). A control TP was also produced which 
bound to another region of the dll4 3’UTR that was not predicted to contain any 
miRNA target sites (dll4-TPcontrol; Table 2.8).  
 
To ascertain the effectiveness of this TP strategy, dll4-TPmiR-30 and dll4-TPcontrol 
were injected into zebrafish embryos at the 1-4 cell stage and dll4 expression 
was examined at 28 hpf. Consistent upregulation of dll4 mRNA in dll4-TPmiR-30 
injected embryos was observed by in situ hybridisation (Fig. 5.10A) and qRT-
PCR (Fig. 5.10B) when compared to embryos injected with dll4-TPcontrol. This 
confirmed that dll4-TPmiR-30 could be used to prevent miR-30 from targeting dll4 
in vivo and also revealed that miR-30 actively targets dll4 during zebrafish 
development.  
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Figure 5.10. Co-injection of dll4-TP
miR-30
 partially rescues the aberrant endothelial cell 
migration and ISV branching caused by miR-30 microinjection. (A) Representative in situ 
hybridization showing expression of dll4 mRNA in the developing vasculature of zebrafish 
embryos injected with 10ng of the indicated TP. Values indicated the number of embryos with 
the predominant, displayed phenotype out of the total number of embryos assayed. (B) 
Expression of dll4 mRNA in whole zebrafish embryos following microinjection of dll4-TP
miR-30
 
measured by qRT-PCR (means + SEM, n=5). Expression is relative to embryos injected with 
the same quantity of dll4-TP
control
. *, p<0.05, ***, p<0.001. (C) Trunk vasculature in uninjected 
Tg(kdrl:EGFP) embryos or embryos injected with the indicated miRNA mimic and/or TP. Left 
panels: advanced sprouting and aberrant endothelial cell migration (yellow arrowheads) at 25 
hpf. Right panels: increased branching of the ISVs (red arrowheads) at 72 hpf.  
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To confirm that the hyperbranching phenotype observed upon miR-30 
overexpression was due to increased dll4 suppression, dll4-TPmiR-30 was co-
injected with miR-30b or miR-30c mimics into Tg(kdrl:EGFP) embryos. When 
injected alone, miR-30b and miR-30c caused hyper-migratory endothelial cells 
and advanced sprouting at 25 hpf (Fig. 5.10C; yellow arrowheads), which later 
developed into extra branches from the ISVs at 72 hpf (Fig. 5.10C; red 
arrowheads). These phenotypes were not seen in uninjected or NTC-injected 
embryos (Fig. 5.10C). Co-injection of dll4-TPmiR-30 led to a partial rescue of 
aberrant ISV development at both 25 and 72 hpf (Fig. 5.10C). Quantification of 
the embryos at 24 hpf showed that the advanced sprouting phenotype was 
reduced by approximately half in co-injected embryos (Fig. 5.11). In this 
experiment ~65% of embryos injected with miR-30b (24/36) and miR-30c 
mimics (19/29) displayed advanced sprouting at 24 hpf (Fig. 5.11). This was 
reduced to 37% (10/27) and 25% (12/47) respectively when the mimics were 
co-injected with dll4-TPmiR-30.  
 
The findings described in this section indicated that dll4 downregulation is a 
significant contributing factor to the advanced sprouting and excessive 
branching phenotypes observed upon miR-30 overexpression. These data also 
suggest that miR-30 can regulate endothelial cell behaviour in vivo and that the 
targeting of dll4 by miR-30 is functionally relevant during vascular development.  
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Figure 5.11. Quantification of zebrafish embryo phenotypes following co-injection of dll4-
TP
miR-30
 with miR-30 mimics. (A) Quantification of ISV sprouting defects at 24 hpf in non-
injected control (NIC) Tg(kdrl:EGFP) embryos or embryos injected with the indicated mimic 
and/or dll4-TP
miR-30
. Embryos with severe morphological defects which prevented ISV 
phenotyping were discounted. n values per group ranged from 25-100 and are given in Table  
2.10. Missing ISVs: embryos lacking one or more ISVs. Advanced ISVs: embryos with ISVs that 
have reached a more dorsal position in the trunk compared to wildtype embryos, including those 
displaying premature DLAV formation and vessel-free, hyper-migratory endothelial cells. 
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5.7. Increased dll4 expression synergises with partial 
loss of Vegfa signalling to inhibit angiogenesis   
When dll4-TPmiR-30 was injected alone into zebrafish embryos, 36% were 
missing one or more ISV sprouts at 24 hpf (18/50), compared to 6% of 
uninjected embryos (4/66) (Fig. 5.11). Missing ISVs were also observed in 22% 
of NTC-injected embryos (6/27), suggesting that microinjection could be 
causing this effect. However, the number of NTC-injected embryos displaying 
missing ISVs increased to 42% upon co-injection with dll4-TPmiR-30 (25/59). 
These data suggested that upregulation of dll4 upon dll4-TPmiR-30 injection 
inhibits ISV sprouting to a small extent.  
 
To investigate this phenotype further, embryos were injected with either dll4-
TPcontrol or dll4-TPmiR-30 and in situ hybridisations were performed at 27 hpf to 
examine the expression of various vascular markers (Fig. 5.12). A literature 
review was conducted to identify genes that are regulated by DLL4 and 
therefore potentially altered upon dll4 upregulation in embryos injected with dll4-
TPmiR-30 (Table 5.1). From this list efnb2, hey2, flt1, and kdrl were chosen for 
further analysis (Fig. 5.12). Previous experimental evidence would predict an 
upregulation of efnb2, hey2 and flt1 and a downregulation of kdrl upon dll4 
upregulation in dll4-TPmiR-30 injected embryos (Table 5.1). The expected 
changes were not observed for efnb2, hey2 and flt1. This could be due to 
insufficient dll4 upregulation or the differences between the zebrafish model and 
the in vitro or mouse systems in which the studies listed in Table 5.1 were 
conducted. In fact, changes in expression of these markers have not been 
observed upon dll4 knockdown in zebrafish (Hogan et al., 2009b; Leslie et al., 
2007). However, kdrl mRNA was clearly downregulated in the ISVs and DA of 
dll4-TPmiR-30 injected embryos (Fig. 5.12).  
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Human 
gene ID 
Zebrafish 
gene ID 
Upregulated by 
DLL4/NOTCH 
Downregulated by 
DLL4/NOTCH 
Publications 
ABL1 abl1 X  
(Crowner et al., 2003; Le Gall 
et al., 2008) 
BGN 
bgna 
bgnb 
X  (Harrington et al., 2008) 
CDH5 cdh5 X  (Trindade et al., 2008) 
CDH11 cdh11 X  (Harrington et al., 2008) 
COL1A1 
col1a1a 
col1a1b 
X  (Trindade et al., 2008) 
COL3A1 N/A   (Harrington et al., 2008) 
COL4A1 col4a1 X  (Trindade et al., 2008) 
CXCR4 
cxcr4a 
cxcr4b 
 X 
(Harrington et al., 2008; 
Williams et al., 2008) 
EFNB2 
efnb2a 
efnb2b 
X  
(Harrington et al., 2008; Patel 
et al., 2005; Trindade et al., 
2008) 
ELN 
elna 
elnb 
X  (Harrington et al., 2008) 
EPHB4 
ephb4a 
ephb4b 
 X (Trindade et al., 2008) 
FBLN5 fbln5 X  (Harrington et al., 2008) 
FGF2 fgf2 X  (Harrington et al., 2008) 
FLT1 flt1 X  
(Harrington et al., 2008; 
Suchting et al., 2007; Trindade 
et al., 2008) 
(soluble 
FLT1) 
(soluble 
flt1) 
X  (Harrington et al., 2008) 
FLT4 flt4  X 
(Djokovic et al., 2010; 
Siekmann and Lawson, 2007) 
FLT4 flt4 X  (Shawber et al., 2007) 
FN1 
fn1 
fn1b  
X  (Trindade et al., 2008) 
GJA4 cx39.4 X  (Trindade et al., 2008) 
HES5 her2 X  (Trindade et al., 2008) 
HEY1 hey1 X  
(Patel et al., 2005; Trindade et 
al., 2008) 
HEY2 hey2 X  
(Harrington et al., 2008; 
Trindade et al., 2008; Williams 
et al., 2006) 
INHBA 
inhbaa 
inhbab 
X  (Harrington et al., 2008) 
ITGB3 
itgb3a 
itgb3b 
 X (Harrington et al., 2008) 
JAG1 
jag1a 
jag1b 
X  (Harrington et al., 2008) 
KDR 
kdr 
kdrl 
 X 
(Harrington et al., 2008; 
Henderson et al., 2001; Li et 
al., 2006; Suchting et al., 
2007; Williams et al., 2006) 
LAMA1 lama1 X  (Trindade et al., 2008) 
LAMB1 
lamb1a 
lamb1b 
X  (Trindade et al., 2008) 
LAMC1 lamc1 X  (Trindade et al., 2008) 
MET met  X (Harrington et al., 2008) 
MMP1 N/A  X (Trindade et al., 2008) 
MMP2 N/A  X (Trindade et al., 2008) 
MMP9 mmp9  X (Trindade et al., 2008) 
MMP10 N/A X  (Harrington et al., 2008) 
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Table 5.1A. Genes regulated by DLL4: A-M. For ease, human and zebrafish gene IDs have 
been given even if the link between DLL4 and the specified gene was made in another species.  
Human 
gene ID 
Zebrafish 
gene ID 
Upregulated by 
DLL4/NOTCH 
Downregulated by 
DLL4/NOTCH 
Publications 
NOTCH3 notch3 X  (Harrington et al., 2008) 
NR2F2 nr2f2  X (Diez et al., 2007) 
NRARP 
nrarpa 
nrarpb 
 X 
(Krebs et al., 2001; Lamar et 
al., 2001; Pirot et al., 2004) 
NRP1 
nrp1a 
nrp1b 
 X 
(Harrington et al., 2008; 
Williams et al., 2006) 
NRP2 
nrp2a 
nrp2b 
 X 
(Harrington et al., 2008; 
Trindade et al., 2008) 
PCDH12 N/A  X (Harrington et al., 2008) 
PDGFRB pdgfrb  X (Djokovic et al., 2010) 
PIGF pigf  X (Harrington et al., 2008) 
RASSF2 
rassf2a 
rassf2b 
 X (Harrington et al., 2008) 
ROBO4 robo4  X (Trindade et al., 2008) 
RND1 
rnd1 
rnd1l 
X  (Harrington et al., 2008) 
SEMA5A sema5a X  (Harrington et al., 2008) 
SDC1 N/A X  (Harrington et al., 2008) 
SLIT2 slit2 X  (Harrington et al., 2008) 
SLIT3 slit3 X  (Harrington et al., 2008) 
SNAI2 snai1 X  (Harrington et al., 2008) 
STAT1 
stat1a 
stat1b 
X  (Harrington et al., 2008) 
TEK tek X  (Djokovic et al., 2010) 
UNC5B unc5b X  (Trindade et al., 2008) 
VCAM1 vcam1 X  (Harrington et al., 2008) 
VEGFA 
vegfaa 
vegfab 
 X (Djokovic et al., 2010) 
VEGFC vegfc  X (Djokovic et al., 2010) 
Table 5.1B. Genes regulated by DLL4: N-Z. For ease, human and zebrafish gene IDs have 
been given even if the link between DLL4 and the specified gene was made in another species.  
 
Notch signalling via DLL4 is known to negatively regulate KDR expression 
(Harrington et al., 2008; Henderson et al., 2001; Li et al., 2006; Suchting et al., 
2007; Williams et al., 2006). This regulation is thought to occur through direct 
binding of HEY1 to the KDR promoter (Henderson et al., 2001; Holderfield et 
al., 2006). Decreased expression of kdrl upon dll4-TPmiR-30 injection suggested 
that transcription of kdrl is also controlled by Dll4-induced Notch signalling and 
that endogenous miR-30 could indirectly affect kdrl levels by negatively 
regulating dll4 expression.  
 
To investigate the functional implications of this potential regulatory network, 
vascular development was examined in Tg(fli1a:EGFP) embryos following 
microinjection of various MOs and TPs (Fig. 5.13A).  
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Figure 5.12. Expression of zebrafish vascular markers following microinjection of dll4-
TP
miR-30
. (A) Representative in situ hybridizations showing expression of efnb2, hey2, flt1 and 
kdrl mRNA in the developing vasculature of wildtype (WT) zebrafish embryos or embryos 
injected with 10ng of the indicated TP. Values denote the number of embryos with the 
predominant, displayed phenotype out of the total number of embryos assayed. Microinjections 
and in situ hybridisations were performed by Gemma Bridge and Rui Monteiro. Images were 
taken by Rui Monteiro.  
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The Tg(kdrl:EGFP)  line could not be used for these experiments as the 
intention was to interfere with kdrl expression which would subsequently affect 
EGFP expression. Tg(fli1a:EGFP) embryos differ slightly from Tg(kdrl:EGFP) 
embryos as both lymphatic and blood endothelial cells fluoresce in 
Tg(fli1a:EGFP) embryos. The Tg(fli1a:EGFP) line was chosen, because it had 
previously been used to characterise the relationship between Kdr and Kdrl with 
respect to Vegfa signalling and ISV sprouting (Bahary et al., 2007). The kdr and 
kdrl MOs used in this study were also adopted and injected in the quantities 
previously specified (Table 2.8).  
 
When kdr MO was injected alone, it had a modest impact on ISV sprouting (Fig. 
5.13A ii; B). Approximately half the embryos displayed normal ISV development 
at 28 hpf compared to uninjected control embryos (19/40) (Fig. 5.13A i and ii; 
B). The majority of the remaining embryos had moderate impairment of ISV 
sprouting, lacking at least one ISV, but with a minimum of 6 intact ISVs (19/40) 
(Fig. 5.13B). The kdrl MO had a more significant impact, as the majority of 
embryos displayed stunted or missing ISVs (29/41) (Fig. 5.13A iii; B). However, 
this impairment was mainly moderate (21/41), and 20% of embryos had WT 
ISVs (12/41) (Fig. 5.13B). These findings concur with the work of Bahary and 
colleagues (Bahary et al., 2007), and confirm that Vegfa signalling can continue 
to some extent in the absence of one zebrafish VEGFR2 orthologue. If Vegfa 
signalling was completely abolished, as occurs upon vegfaa knockdown, ISV 
development would be entirely inhibited (Christie et al., 2010; Nasevicius et al., 
2000). 
 
Simultaneous knockdown of kdr and kdrl has previously been shown to cause 
complete loss of ISVs (Bahary et al., 2007), and this phenotype was 
successfully recapitulated with MOs (Fig 5.13B iv). When dll4-TPmiR-30 was 
injected alone, ~40% of embryos exhibited moderate impairment of ISV 
sprouting (19/50) (Fig. 5.13B). This concurred with the missing ISVs observed 
in Tg(kdrl:EGFP) embryos injected with  dll4-TPmiR-30 (Fig. 5.11). This effect was 
not seen in embryos injected with dll4-TPcontrol (Fig. 5.13B) and suggested that a 
decrease in kdrl expression in dll4-TPmiR-30 injected embryos was affecting 
efficient Vegfa signalling. Co-injection of dll4-TPmiR-30 with kdr MO resulted in a 
significantly greater loss of ISV sprouting when compared to dll4-TPmiR-30 alone 
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(Fig. 5.13A vii and viii; B). Approximately 80% of dll4-TPmiR-30 + kdr MO injected 
embryos had some form of ISV inhibition (30/37) and ~30% had 5 or less intact 
ISVs (11/37) (Fig. 5.13B). It was concluded that loss of ISV sprouting in dll4-
TPmiR-30 + kdr MO injected embryos is caused by the combined downregulation 
of kdrl and kdr, because this is a partial phenocopy of kdr and kdrl MO-
mediated knockdown (Fig. 5.13A iv) and kdrl expression was shown to be 
reduced upon dll4-TPmiR-30 injection (Fig. 5.12). The reduction in ISV sprouting 
in TPmiR-30 + kdr MO injected embryos probably occurs because these genes 
encode the two zebrafish Vegfa receptors (Bahary et al., 2007; Covassin et al., 
2006).  
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Figure 5.13. Loss of dll4 
regulation by miR-30 
synergises with partial Vegfa 
signalling knockdown to block 
angiogenesis. (A) Trunk 
vasculature in uninjected 
Tg(fli1a:EGFP) embryos or 
embryos injected with the 
indicated MO and/or TP at 28 hpf. 
(B) Quantification of ISV sprouting 
defects following injection of the 
MOs and/or TPs indicated. 
Columns are the average of two 
independent experiments with 15-
30 embryos counted per sample 
per experiment. Moderate 
phenotype: embryos lacking 1 ISV 
but with a minimum of 6 ISVs. 
Severe phenotype: embryos with 
5 or less ISVs. To determine 
statistical significance, a Wilcoxon 
rank-sum test was performed. ***, 
p<0.001. Microinjections were 
performed by Rui Monteiro. 
Fluorescent imaging was 
performed by Rui Monteiro with 
the assistance of Gemma Bridge. 
Phenotype quantification was 
performed by Gemma Bridge. 
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5.8. Discussion 
The work discussed in this chapter confirmed that miR-30 can suppress dll4 in 
vivo and demonstrated that increased targeting of dll4 through miR-30 
overexpression results in aberrant ISV development. Active targeting of dll4 by 
endogenous miR-30 was demonstrated through the use of a target protector, 
and this regulation was shown to provide robustness to Vegfa signalling by 
indirectly influencing kdrl expression.  
 
Analysis of zebrafish RNA from various developmental time points revealed that 
expression of both dll4 and miR-30 can be detected from 6 hpf and is strongly 
induced at 12 hpf. This concurs with previous studies: dll4 mRNA is first 
detected by RT-PCR at 8 hpf, but upregulated at 12 hpf (Leslie et al., 2007); 
zebrafish miRNAs have been detected from 4 hpf by small RNA cloning and 
from 12 hpf by microarray analysis (Chen et al., 2005; Wienholds et al., 2005). 
Of particular interest to this study was the inverse correlation between dll4 and 
miR-30 expression during the first wave of angiogenic sprouting from the DA 
(18-24 hpf). These temporally coincident changes in dll4 and miR-30 are 
consistent with a functional interaction that may contribute to tight control of Dll4 
expression during zebrafish vascular development.  
 
In zebrafish, endothelial cells first begin to sprout from the DA to form SAs at 
~22 hpf (Isogai et al., 2003). The initiation of this angiogenic program requires 
Vegfa signalling via the VEGFR2 functional orthologues, Kdr and Kdrl (Bahary 
et al., 2007; Habeck et al., 2002). This promotes loosening of cell junctions, cell 
division and migratory behaviour in endothelial cells of the DA (Ellertsdóttir et 
al., 2010). DLL4 is known to suppress KDR (VEGFR2) expression (Harrington 
et al., 2008; Henderson et al., 2001; Li et al., 2006; Suchting et al., 2007; 
Williams et al., 2006). I therefore hypothesised that the observed 
downregulation of dll4 at 18 hpf, continuing until 24 hpf, would permit sufficient 
Vegfa signalling for successful SA development.  
 
dll4 expression was found to increase again at 30 hpf, which coincides with the 
end of the first wave of angiogenic sprouting. A secondary wave of angiogenic 
sprouting begins at 32 hpf from the PCV; these sprouts connect with an existing 
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SA to form a SV (Isogai et al., 2003). However, Vegfa signalling is not required 
for SV formation, therefore high Dll4 expression is not an impediment to this 
process (Covassin et al., 2006; Covassin et al., 2009; Lawson et al., 2003). 
Venous development in zebrafish is dependent on Vegfc/Flt4 signalling, but in 
the absence of Dll4, arterial endothelial cells are also stimulated by Vegfc 
(Covassin et al., 2006; Hogan et al., 2009b). This is because Dll4 acts to 
suppress the ability of arterial endothelial cells to respond to Vegfc/Flt4 
signalling, whereas venous endothelial cells do not express Dll4 and therefore 
are able to respond to Vegfc (Hogan et al., 2009b). As such, the high levels of 
dll4 observed in this study at 30 hpf might be acting to suppress arterial 
angiogenesis in response to Vegfc during the period of SV formation.  
 
It was concluded from the work shown in Chapter 4 that DLL4 is a genuine 
target of miR-30 in human endothelial cells in vitro and that this targeting occurs 
via a specific target site within the DLL4 3’UTR. Here, injection of miR-30 
mimics into zebrafish embryos proved that dll4 is also downregulated by 
exogenous miR-30 in vivo. Intriguingly, when injected at high concentrations, 
miR-30 mimics caused severe morphological abnormalities which could not be 
attributed solely to dll4 targeting. Due to the small size of miRNA target sites 
and the wide range of canonical, marginal and atypical sites, each miRNA has 
the potential to target hundreds or even thousands of genes (Bartel, 2009). The 
current version of TargetScanFish predicts 7037 gene targets for the miR-30 
family. One potential target for future investigation is the Wnt family member 
wingless-type MMTV integration site family member 5b (wnt5b). This gene is 
required for tail formation in zebrafish embryos (Rauch et al., 1997), and 
therefore its downregulation could potentially explain the aberrant tails observed 
when miR-30 was injected at high concentrations. 
 
Other predicted targets of miR-30 include the Notch ligands deltaC (dlc) (DLL3 
orthologue), jag1a and jag2 and the Notch target genes hairy-related 1 (her1) 
(HES7 orthologue), her3 (HES3 orthologue) her4.3 and her4.4. Previous work 
suggests that downregulation of dlc and her1 could directly interfere with the 
oscillator mechanism of somite generation (Holley et al., 2002). Therefore, there 
are multiple possible routes whereby miR-30 could interfere with somitogenesis 
leading to aberrant embryonic patterning. This could potentially explain the 
205 
 
defects in tail development observed in embryos injected with large quantities of 
miR-30 mimic.  
 
It is known that Notch signalling plays a fundamental role in zebrafish 
somitogenesis. Mutations in notch1a, dlc and deltaD (dld) (DLL1 orthologue) all 
cause defective somitogenesis (Holley et al., 2002; vanEeden et al., 1996). Dll4 
predominantly signals through Notch1b rather than Notch1a, as only notch1b 
morphants recapitulated the vascular phenotype of dll4 morphants, dll4 mutants 
and DAPT-treated embryos (Leslie et al., 2007). However, additional signalling 
through Notch1a could also occur because, although morpholinos against 
notch1a were used by Leslie and colleagues, the phenotypes of these embryos 
were not described (Leslie et al., 2007). Therefore, Dll4 could play a minor role 
in somitogenesis. When several other relevant somitogenic regulators are 
downregulated in the context of miR-30 overexpression, such as dlc and her1, 
significant dll4 suppression could contribute to defective patterning. Mutations in 
notch1a, dlc and dld are also known to cause defective neurogenesis, therefore 
the predicted regulation of dlc and her1 by miR-30 could also be of relevance to 
this process (Gray et al., 2001; Julich et al., 2005). When runx1 expression was 
examined in miR-30 overexpressing embryos, abnormal neural patterning was 
indeed observed. 
 
The expression of runx1 following miR-30 overexpression was assessed 
alongside the expression of several other vascular markers. This demonstrated 
that runx1, dab2 and flt4 are all downregulated in the trunk of miR-30 injected 
embryos when compared to WT or NTC-injected embryos. Downregulation of 
runx1 was not due to inhibition of haematopoietic endothelium specification, as 
seen in the dll4 morphants. runx1 positive cells could still be identified, but with 
a reduced level of runx1 expression. This suggested that dll4 suppression in 
miR-30 overexpressing embryos is not sufficient to impair HSC emergence, as 
seen upon Notch inhibition (Burns et al., 2005; Gering and Patient, 2005).  
Decreased runx1 expression in miR-30 injected embryos could be due to direct 
targeting of runx1 by miR-30. Exogenous miR-30c has been shown to target the 
RUNX1 3’UTR using a luciferase reporter assay and the miR-30 family is known 
to regulate human adipogenesis by targeting another RUNX family member, 
RUNX2 (Ben-Ami et al., 2009; Zaragosi et al., 2011). When the predicted 
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targets of the zebrafish homologue of miR-30, dre-miR-30, were examined, 
runx2a, runx2b and runx3 were all found to contain one or more miR-30 target 
sites within their 3’UTRs. However, it was not possible to assess the likelihood 
of runx1 targeting by dre-miR-30 as the 3’UTR of this gene is not currently 
contained within the TargetScanFish database (Version 6.2). If runx1 is a 
functional target of miR-30 in vivo, this could implicate the miR-30 family in 
regulating the emergence and maintenance of HSCs by providing a fine-tuning 
mechanism to restrict excessive or ill-timed runx1 expression.  
 
Two venous markers, dab2 and flt4, were downregulated in the trunk region of 
miR-30 overexpressing embryos and to a lesser extent in the head, a 
phenotype not seen in dll4 morphants. dab2 mRNA suppression could be due 
to direct targeting of dab2 by miR-30, as two of the four dab2 3’UTRs expressed 
during zebrafish development contain predicted miR-30 target sites 
(TargetScanFish). However, flt4 is not a predicted target of miR-30 therefore flt4 
expression in miR-30 overexpressing embryos is probably altered due to 
changes in other miR-30 targets.  
 
The pattern of dab2 and flt4 staining in the miR-30 overexpressing embryos at 
26-27 hpf also revealed that exogenous miR-30 impairs venous positioning. A 
wider gap was seen between the cardinal veins post-bifurcation, the DCs were 
larger and disorganised, and in the case of flt4, two lines of cells could be seen 
in a region where only the single path of the PCV should be marked. In addition, 
dab2 and flt4 positive cells had not migrated to the midline correctly at the 14 
somite stage (16 hpf) in miR-30 overexpressing embryos (data not shown). 
These data suggest that one or more miR-30 targets are involved in angioblast 
migration and/or venous cell specification.  
 
Vasculogenesis of the DA and PCV is initiated in zebrafish when two lateral 
stripes of angioblasts begin to migrate towards the midline at 14 hpf and 
coalesce to form a vascular cord. Overexpression of miR-30 appears to prevent 
complete angioblast migration. This could be due to three predicted targets of 
dre-miR-30: semaphorin 3ab (sema3ab) and the genes that encode the 
Sema3a receptors, nrp1a and nrp1b. One of the duplicate sema3a zebrafish 
genes, sema3aa, has been shown to act as a guidance factor in the migration 
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of angioblasts by signalling through a receptor complex which contains Nrp1 
(Shoji et al., 2003). miR-30 is predicated to target the other sema3a gene, 
sema3ab, and also both of the nrp1 genes (nrp1a and nrp1b). By 
downregulating a key guidance factor and the receptor through which it signals, 
exogenous miR-30 may impair angioblast migration in miR-30 injected 
embryos. The predicted targeting of sema3a by miR-30 in zebrafish is 
supported by the finding that exogenous miR-30b and -30d suppress SEMA3A 
mRNA levels and target the SEMA3A 3’UTR in vitro (Gaziel-Sovran et al., 
2011).  
 
Arterio-venous specification of the primary vascular cord in zebrafish occurs 
through the differential expression of either efnb2a (arterial) or ephb4a (venous) 
and ventral sprouting begins at 21 hpf to form the PCV (Herbert et al., 2009). 
dre-miR-30 is predicted to target many zebrafish ephrins and ephrin receptors 
(TargetScanFish). Among these are efna1a, efnb2a, epha2, ephb2a, ephb2b 
and ephb3a, which have all been linked to endothelial cell migration and 
angiogenesis (www.genecards.org). Further investigation into the factors 
regulating cardinal vein bifurcation and DC development is required before 
potential miR-30 targets can be linked to these processes.  
 
Injection of dll4 MO was used as a positive control for dll4 knockdown in this 
work and successfully recapitulated the hyper-migratory endothelial cells and 
ISV hyperbranching reported in previous studies (Biyashev et al., 2011; Hogan 
et al., 2009b; Leslie et al., 2007). Biyashev et al. also observed the formation of 
a single dorsal vessel in dll4 morphants, rather than the expected DA and PCV 
(Biyashev et al., 2011), a phenotype which was not seen in this work. They 
explained that this was consistent with previous observations by Herbert et al., 
where hey2 MO injection and the Notch inhibitor DAPT promoted the loss of the 
DA (Herbert et al., 2009). It should be noted that hey2 knockdown and Notch 
inhibition will interfere with all Notch signalling and are not specific to Dll4 
signalling via Notch1.  
 
Overexpression of miR-30 in zebrafish embryos phenocopied dll4 knockdown. 
At 24 hpf, overly advanced ISV sprouts and hyper-migratory endothelial cells 
were observed leading to premature DLAV formation. Excessive motility of 
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endothelial cells in dll4 morphants has been attributed to a lack of tip cell fate 
restriction (Biyashev et al., 2011). This concurs with the work of Hellström et al. 
in the developing mouse retina, where Dll4-Notch1 signalling between 
endothelial cells within the angiogenic sprout was shown to maintain the optimal 
ratio of tip and stalk cells (Hellström et al., 2007). However, the tip cell markers 
dll4 and flt4 are expressed in both tip and stalk cells within the sprouting ISV of 
zebrafish (Hogan et al., 2009b; Leslie et al., 2007; Siekmann and Lawson, 
2007). Additionally, tip and stalk cells proliferate at similar rates in zebrafish 
ISVs (Blum et al., 2008). Therefore, the model of clearly defined tip and stalk 
cells is not directly transferable to the zebrafish system. More recent work has 
shown that tip cell specification in the mouse is actually a dynamic process as 
endothelial cells within the sprout continually compete for the leading position 
(Jakobsson et al., 2010). This process is based on differing levels of VEGFR1 
and VEGFR2; those cells expressing low VEGFR1 and high VEFR2 obtain the 
tip cell position, whereas cells with high VEGFR1 and low VEGFR2 temporarily 
assume the stalk cell position. As receptor levels fluctuate in response to 
VEGFA signalling and cells continually meet new neighbours the relative ratio of 
VEGFR1:VEGFR2 is constantly reassessed and cells switch positions 
(Jakobsson et al., 2010). However, for differential VEGFR levels to impact on tip 
and stalk specification, DLL4/Notch signalling must be active (Jakobsson et al., 
2010). If this dynamic equilibrium also occurs during zebrafish angiogenesis, 
downregulation of dll4 upon miR-30 overexpression may abrogate the tip cell 
advantage of cells with higher Kdr or Kdrl whilst simultaneously increasing Kdrl 
expression, allowing more cells to respond to Vegfa gradients. Therefore, the 
hyper-migratory endothelial cells seen upon miR-30 overexpression and dll4 
knockdown may arise due to perturbations in the Flt1:Kdr equilibrium when 
Notch/Dll4 signalling is repressed.   
 
The excessive ISV branching observed at 72 hpf in both miR-30 and dll4 MO 
injected embryos is a later consequence of the aberrant tip cell regulation 
observed at 24 hpf. However, it is also linked to the role of Dll4 in restricting the 
exploratory behaviour of endothelial cells once ISV sprouting has finished and 
the DLAV is formed. In dll4 morphants, endothelial cells comprising the DLAV 
and ISVs are not quiescent but continue to extent and retract filopodia and 
advance into ectopic locations, forming extra ISV branches (Leslie et al., 2007).   
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A reduction in DA diameter was observed in zebrafish embryos upon dll4 
knockdown by either dll4 MO or miR-30 mimic. A similar phenotype has been 
observed in mice following Dll4 knockdown and DLL4 upregulation is known to 
promote vessel maturation and increase vessel size in both human cancer and 
mouse development (Duarte et al., 2004; Gale et al., 2004; Li et al., 2007; Patel 
et al., 2006; Trindade et al., 2008). However, this is the first report of a decrease 
in DA width upon dll4 knockdown in zebrafish.  
 
Co-injection of miR-30 with a TP specific to the dll4/miR-30 target site 
demonstrated that the excessive vascular sprouting caused by miR-30 
overexpression could be explained by dll4 targeting. The TP was also an 
elegant tool with which to explore the endogenous role of miR-30 during 
zebrafish vascular development. It was used to specifically block the interaction 
of miR-30 with dll4 mRNA during development, whilst still allowing miR-30 to 
interact with its other targets. When the normal control of dll4 by miR-30 was 
inhibited, dll4 mRNA was elevated and ISV formation was impaired. This finding 
suggests that miR-30 actively suppresses dll4 during normal ISV sprouting, 
helping to maintain tight control of angiogenesis.  
 
When dll4 levels were increased using the TP, kdrl, a functional orthologue of 
VEGFR2, was downregulated. Vegfa signalling in zebrafish is mediated through 
the synergistic action of Kdrl and another Vegfa receptor, Kdr (Bahary et al., 
2007; Covassin et al., 2006). ISV sprouting was moderately to severely inhibited 
in the majority of embryos when dll4-TPmiR-30 injection was combined with kdr 
knockdown. This partially recapitulated the phenotype seen when the 
expression of both kdrl and kdr was blocked using morpholinos and also the 
phenotype observed upon vegfaa knockdown (Bahary et al., 2007; Christie et 
al., 2010; Nasevicius et al., 2000).   
 
It is proposed that minor increases in dll4 expression are controlled by miR-30 
to ensure appropriate kdrl expression and hence ISV development. This model 
is supported by several studies which show that the majority of miRNAs act to 
fine-tune the expression of target genes (Baek et al., 2008; Selbach et al., 
2008). This work has therefore revealed that the miR-30 family indirectly 
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regulates Vegfa signalling by controlling dll4 expression and that this regulatory 
axis confers robustness to Vegfa-mediated angiogenesis. 
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Chapter 6. Discussion and future work 
6.1 Summary 
An investigation into the predicted targets of miRNAs with altered expression in 
KLEC led to the discovery that the miR-30 family targets the Notch pathway 
ligand DLL4 and that this interaction is relevant to endothelial biology in vivo. 
The main findings of this work are: 
 
Evaluation of the predicted targets of miRNAs altered upon KSHV infection of 
LEC (Chapter 3) 
 Detailed analysis of in silico target prediction results of KSHV-regulated 
miRNAs and cross-comparison with angiogenic genes.  
 Identification of a putative regulatory relationship between miR-30 and 
DLL4. 
 Confirmation of miR-30 upregulation and DLL4 downregulation in human 
dermal LEC. 
 
miR-30b and miR-30c target DLL4 (Chapter 4) 
 DLL4 is an experimentally validated target of miR-30b and miR-30c in 
vitro. 
 Overexpression of miR-30 attenuates upregulation of DLL4 in KLEC. 
 miR-30b promotes sprouting angiogenesis in vitro. 
 
miR-30-mediated regulation of dll4 affects endothelial cell behaviour during 
zebrafish development (Chapter 5) 
 dll4 is an experimentally validated target of miR-30b and miR-30c in vivo. 
 Exogenous expression of miR-30 induces aberrant intersegmental vessel 
development and branching in zebrafish by way of dll4 targeting. 
 Disruption of miR-30/dll4 targeting causes increased dll4 expression and 
hence downregulates kdrl and inhibits angiogenesis, particularly in 
synergy with kdr loss.  
 miR-30 regulation of dll4 expression during development confers 
robustness to Vegfa-mediated angiogenesis.  
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6.2 Conclusions 
The discovery of miRNAs in 1993 has revealed a highly complex additional 
layer of gene regulation that appears to function in a diverse range of cellular 
processes. It is therefore not surprising that several miRNAs have been 
identified as key regulators of endothelial cell behaviour and angiogenesis 
(Anand et al., 2010; Biyashev et al., 2011; Bonauer et al., 2009; Chen and 
Gorski, 2008; Fang et al., 2011; Fasanaro et al., 2008; Fish et al., 2008; Lee et 
al., 2007; Nicoli et al., 2010; Poliseno et al., 2006; Suarez et al., 2008; Urbich et 
al., 2012; Wang et al., 2008). However, at the onset of this work, the list of 
angiomiRs was not as extensive and miRNA regulation of key endothelial 
signalling pathways, such as the Notch pathway, had not been reported. KSHV 
infection of endothelial cells provided a tractable model with which to study the 
involvement of miRNAs in vascular biology (Mesri et al., 2010; Wang et al., 
2004).  
 
6.2.1 DLL4: a new target of the miR-30 family 
This work shows that two members of the miR-30 family, miR-30b and miR-30c, 
target the Notch ligand DLL4 and can influence endothelial cell behaviour in 
vitro. Currently validated targets of one or more members of the miR-30 family 
include B-cell lymphoma 6 (BCL6) (Lin et al., 2011), LIM homeobox 1 (lhx1) 
(Agrawal et al., 2009), lin-28 homolog (LIN28) (Zhong et al., 2010), v-myb 
myeloblastosis viral oncogene homolog (avian)-like 2 (MYBL2) (Martinez et al., 
2011), RUNX2 (Zaragosi et al., 2011) and snail family zinc finger 1 (SNAI1) 
(Zhang et al., 2012). Members of the miR-30 family have previously been 
implicated in adipogenesis (Zaragosi et al., 2011), cancer (Braun et al., 2010; 
Yu et al., 2010), cellular senescence (Martinez et al., 2011), epithelial-to-
mesenchymal transition (EMT) (Braun et al., 2010; Zhang et al., 2012), 
myocardial matrix remodelling (Duisters et al., 2009), osteoblast differentiation 
(Wu et al., 2012) and pronephros development (Agrawal et al., 2009). This is 
the first time that the miR-30 family has been shown to target a member of the 
Notch signalling pathway and play in role in angiogenesis. 
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6.2.2 miRNA regulation of the Notch pathway 
The work presented in this thesis validates miR-30b and miR-30c as two 
miRNAs that target the Notch ligand DLL4. When this work was begun, miRNA 
targeting of the Notch ligand DLL4 had not been described. However, in late 
2011, it was reported that miR-27b targets dll4 in endothelial cells (Biyashev et 
al., 2011). Knockdown of miR-27b in zebrafish embryos resulted in a severe 
impairment of ISV and DLAV formation. Interestingly, miR-27b morphants 
observed in another study did not display as severe a phenotype, perhaps due 
to differences in morpholino design and injection quantities (Urbich et al., 2012). 
The phenotype described by Biyashev and colleagues was attributed to dll4 and 
sprouty homolog 2 (spry2) targeting, because knockdown of these two genes 
rescued the defective sprouting, whereas overexpression of spry2 induced a 
similar phenotype (Biyashev et al., 2011). However, with each miRNA possibly 
regulating hundreds of individual genes, it is possible that one or more 
additional miR-27b targets could be involved. For example, the angiogenesis 
inhibitor semaphorin 6A (SEMA6A) has also been identified as a target of miR-
27b and silencing of SEMA6A partially reversed the inhibition of endothelial cell 
sprouting caused by miR-27b inhibition (Urbich et al., 2012). Further studies 
using target protector morpholinos, as carried out here for miR-30, would allow 
the delineation of the respective contributions of dll4 and spry2 to the phenotype 
observed upon miR-27b knockdown. From the use of target protectors in this 
thesis, it can be concluded that dll4 downregulation is a significant contributing 
factor to the advanced sprouting and excessive branching phenotypes observed 
upon miR-30 overexpression.  
 
6.2.3 A novel regulatory axis that confers robustness to Vegfa-
mediated angiogenesis 
A common reported function of miRNAs in a multitude of biological contexts is 
that they “confer robustness” to a particular cellular process or signalling 
pathway (Ebert and Sharp, 2012). Some of these biological processes cannot 
tolerate fluctuations in mRNA copy number and miRNAs act to suppress any 
variability, for example during cell fate induction and differentiation 
(Lüningschrör et al., 2013).  
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Figure 6.1. A schematic representation of the functional consequences of DLL4 targeting 
by miR-30. (A) A zebrafish embryo at 72 hpf is depicted. A section of the intersegmental 
vessels (ISV) has been enlarged. The dorsal aorta (DA) and posterior cardinal vein (PCV) have 
also been depicted in red and blue respectively. The dorsal longitudinal anastomotic vessel 
(DLAV) is shown in purple. (B) When miR-30 is overexpressed, dll4 is downregulated and a 
deregulated network of intersegmental vessels forms as the tip cell phenotype is not restricted 
and excessive sprouting occurs. (C) When miR-30 regulation of dll4 is blocked using a target 
protector, dll4 is upregulated and consequently kdrl expression is reduced. When combined with 
kdr knockdown, the restriction of tip cell specification and inhibition of Vegfa signalling which 
ensues prevents normal intersegmental vessel sprouting and the DLAV does not form. (Figure 
adapted from Figure 6 of Bridge et al., 2012). 
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Other systems require the reinforcement of transcriptional programmes in order 
to elicit the required outcome, as seen in the response to hypoxia (De Lella 
Ezcurra et al., 2012). The model that is proposed in this thesis concurs with the 
former scenario. This work has shown that miR-30 acts to fine tune dll4 levels 
during zebrafish vascular development, allowing sprouting angiogenesis to 
occur to the required extent (Figure 6.1A). When miR-30 is overexpressed, dll4 
is downregulated so tip cell fate is not restricted; this results in excessive 
branching from the ISVs (Figure 6.1B). If the interaction between miR-30 and 
dll4 is inhibited, the latter is up-regulated and consequently there is a reduction 
in kdrl expression (Figure 6C). If kdr is also suppressed, the subsequent lack of 
Vegfa signalling impairs ISV sprouting (Figure 6C). It is suggested that this 
phenotype is due to impaired Vegfa signalling because Kdr and Kdrl are the two 
known receptors for Vegfa in zebrafish and co-injection of dll4-TPmiR-30 and the 
kdr MO partially phenocopies knockdown of both kdr/kdrl and vegfaa (Bahary et 
al., 2007; Christie et al., 2010; Covassin et al., 2006; Habeck et al., 2002; 
Nasevicius et al., 2000). 
 
6.3 Future work 
6.3.1 Target identification for miRNAs altered upon KSHV 
infection 
Confirmation that DLL4 is a functional target of miR-30 has validated the target 
prediction strategy adopted in Chapter 3. The identification of miRNA/mRNA 
pairs that display converse expression changes as a result of an external 
stimulus is a valuable tool. At the present time, the targets of only two other 
KSHV-regulated miRNAs have been identified (Lagos et al., 2010; Punj et al., 
2010). Punj et al. have demonstrated that miR-146a is upregulated by vFLIP in 
vascular endothelial cells and that enhanced miR-146a expression decreases 
chemokine receptor 4 (CXCR4) levels (Punj et al., 2010). It is possible that miR-
146a mediated CXCR4 suppression promotes the premature release of KSHV-
infected endothelial progenitors into the circulation, thereby contributing to KS 
development (Punj et al., 2010). Upon KSHV infection in LEC, miR-132 is highly 
upregulated due to CREB-induced transcriptional activation (Lagos et al., 2010). 
miR-132 facilitates viral replication by inhibiting expression of p300, a 
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transcriptional co-activator, and this function of miR-132 is also required during 
herpes simplex virus-1 (HSV-1) and human cytomegalovirus  (HCMV) infection 
(Lagos et al., 2010). Further investigations into the targets of putative KSHV-
regulated miRNAs could reveal several other miRNA-mRNA interactions that 
may be relevant to KSHV biology, the viral immune response, KS pathogenesis 
or angiogenesis. For example, the pro-angiogenic gene FGFR2 is upregulated 
in KLEC and is predicted to be a target of the downregulated miRNAs miR-494 
and miR-513. Whereas, a panel of miRNAs that are upregulated in KLEC are 
predicted to target the putative anti-angiogenic gene NARG1 which is 
downregulated in KLEC.  
 
6.3.2 Additional roles of miR-30 during zebrafish development 
When miR-30 mimics were injected into zebrafish embryos at high 
concentrations, severe morphological defects were observed that were not 
present in the NTC-injected mimics. Additionally, abnormal expression and 
patterning of runx1, dab2 and flt4 was observed in miR-30 overexpressing 
embryos and these changes differed from those seen in dll4 morphants. This 
suggests that miR-30 has one or more functional targets in zebrafish that are 
required for vascular and possibly whole embryo patterning. To investigate this 
further, TPs could be used to identify which targets are contributing to these 
phenotypes and exactly what contribution they make to the observed 
abnormalities. TPs would be designed against predicted miR-30 target sites 
within in the 3’UTRs of possible candidates. These would include nrp1, sem3aa, 
efna1a, efnb2a, epha2, ephb2a, ephb2b, wnt4a, wnt16, wnt6b, wnt7a, wnt5b, 
wnt10a, wnt2bb and wnt9a. Nrp1, Sem3a and the ephrins and EPH receptors 
are all known to be involved in cell migration and guidance. Wnt signalling is 
vital for numerous developmental processes including planar cell polarity, 
neural tube patterning, axon guidance, stem cell differentiation and axis 
formation. Without the Wnt pathway, cell fate decisions and tissue patterning in 
both early and late development is severely affected. The fact that exogenous 
miR-30 is embryonically lethal at concentrations that did not produce whole 
embryo abnormalities for other miRNA mimics suggests that miR-30 expression 
may be tightly controlled in the developing zebrafish embryo. Elucidating the 
other key targets of dre-miR-30 may reveal previously unknown signalling 
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pathways or regulatory interactions that are vital for zebrafish and vertebrate 
development.  
 
6.3.3 miR-30/DLL4 regulation during tumour angiogenesis 
DLL4 is overexpressed in human tumours, often in association with markers of 
inflammation, hypoxia and angiogenesis (Jubb et al., 2009; Jubb et al., 2010; 
Patel et al., 2005; Patel et al., 2006). It appears that DLL4 expression is 
required for successful tumour angiogenesis as inhibition of DLL4 suppresses 
experimental tumour growth by inducing non-productive, deregulated 
angiogenesis (Noguera-Troise et al., 2006; Ridgway et al., 2006). Alongside 
this, downregulation of the miR-30 family is associated with enhanced 
tumourigenesis in breast cancer and anaplastic thyroid carcinoma (Braun et al., 
2010; Yu et al., 2010). One outcome of this thesis was the discovery that there 
is a significant negative correlation between one or more miR-30 family 
members and DLL4 expression in breast adenocarcinoma, ovarian serous 
cystadenocarcinoma, and the highly angiogenic renal clear-cell carcinoma. 
These findings suggest that overexpression of miR-30 during tumour 
development could suppress tumour progression by downregulating DLL4 
expression, thereby promoting inefficient vascular growth. Intratumoural and 
systemic delivery of the tumour suppressive miRNA miR-34a has been 
previously achieved using lipid-based delivery reagents (Liu et al., 2011; 
Wiggins et al., 2010). Therefore, these methods could be used to investigate 
tumour response to exogenous miR-30 in a colorectal xenograft model.  
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